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1 General introduction 
Chalcones belong to the large group of polyphenolic compounds. They are precursors of 
flavanones, which exhibit an open C ring, a phloroglucinol A ring and a phenylpropanoid 
B ring (Figure 1-1). 
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Figure 1-1: Chalcone skeleton with substituted A-Ring. 
 
Chalcones biosynthetically derived from phenylpropanoic acids such as 4-coumaroyl-CoA 
which are synthesized via the shikimate pathway (Figure 1-2). 
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Figure 1-2: Biosynthesis of the chalcone xanthohumol (XN) (adaped from [1]). 
 
The phloroglucinol A ring is built from malonyl-CoA units via the acetate malonate pathway. 
3 Malonyl CoA units are added at the carbonyl function of the activated phenylpropanoic 
acids via the elimination of 3 carbon dioxide molecules and 3 CoASH. 
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The chalcone biosynthesis in plants is catalyzed by the chalcone synthase (CHS) [2–4]. 
There are many different chalcones which are synthesized in plants such as kuraridin, 
xanthohumol (XN), isosalipurposide and isoliquiritin. In addition, there are a variety of 
synthetic chalcones. 
The synthesis of chalcones is correlated with bioassay testing, which leads to a fast 
development of potent synthetic compounds [5–7]. However it is out of the scope of this work 
to summarize the biological and pharmacological activity of synthetic chalcones. In the 
following, the focus lays on the activity of natural chalcones in general and XN in particular. 
The difference in the structure of natural chalcones is processed mainly after the chalcone 
synthesis. The prenylated hop chalcone XN, for instance, is first prenylated by the 
Humulus lupulus prenyltransferase-1 (HlPT-1) [8] and then O-methylated by an 
O-methyltransferase (OMT) [1] (see Figure 1-2). The chalcones can be further isomerized 
into flavanoids. Chalcone flavanone isomerase catalyzes the isomerization from the chalcone 
to the correspondent flavanone. This isomerization can happen also under non enzymatic 
conditions such as fermentation of beverages [9]. Chalcones are found in vegetables (e.g. 
tomatoes [10]), fruits (e.g. Citrus kinokuni [11]), beverages (e.g. beer [12]), various medicinal 
plants (e.g. Glycyrriza glabra [13]) and spices (e.g. Carthamos tinctorius [14,15]). They show 
remarkable pharmacological activity in a wide range of assays such as anti-bacterial or 
anti-fungal. Moreover the initiation promotion and progression of cancer is effected by 
different chalcones, too. 
Microorganisms live for example on the dermis and in the intestine of humans. They maintain 
a human’s defense against harmful microorganisms and produce beneficial vitamins. Beside 
the beneficial effects, there are microorganisms which can lead to harmful diseases. 
Methicillin-resistant Staphylococcus aureus (MRSA) accounts for about 170 000 new 
infections and 5 000 deaths per year in Europe [16]. An emerging risk is the widespread 
infection not only with health care associated methicillin-resistant Staphylococcus aureus 
(HA-MRSA), but also with community associated methicillin-resistant Staphylococcus aureus 
(CA-MRSA). Understandably, many investigations are being performed to find effective 
antibiotics also in the group of plant secondary metabolites. Kuraridin isolated from the 
Chinese herb Sophora flavescens AIT. showed an anti-bacterial effect on MRSA. The 
minimum inhibitory concentration (MIC) of kuraridin, saphorflavanone G and antibiotics on 
several MRSA strains were investigated. In addition to the investigation of MIC, the cytotoxic 
effect of kuraridin on human peripheral mononuclear cells was determined. Kuraridin 
inhibited the growth of MRSA strain ATCC 25923 at a MIC of 8 µg/ml in comparison to 
oxacillin at 0.13 µg/ml. The growth of MRSA strain 11998 was inhibited at a MIC of 16 µg/ml 
kuraridin and by ciprofloxacin at a MIC of 16 µg/ml. Interestingly, kuraridin showed no 
cytotoxic effect on human peripheral mononuclear cells up to a concentration of 64 µg/ml 
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[17]. Licochalcone A, a chalcone from Glycyrrhiza glabra L., showed a MIC of 16 µg/ml 
against a further MRSA strain. Hatano and co-workers [18] discussed an interaction of the 
prenyl chain with the cell membrane of bacteria as a possible mechanistic explanation for the 
observed activity [18]. However, the anti-bacterial effect of chalcones is not restricted to 
MRSA strains. Also, Micrococcus luteus, Staphylococcus epidermis, Bacillus subtilis [19] and 
further strains [20–23] were inhibited by chalcones. Not only antiviral [24,25], but also 
anti-plasmodial effects [25,26] were observed during the pharmacological investigation of 
chalcones. The anti-plasmodial effect was observed only for a few natural chalcones such as 
licochalcone A [27] and uvaretin [28]. Thus, new anti-plasmodial chalcones were mainly 
developed through synthesis [27]. Licochalcone A also showed an inhibitory effect on 
Leishmania major and Leishmania donovani [29]. In addition, chalcones such as geranyl 
substituted chalcones from Artocarpus nobilis THW. [30], aurentacin A from Myrica serrata 
LAM. [31], isobavachalcone from Maclura tinctoria (L.) D.DON EX STEUD. [32] and 
licochalcone A [33] showed anti-fungal activity. However, chalcones were also active against 
cancer and inflammation. 
 
Cancer can occur in several places in the organism. It is an independent up regulation of cell 
growth from the neighbor cells and invasion as well as the spread into other 
compartments/tissues of the organism. There are more than 100 types of cancer with 
different characteristics. The molecular mechanisms differ between the cancer types [34]. 
Beside the different cancer characteristics the stages of carcinogenesis can be classified 
equally. First a cell must mutate to turn up its growth independently from its environment 
(initiation). Without an intervention the cell may proliferates further (promotion). After the 
promotion malignant cells can leave the side of origin and metastasize into other tissues 
(progression). These stages are possible points of attack. For example the inhibition of 
growth might inhibit the promotion of cancer. With this cancer stage subsumption, potent 
anticancer substances can be classified. Understandably, the initiation, promotion and 
progression are stages of cancer that are not separated from each other. For example the 
apoptotic action of compounds during the promotion stage might also be beneficial in the 
progression of cancer. The cancer stage model is quite simple and today a complex and 
multi process of carcinogenesis is discussed [35]. Nevertheless, for the effect classification of 
compounds, the initiation, promotion and progression cancer stage model is used in the 
literature (e. g. [36]) and in this thesis. 
“Chemoprevention is the use of pharmacologic or natural agents that inhibit the development 
of invasive cancer either by blocking the DNA damage that initiates carcinogenesis or by 
arresting or reversing the progression of premalignant cells in which such damage has 
already occurred” [37]. In the initiation stage chemoprevention is often attributed to 
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anti-oxidative and anti-inflammatory properties, and the ability to induce phase II and inhibit 
phase I enzymes [36,38,39]. Therefore, anti-oxidative and anti-inflammatory effects of 
chalcones were studied in different bioassays. Some chalcones were able to spread 
chemopreventive effects such as panduratin A [40], isoliquiritigenin [41] and xanthohumol 
(XN) [36]. 
Usually inflammation is a temporary physiological reaction, but in some cases inflammation 
remains and leads to a chronic disease. Chronic inflammation is correlated with higher risk to 
initiate cancer [34] and is therefore correlated with the initiation cancer stage for example. 
Several common chalcones were screened concerning their ability to inhibit inflammation 
such as licochalcone A, butein and hydroxysafflor yellow A (HYSA). The investigated 
chalcones were able to influence and inhibit inflammation through different mechanism such 
as inhibition of NF-κB [42] but also had anti-oxidative activity. Liquiritigenin, for instance, 
showed moderate activity against LDL peroxidation [13] whereat butein showed remarkable 
effect as scavenger of reactive oxygen species (ROS) [43]. 
The other main ability of chemopreventive compounds is to induce phase II and to inhibit 
phase I enzymes of the biotransformation. During the biotransformation, enzymes convert 
lipophilic compounds into more hydrophilic ones. In doing so, phase I enzymes activate the 
compound and phase II transfer hydrophilic groups. Chalcones were found to be more potent 
phase II inducers than phase I inhibitors. CYP3A4 was inhibited by isoliquiritigenin at an IC50 
value of 29 µM (IC50 values without a standard deviation (SD)) [44] and the mRNA level of 
CYP1A1 was decreased by phloretin in combination with an CYP1A1 inducer in the human 
colorectal cell line (Caco-2) at 100 µM [45]. However, Kinghorn et al. [46] reviewed its 
collaboration work on chemopreventive natural compounds. Several chalcones induced the 
phase II enzyme NAD(P)H:quinone reductase (QR) such as flavokawain B (concentration to 
double induction (CD) of QR = 1.7 µg/ml, mouse Hepa 1c1c7) [47] and isoliquiritigenin (CD of 
QR = 0.7 µg/ml, mouse Hepa 1c1c7) [48], (CD of QR = 2 µM, mouse Hepa 1c1c7) [49]. 
Further phase II enzymes such as the heme oxygenase-1 (HO-1) and the glutathione 
S-transferase (GST) were also affected by different chalcones. After 24 h treatment with 
25 µM butein the mRNA level of GST in rat primary hepatocytes increased to 211% and the 
enzyme activity by 27%, for instance [50]. After 12 h 10 µM isoliquiritigenin induced the HO-1 
mRNA as well as HO-1 protein levels in RAW 264.7 macrophages [51]. 
After cancer is initiated, the growth and proliferation of cancer can be affected. This concerns 
the induction of cell death in cancer cells and the inhibition of the inflammatory process in the 
environment of cancer. Depending on the types of cancer, the inhibition of inflammation can 
inhibit cancer and is thus a point of attack. Chalcones are potent anti-inflammatory drugs as 
mentioned before and are additionally able to induce cell death in cancer cells, like alpinetin 
chalcone [52], phloretin [53] and isoliquiritigenin [54]. There are different cell death 
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mechanism such as necrosis, apoptosis and autophagy. The mechanism of cell death 
induction by chalcones was investigated in different assays. Chalcones such as butein, 
licochalcone A [55], phloretin [56] and uvaretin [57] induced cell death in cancer cell lines via 
apoptosis. Isoliquiritigenin triggered adenoid cystic carcinoma cells into death through 
apoptosis and autophagy [58]. Furthermore, the activity to inhibit cancer growth in vivo was 
also studied for some chalcones, like isobavachalcone. Isobavachalcone inhibited the skin 
carcinogenesis induced by 7,12-dimethylbenz[α]anthracene and promoted via 12-O-
tetradecanoylphorbol-13-acetate in mice [59]. 
The difference between a benign and malignant cancer is the ability to metastasize, invade 
and induce angiogenesis [34]. Therefore, the inhibition of this ability is a target in order to 
affect cancer. Isoliquiritingenin, for instance, showed anti-angiogenetic [60] and 
anti-metastatic ability [61] as well as butein [62,63] and licochalcone A [64,65]. 
Apart from the anti-infective and anti-cancer effects of chalcones, other beneficial effects 
were observed such as the influence of phlorizin, kuraridin, iso- and bavachalcone on the 
carbohydrate metabolism [66–69], the effect on osteoporosis of licochalcone A and 
isoliquiritin [70,71] and the influence of butein, licochalcone and kuraridin on 
hyperpigmentation [72,73]. Furthermore, isoliquiritin spread effects, in the estrogen 
metabolism and is judged as a phytoestrogen. In addition to these effects the ability to 
protect cells was determined, too. HSYA protected pheochromocytoma cells against 
apoptosis induced by oxygen and glucose deprivation in a dose dependent manner [74] and 
spread neuroprotective effects in vivo and in vitro [75]. 
Chalcones influenced positively the aforementioned abilities which were mostly determined 
in in vitro bioassays. In order to spread the activity also in vivo, the required concentration 
has to be reached. Therefore, bioavailability and metabolism studies were conducted to 
determine the behavior of HSYA [76,77], isoliquiritigenin [41] and butein [78], for instance. 
The absorption after oral intake of HYSA was determined in rats and humans and showed 
after ingestion of 100 mg/kg in rats and 100 mg HSYA in humans serum levels of 
8.27 ± 0.38 µM HSYA [76] and 0.13 ± 0.01 µM HSYA [77] respectively after 1 h. The 
observed discrepancy concerning the values is due to species related aspects and different 
amounts of ingestion. However, the serum levels of HSYA in rats reaches the impressive 
concentration of 8.27 ± 0.38 µM and might therefore be suitable to spread the determined 
in vitro effects. 
 
Chalcones showed a wide range of biological and pharmacological abilities such as 
anti-infective, anti-oxidative and anti-cancer. Thus the activity of XN, a prenylated chalcone 
of hops [79], was also investigated in different bioassays (1.1 Xanthohumol). XN spread 
activity in a variety of in vitro assays and is a compound with multifunctional abilities. 
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Therefore, the effects of XN were investigated in a variety of in vivo models to determine the 
activity, absorption and the metabolism. 
 
1.1. Xanthohumol 
XN is accumulated in female inflorescences of Humulus lupulus L. (Cannabinaceae) and was 
isolated by different research groups [79,80]. 2005 Jung and co-workers identified 
Sophora flavescens as second plant source of XN [81]. XN as the most abundant prenylated 
chalcone in the resin of leaf glands of hops account for 80-90% of the chalcones, and is 
accompanied by desmethylxanthohumol (2-3%), xanthohumol C (2-4%), xanthohumol B 
(3-5%) and isoxanthohumol (<1-2%) [12] as well as one further secondary metabolite named 
xanthogalenol [82]. Xanthogalenol was found in American (Humulus lupulus var. cordifolius) 
and Japanese hop cultivars, but was absent in European and southwest American plants. 
This pointed to at least two separate lineages [82]. In humans nutrition prenylated chalcones 
could be found as an ingredient of beer. XN content differ in bearer as well as in the beer 
sorts, because of spontaneous decomposition or environmental impact. The XN 
concentration was determined in different hop products such as pellets, ethanolic and CO2 
extracts [83] and beer sorts [84]. The ethanolic extracts contained 3.75 ± 0.05 g XN/100 g 
and were the richest in XN. In comparison 0.62 ± 0.01 g XN/100 g was found in pellets and 
0.089 ± 0.001 g XN/100 g in the CO2 extracts. Imported lager contained 0.002 mg/l 
equivalent to 0.01 µM XN (isoxanthohumol 0.04 mg/l) and American porter 0.69 mg/l 
equivalent to 1.95 µM XN (isoxanthohumol 1.33 mg/l) [84]. However, at least 95% of XN is 
lost during the brewing process [85]. There are four main reasons for the loss of XN. First, 
XN is converted to isoxanthohumol during the wort production. Second, the hydrophobic 
properties of XN lead to an inefficient extraction from hops, third the adsorption to malt 
proteins and extraction with the filtered trub [9] and at least the water solubility is low. 
Wunderlich et al. [85] achieved a much higher finale XN concentration of up to 10 mg/l in 
dark beer, by changing the brewing process in few ways. They used XN enriched hop cones, 
added the hop cones 5 min before the end of word boiling and used intensively roasted malt. 
 
Since 1997 XN has been tested in a variety of assays and has been described in 120 
published articles (pubmed since 1997 - search properties “xanthohumol”). XN was found to 
be a chalcone with a broad spectrum of pharmacological effects. Examples include 
anti-infective, anti-obesity, anti-osteoporotic, anti-oxidative, chemopreventive, 
anti-inflammatoric effects as well as pro-apoptotic effects in cancer cell lines and tumor cells. 
XN is able to inhibit cancer initiation, promotion and progression by blocking of metastasis, 
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invasion and angiogenesis. Furthermore XN was found to have beneficial effects on normal 
cells (1.2 Safety studies). 
 
cells
cancer cells
Anti-infection
− Anti-bacterial
− Anti-viral
− Anti-fungi
− Anti-protozidal
− Anti-cocoidal
Anti-inflammation
− NF-κB inhibition
− Inhibition of   
Inflammatory enzyme,
factors
− Inhibition of JAK/STAT
Anti-apoptosis
− Erythrocytes
Chemoprevention
− Inhibition of  CYP 450
− Induction of  phase II 
enzymes  
− Estrogen modulator
Pro-apoptosis
− ROS inducer
− Akt, NF-κB inhibition
− Induction pathways 
s. figure 1-7  
Anti-invasion
− E-cadherin/catenin
− Pro-apoptotic
Anti-metastasis
− Inhibition of MMP  XN
O
OH
O
OHHO
Anti-angiogenesis
− Akt, NF-κB inhibition
− VEGF inhibition
Anti-oxidation
− Scavenger of hydroxyl
and RNS radicals
Anti-obesety
− Inhibition of DAGT
− Inhibition of TG 
synthesis, packaging
− Influence of FXR
− …
 
 
Figure 1-3: Summary of XN effects and mechanism (in vitro) on cells and cancer cells. XN lead 
to a wide range of abilities as it is displayed. The effects are grouped and the roughly outlined 
mechanism is listed beyond. The groups cannot be seen as bordered and might overlap. For 
the sake of clarity the groups were divided and overlapping effects were not noted in each 
group. 
 
XN has anti-infective activity such as anti-bacterial, anti-viral, anti-plasmodial, anti-protozoal 
and anti-coccidial against different microorganisms. 
 
1.1.1. Anti-infective activity 
1.1.1.1 Anti-bacterial activity 
Anti-infective activity is a well established investigation and a benefit in the development of 
diverse application e.g. mouthwash or in teas for treatment of a sore throat. XN was studied 
in several anti-infective assays and exhibited inhibition on the growth especially of gram 
positive bacteria. Different studies were conducted to detect the MIC, to investigate if XN 
spread a low MIC and could be used for the treatment of e.g. dental caries [86] and 
acne vulgaris [87]. Bhattacharya et al. [86] determined the MIC of XN for 
Streptococcus mutans, which are the main initiators of dental caries. XN (MIC of 12.5 µg/ml 
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(35.3 µM)) inhibited the growth of S. mutans and exhibited a stronger antibacterial activity 
than thymol (MIC of 150 µg/ml (999 µM)) at pH 7.5. Additionally, XN was found to have 
anti-bacterial activity against Streptococcus salivarius and Streptococcus sanguis [86] too. 
Staphylococcus aureus is one of the normal substituents of our bacterial flora present in the 
nasal passages and perineum [88]. Usually S. aureus causes no infection in humans with an 
intact immune system, but in abnormal terms, it can induce harmless skin disease as well as 
critical diseases such as pneumonia. XN was tested concerning its effects on S. aureus and 
showed MIC of 6.25 µg/ml (17.6 µM) [89]. 
In a further study, XN was tested concerning the growth inhibition of MRSA and their virulent 
factor staphyloxanthin [90]. The results indicated an inhibition of MRSA staphyloxanthin by 
XN, but no effects on their growth. Staphyloxanthin, a carotenoid pigment, is a virulent factor 
that exhibits anti-oxidative properties. Staphyloxanthin reacts with reactive oxygen species 
from the immune system and renders them harmless [91]. XN might be therefore indicated 
as co-treatment because it reacts with staphyloxanthin and this might lead to a more 
effective action of the immune system. 
XN was also tested for the treatment of acne vulgaris. Acne vulgaris is a dermatological 
disease and has four main pathological factors: Follicular hyperkeratosis, increased sebum 
production, Propionibacterium acnes colonization and inflammation. Each pathological factor 
can be treated with different therapeutics [92,93]. XN as a known anti-bacterial agent, was 
tested concerning its effect on the acne vulgaris strains Propionibacterium acnes, 
Staphylococcus epidermis, Staphylococcus aureus, Kocuria rhizophila and 
Staphlycoccus pyogenes [87]. XN showed anti-bacterial activity against these strains and 
thus might find application in the treatment of acne vulgaris in the future. 
 
1.1.1.2 Anti-fungal activity 
Anti-infective activity also includes anti-fungal activity. XN was examined in anti-fungal 
assays, but has shown low effectiveness so far. E.g. Mizobuchi et al. [89] investigated the 
pathogenicity of five fungi during stimulation with XN. Two fungi that were investigated 
usually induce dermatosis: Trichophyton mentagrophytes and Trichophyton rubrum. In 
addition Candida albicans that usually causes candidosis, Fusarium oxysporum a plant 
pathogenous that causes fusariosi and Mucor rouxianus were investigated. 
T. mentagrophytes and T. rubrum were both inhibited with a MIC of 8.83 µM XN. 
M. rouxianus was inhibited with a MIC of 141.08 µM XN. No inhibitory effect was observed 
during the incubation of C. albicans and F. oxysporum with XN. 
Srinivasan et al. investigated the inhibitory effect of XN and other hop components on mold 
fungi [94]. XN showed only anti-fungal activity against Rhizopus nigricans, a producer of 
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bread mold [95]. Unfortunately the results within the tables 9 and 10 are not included in the 
paper and are replaced by the IC50 values of anti-plasmodial results. Furthermore, they 
measured an effect by R. nigricans and Penicillium roqueforti in the disc diffusion test at 
200 µg/disc. Srinivasan et al. [94] described the disc diffusion assay as a screening method 
for potential anti-fungal compounds, but the outcome of the assay is not valuable enough for 
effective determination of an inhibitory concentration. 
 
1.1.1.3 Anti-viral activity 
The anti-viral potency of XN was determined against several RNA and DNA viruses [96]. XN 
was found to inhibit bovine viral diarrhea virus (BVDV) at IC50’values of 4.80 ± 3.95 µM, 
herpes simplex-1 (HSV-1) at IC50’values of 7.05 ± 1.58 µM, herpes simplex-2 (HSV-2) at IC50 
values of’7.62 ± 4.80 µM and cytomegalovirus (CMV) at IC50 values of’1.5 ± 0.35 µM. The 
therapeutic dose of a compound also called therapeutic index (TI) is calculated by division of 
the toxic concentration and the inhibitory concentration. The RNA virus BVDV reached an IT 
of 4.2 and the DNA viruses HSV-1 of 3.7, the HSV-2 of 6.3 and CMV of 2.6. In comparison 
with the inhibition of the four viruses before, XN were more potent than IXN. But IXN showed 
activity in the RNA rhino virus at IC50 values of’18.62 ± 9.31 µM (XN not reached). Comparing 
the studies of Buckwold´s et al. [96] and Wang et al. [97] the results differ concerning the 
activity at the HIV-1 RNA virus. Wang et al. [97] described an activity of XN at the HIV-1 
virus. In contrast to this result, Buckwold et al. [96] report no effects using an extract enriched 
with 8.4% (w/w) XN. Pure XN was not tested. Wang et al. [97] showed that XN inhibited the 
HIV-1 induced cytopathic effect at EC50 0.82 µg/ml (2.00 µM). The production of viral p24 
antigen at EC50 1.28 µg/ml (3.21 µM) and the reverse transcriptase at EC50 0.50 µg/ml 
(1.22 µM) in C8166 lymphocytes, were described to be inhibited too. They also found an 
inhibition of the HIV-1 replication at EC50 of 20.74 µg/ml (50.55 µM) and a TI of 10.8 in 
peripheral blood mononuclear cells (without a SD). However, XN exhibited no effect on 
recombinant HIV-1 reverse transcriptase and the HIV-1 entry, thus a possible inhibition of 
enzymes concerning the after transcription period was discussed [97]. 
As already mentioned, XN showed inhibitory activity also at the BVDV. In a study conducted 
by Zhang et al. [98] this activity was determined in a surrogate model for the hepatitis C virus 
(HCV) on the basis of primary calf testis cells. The activity of XN was compared to ribavirin 
and interferon-α. Ribavirin a nucleoside analogous and interferon (IFN)-α (pegylated) are 
used in combination or on its own in the therapy of chronically courses of the HCV [99]. XN 
was found to inhibit the replication of the BVDV and the cytopathic effect [96]. CT cells were 
incubated with BVDV at 1000 tissue culture inhibition dose of 50% (TCID50) and 100 TCID50. 
The determined EC50 of XN was 3.24 ± 0.02 mg/l (9.14 ± 0.06 µM at 1000 TCID50) and 
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2.77 ± 0.19 mg/l (7.82 ± 0.54 µM at 100 TCID50) with a TI of 7.72 and 9.03, respectively. An 
inhibition of E2 expression and the viral RNA levels were described too. However even 
higher concentrations of XN could not eliminate the viral RNA completely. The effectiveness 
of XN was better compared to ribavirin but worse compared to IFN-α [98]. In a second study 
of the same group, a possible synergistic effect of XN and IFN-α was assayed. The 
combination of both showed a significant (p< 0.001) better inhibitory effect than either 
substance on its own [100]. The life cycle of the HCV is dependent on the lipid metabolism. 
XN interacts with different enzymes within the lipid metabolism (1.1.2 Anti-obesity activity) 
such as DGAT and MTP. Zhang et al. [98] explained a possible inhibitory mechanism of HCV 
via DGAT and MTP inhibition by XN. 
 
1.1.1.4 Anti-protozal activity 
Protozoa are grouped in the termini of eukaryota [95]. The group of protozoa exhibits a cell 
nucleus and some are able to move. Some protozoa are known as pathogens for human and 
animals. They can induce different diseases such as leishmaniosis, amoebiasis, malaria and 
toxoplasmosis [99]. Plasmodium falciparum, one of three inducers of malaria, is responsible 
for estimated 665.000 malaria deaths in 2012 [101]. Plasmodium falciparum is passed 
through a bite of the Anopheles mosquito. Different malaria treatments are available, that 
affect the life cycle of P. falciparum, e.g. with chloroquine. Chloroquine inhibits the haem 
polymerase, an enzyme that induces the polymerization of haemin in the digest vacuole of 
P. falciparum. For quite some time, physicians and researchers have been confronted with 
the chloroquine resistance. The chloroquine resistance is attributed to the mutation of 
P. falciparum chloroquine resistant transporter (PfCRP), which is located in the digest 
vacuole membrane [102] and significantly reduces the chloroquine concentration. 
Three groups tested the ability of XN to inhibit P. falciparum of chloroquine-sensitive (CS) 
and chloroquine-resistant (CR) strains. In the study of Herath et al. [103] two fungi were used 
to produce four XN metabolites. In the next step they investigated the anti-plasmodial and 
cytotoxic effects of XN and the produced metabolites. Both strains were fragile to XN, at an 
IC50 value of 9.31 µM (CS) and at 2.82 µM (CR) (IC50 values without SD)) which were 
determined by a lactate dehydrogenase assay (LDH). Notably XN has a stronger ability to 
inhibit the CR than the CS strain [103]. 
In a second study, Frölich et al. [26] investigated the inhibitory activity of XN, 6 different XN 
metabolites and chloroquine on P. falciparum. The [3H]hypoxanthine assay was used to 
determine the IC50 values. An IC50 value of 8.2 ± 0.3 µM (CS) and an IC50 of 24.0 ± 0.8 µM 
(CR) were determined for XN. The IC50 values determined for chloroquine 
were 0.015 ± 0.002 µM (CS) and IC50 0.14 ± 0.012 µM (CR) respectively. Among the test 
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compounds XN was the most potent inhibitor of the CS strain in this study. 
Dihydroxanthohumol C (see Figure 3-1) was the most potent inhibitor of the CR strain. The 
authors proposed that the anti-malarial activity of chalcones is based on binding haemin. The 
ability to bind haemin was evaluated in a GSH-haemin interaction assay. XN bound to 
approximately 60% haemin, chloroquine up to 80% and dihydroxanthohumol C to less than 
5% compared to the drug free control [26]. 
In a third study, the inhibition of CS and CR plasmodium strains by a combination of XN and 
CO2 was investigated [94]. Unfortunately the plasmodium strain number is not mentioned 
and the reference of the used method for the determination of IC values is incorrect. 
However, a 61% inhibition of the CS plasmodium strain by XN was achieved at a XN 
concentration of 5.64 µM (3% CO2). In a further experiment they changed the CO2 
concentration and investigated both the CS and the CR strain. The study revealed an 
inhibition of 47% (3% CO2) and 61% (5% CO2) for the CS strain, and 40% (5% CO2) for the 
CR strain. In the second part of this study the ability to cause death of different protozoa was 
determined in a time dependent manner. The protozoa investigated were 
Paramecium candatum also known as slipper animalcules and Chaos sp. that belongs to the 
amoebae. XN exhibited activity against both protozoa [94]. 
Summing up, XN exhibits inhibitory activity against gram positive bacteria, some fungi strains 
and viruses. Furthermore XN exhibits inhibitory effects against P. falciparum, which cause 
malaria. XN was also tested concerning its activity against the initiation, promotion and 
progression of cancer as well as the activity against obesity. 
 
1.1.2. Anti-obesity activity 
Hyperlipidemia and –glucosemia are indicators for insulin resistance, which is often a 
consequence of obesity. Diabetes mellitus II, the metabolic syndrome, and atherosclerosis 
are rising problems worldwide [104]. In this context, XN´s influence on the carbohydrate 
metabolism was investigated by different research groups. Tabata et al. [105] investigated 
the ability of XN to inhibit the enzyme diacylglycerol acyltransferase (DGAT). DGAT 
catalyzes the last step within the triacylglycerol synthesis. XN showed an inhibitory effect in a 
rat liver microsomal radioactive assay at a concentration of 50.3 µM (IC50 values without a 
SD) [105]. 
XN´s effect on the uptake of [14C]-oleic acid, the synthesis and amount of triacylglycerides, 
the synthesis of cholesterol esters, the accumulation of lipid droplets, the cell proliferation 
and the cell motility was investigated under normoxia (21% O2) and hypoxia (1% O2) by Goto 
et al. [106]. An increase in the synthesis of triacylglycerides, cholesterol esters and the 
accumulation of lipid droplets was observed under hypoxic conditions. The incubation with 
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XN (3 µM) under hypoxia decreased the aggregation of lipid droplets, the proliferation and 
the cell motility. The inhibitory effect of XN was solely observed under hypoxic conditions and 
was attributed to an inhibitory effect on enzymes necessary for the lipogenesis of 
triaclyglycerides. The synthesis and accumulation of neutral lipids such as triglyceride was 
attributed to the protection of pH decrease within the cancer cells and the survival. The 
decrease of pH is induced by the metabolism of glucose to lactic acid under hypoxic 
conditions [106]. 
Because of the lipophilic character of triglycerides and the amphiphilic character of 
phospholipids, cholesterols and cholesterol esters cannot be transported in the blood stream 
on their own. They are packed in so-called lipoproteins. Lipoproteins are separated in two 
segments, a shell and a core. The shell is composed of phospholipids, apoproteins and 
cholesterol. It separates the lipophilic core from the hydrophilic blood and has an amphiphilic 
character. The ratio between triglycerides, cholesterol esters, proteins and phospholipids 
depend on the lipoprotein species. For the assembling of lipoproteins with apoprotein B the 
chaperon microsomal triglyceride transfer protein (MTP) is indispensible. MTP consist of 
three active domains. The first is involved in the transfer of triglycerides from the microsomal 
lumen into the lumen of the endoplasmatic reticulum (ER). The second is associating to the 
membrane of the ER and the third binds to apoprotein B [107]. 
The effect of XN on the secretion of apoprotein B, the synthesis and secretion of triglyceride, 
the activity of MTP and DGAT in HepG2 was described by Casaschi et al. [108]. At a 
concentration of 15 µM, XN decreased the synthesis and segregation of triglycerides in the 
presence or absence of oleic acid. This effect was attributed to an inhibition of DGAT. In 
addition to the lowered triglyceride synthesis, the accumulation of triglycerides was inhibited 
to 37% in the cytosol and 64% in the microsomal lumen. A diminished availability of 
triglycerides may lead to an inhibition of the lipoprotein assembling. Besides the influence of 
XN on the triglyceride levels a decreased apoprotein B secretion at a concentration of 5, 10 
and 15 µM XN was detected. Again the observed effects were detected whether or not oleic 
acid was added. The apoprotein B secretion e.g. at a concentration of 15 µM XN was 
lowered to 43 ± 2% (- oleic acid) and 31 ± 2% (+ oleic acid). The authors discussed that 
apoprotein B might be depleted through proteasomes, because the highest recovery of 
apoprotein B was found for the control cells. Further results showed an inhibition of the MTP 
activity of 30 ± 1% (- oleic acid) at a concentration of 25 µM XN and 30 ± 4% (+ oleic acid) at 
a concentration of 15 µM XN [108]. 
In another study the ability of XN to interact with the farneosid X receptor (FXR) was 
investigated in a transient transfection assay using HepG2 cells transfected with the human 
bile salt export pump (BSEP). Additionally the influence of XN on the FXR in KK-Ay mice was 
investigated. In HepG2 cells XN induced the activity of luciferase and pointed to an agonistic 
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effect on FXR [109]. FXR is a bile acid receptor and down-regulates the activity of 
cholesterol-7-hydroxylase (CYP7A1). CYP7A1 converts cholesterol into bile acids via the 
small heterodimer partner (SHP) [110]. FXR were shown to exhibit important function for the 
bile acid and lipid homeostasis [111]. The effect of XN on KK-Ay mice suffering from diabetes 
mellitus, hyperinsulinemia, hyperglycemia and hyperlipidemia was investigated by Nozawa et 
al. [109]. The KK-Ay mice showed lower water intake, reduced white adipose tissue, reduced 
plasma glucose levels and reduced TG levels. In addition an increase of the adiponectin 
concentration was observed. Adiponectin is excreted in adipocytes and leads to a higher 
uptake of insulin, β-oxidation in skeletal muscle and adipose tissue, and an inhibition of 
glucose excretion from hepatic cells [112]. The reduction of the TG and glucose 
concentrations was attributed to an increased adiponectin production after XN feeding of 
KK-Ay mice. In order to verify if XN acts through the FXR in vivo, the liver of the KK-Ay mice 
were analyzed. In doing so the expression levels of the downstream proteins of the FXR 
were determined by real-time PCR. The obtained results from the liver did not confirm the 
results obtained in vitro in the transient transfection assay transfected with the human BSEP 
in HepG2 cells. Compared to the control group, the mRNA concentrations of the liver 
proteins BSEP and SHP were reduced. The amount of mRNA of the CYP7A1 was 
significantly increased and thus implicated that XN may act as an antagonist on FXR. As 
described above FXR is a bile acid receptor and down-regulates the activity of CYP7A1. The 
mRNA levels of Sterol regulatory element binding protein (SREBP) 1c were reduced during 
the stimulation with XN [109]. The transcription factor SREBR-1c is involved in the lipid 
metabolism of fatty acids and cholesterol. Furthermore it is downregulated in obese humans 
and is than upregulated after weight loss [113]. Interestingly, no effect on the cholesterol 
concentration in the liver could be observed [109]. 
In order to investigate the influence of XN on the live death cycle and the level of 
adipogenetic factors such as peroxisome proliferator-activated receptor γ (PPARγ), 
CCAAT/enhancer binding protein α (C/EBPα), adipocyte lipid binding protein (aP2) of 3T3-L1 
mouse embryo fibroblasts, the cells were stimulated with XN concentrations. [114]. The 
performed western blot showed that all aforementioned proteins were diminished. These 
proteins are involved in the differentiation of adipocytes [115]. In addition to an inhibitory 
effect of XN on the proteins of the adipogenesis, the inhibition of the DGAT 1 could be 
confirmed [114]. 
In a second study, the effect of XN with and without the lignane honokiol of 
Magnolia officinalis REHD. et WILS on apoptosis of 3T3-L1 mouse embryo fibroblasts was 
determined [116]. Obesity is associated with diabetes mellitus II, the metabolic syndrome, 
and atherosclerosis, which are diseases with increasing death causes worldwide [104]. 
Obesity is defined as a body mass index of 30 kg/m2 or higher [117] combined with an 
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increase in adipocytes number and storage volume of triglycerides [118]. One therapy 
strategy of obesity might be the induction of apoptosis in adipocytes to limit the fat storage 
[118]. The inhibition of the cell viability by the induction of apoptosis, which was described in 
the study of Yang et al. 2007 [114] could not been confirmed at XN concentrations up to 50 
µM in the second study of Yang et al. 2008 [116]. Further experiments with higher XN 
concentrations were not conducted. However the stimulation with XN in combination with 
honokiol resulted in an increased apoptosis and decreased cell viability of 3T3-L1 mouse 
embryo fibroblasts [116]. 
Mendes et al. [119] investigated the influence of XN on the differentiation of preadipocytes to 
adipocytes. In doing so the effect of XN on the time dependent inhibition of the lipid content, 
the apoptosis, the Ki-67 levels (proliferation marker [120]) and the nuclear factor kappa light 
chain enhancer of activated B-cells (NF-κB) was determined in preadipocytes and adipocytes 
[119]. XN did not influence the lipid content in differentiated adipocytes. However XN 
decreased the lipid content in adipocytes if the preadipocytes were incubated with XN. XN 
significantly increased the amount of apoptotic cells in adipocytes compared to the 
preadipocyte. In addition, XN led to a decrease of the Ki-67 expression in preadipocytes. In 
contrast to Zhang et al. [118] Mendes et al. [119] discussed the decrease of adipocytes 
number contrary. The XN induced decrease of adipocytes number may lead in adipocyte 
hypertrophy. Adipocyte hypertrophy is correlated with insulin resistance, lower adiponectin 
levels and may lead to lysis of the cells. The latter can lead to infiltration of macrophages and 
inflammation. In addition to the performed experiments the level of the inflammatoric 
transcriptional factor NF-κB was determined in the preadipocytes and adipocytes. Increased 
NF-κB levels were found in preadipocytes. No effect on the NF-κB level could be observed in 
adipocytes [119]. 
Summing up, XN was shown to affect the carbohydrate metabolism as well as the 
expression and activity of DGAT in variety of model systems. XN led to a lower lipid 
accumulation and a lower apoprotein B secretion. In addition, XN was shown to induce 
apoptosis in adipocyte cell culture systems. 
 
1.1.3. Anti-osteoporosis activity 
During the menopause and the post menopause the estrogen level decreases. Decreased 
estrogen levels can lead to a variety of pathophysiological effects such as cardiovascular 
diseases, osteoporosis and furthermore non-critical unpleasant climacteric compliance. In 
order to overcome the estrogen deficiency, a hormone replacement therapy was introduced. 
At first a combination of estrogen or estrogen in combination with gestagen was and is the 
therapy of choice [99]. However, an increased risk for mamma carcinoma was observed for 
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the ingestion with estrogen and cardiovascular diseases was correlated with the intake of 
estrogen in combination with gestagen [99]. Additionally, women also use herbal drugs in 
order to relieve the detrimental and painful effects associated with the decreased estrogen 
levels. Extracts of Cimicifuga racemosa (L.) NUTT. [121], Glycine max (L.) MERR. [122] and 
Humulus lupulus L. (literature see below) were found to be promising therapy options. 
Several of their secondary metabolites can be assigned to the group of selective estrogen 
receptor modulators (SERMs). SERMs induce agonistic and antagonistic effects at α and β 
estrogen receptors. Thereby SERMs might positively influence bone homeostasis without 
negatively affecting endometric proliferation. The effects of SERMs depend on the affinity of 
the ligand at its receptor and the structure of the formed ligand-receptor complex binding to 
the estrogen response element [99]. 
8-Prenylnaringenin (8-PN) is the most abundant phytoestrogen in H. lupulus. XN and IXN 
showed no or less activity compared to estrogen [123]. However IXN was found to be a 
proestrogen, because it is converted to 8-PN by the gut microflora and CYP 450. XN was 
found to be spontaneously converted to IXN (1.3 Bioavailability, metabolism). However, XN 
showed noteworthy effects in the prevention of osteoporosis. Osteoporosis is correlated with 
a degradation of bone mass and a change in the bone architecture. These 
pathophysiological conditions can lead to nontraumatic fractures of the vertebral bodies and 
the femoral neck. Already in 1997, Tobe and co-workers [124] described the inhibition of 
bone resorption by XN and humulone in the pit formation assay. Effenberger and co-workers 
[125] investigated the affinity of XN and related metabolites to bind to α and β estrogen 
receptors. In addition, the influence of XN on the expression of down-stream proteins such 
as alkaline phosphatase, which is a bone formation marker, and IL-6 was investigated. In 
human osteosarcoma cells U-2 OS, transfected with the α and β estrogen receptor, the 
expression and activity of alkaline phosphatase was increased by XN. The expression of IL-6 
was decreased (U-2 OS ER α and β; U-2 OS ER α) [125]. 
The performed estrogen receptor affinity studies showed that XN (ER α: 1.94; ER β: 0.73) 
exhibit a three orders of magnitude lesser affinity to the estrogen receptor than 8-PN (ER α: 
1.53 x 10-3; ER β: 1.88 x 10-3). XN, 8-PN, 6-PN and IXN affected the expression of proteins 
such as alkaline phosphatase and IL-6 in a dose dependent manner. For example 8-PN 
exhibited the highest activity to induce alkaline phosphatase mRNA expression (in U-2 OS 
ER α cells) at a concentration of 0.1 (approximately 7.6 densitometry of the bands of 
RT-PCR without SD) and 1.0 µg/ml XN (approximately 11.2 without SD). At a concentration 
of 10 µg/ml the activity of XN to induce the alkaline phosphatase mRNA expression 
decreased (approximately 3.8 without SD). Thus Effenberger and co-workers [125] 
suggested a review of the suitable doses of herbal drugs. 
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In another study the effects of XN on osteoporosis related factors were investigated in a 
mesenchymal stem cell line [126]. Osteoblast markers, alkaline phosphatase, bone 
morphogenic protein 2, collagen type 1α, bone sialoprotein and osteocalcin were 
up-regulated after stimulation with XN. The osteoblast differentiation, the expression of 
Runt-related transcription factor 2 (RUNX2) and the transcriptional activity were increased 
via the p38 MAPK and the ERK pathway. RUNX2 is an essential transcription factor for the 
differentiation and the proper function of osteoblasts [127]. 
Summing up, XN is a potent osteoblast stimulus and might relieve the detrimental and painful 
effects associated with decreased estrogen levels during and after the menopause. 
 
1.1.4. Influence of XN on phase I and phase II enzymes 
The chemopreventive effects of substances are correlated with the ability to inhibit phase I 
and to induce phase II enzymes (see Chapter 1). Chemopreventive substances might inhibit 
the production of genotoxic substances such as heterocyclic aromatic amine e.g. 2-amino-3-
methylimidazol[4,5-f]quinoline (IQ), benzo(a)pyrene (BaP), 2-amino-1-methyl-6-
phenylimidazol[4,5-b]pyridine (PhIP), 2-amino-3,8-dimethylimidazol[4,5-f]quinoxaline 
(MelQx). IQ is activated in a two step reaction by the CYP1A/CYP1A2/N-acetyltransferase 
and sulfotransferase. During this reaction active genotoxic esters are formed [128]. 
The effect of XN on inhibition of genotoxicity was determined in different assays. Miranda et 
al. [129] investigated the ability of XN to inhibit the mutagenic effect of IQ using the Ames 
Salmonella assay. In addition, the ability of XN to inhibit the binding of IQ to DNA and 
proteins was determined in a radioactive assay. XN showed a significant inhibition at 10 µM 
in both assays [129]. 
In another study the cell based Comet assay (in HepG2) yielded comparable results. XN 
showed significant inhibition of IQ and BaP induced genotoxicity at 0.01 µM. XN itself 
showed no genotoxicity up to concentrations of 10 µM [130]. 
Viegas et al. [131] investigated the ability of XN to inhibit the genotoxicity of MelQx and PhlP. 
During co-incubation with MelQx and PhlP, XN showed protective effects at concentrations 
between 0.01-1 µM. DNA strand breaks were induced during the incubation with PhlP and 
XN at 10 µM. The authors discussed an additional prooxidative effect of PhlP and XN at 
higher XN concentrations [131]. 
The effect of XN to inhibit the genotoxicity of IQ was also tested in vivo. The foci 
(preneoplastic alteration) and the DNA damage of colon and liver were investigated in F344 
rats. XN inhibited genotoxic effects induced by IQ in both tissues [132]. 
HAA´s are metabolized in the organism to genotoxic intermediates through P450 enzymes 
(see above). Thus the ability of XN to affect phase I and phase II enzymes was discussed. 
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Phase I enzymes are responsible for the activation of drugs and thus permit a conjugation 
e.g. with glucuronic acid by phase II enzymes. Usually the conjugation enhances the 
hydrophilicity of compounds, thereby allowing the fast renal excretion of toxic metabolites 
[99]. Various studies were conducted in order to investigate the effect of XN on the phase I 
and phase II metabolism [36,131,133,134,135]. Henderson et al [133] investigated the effect 
of XN on the CYP 450 in microsomes of insect cells. XN inhibited the catalytic activity of 
CYP1A1 and CYP1B1. A moderate inhibitory effect was observed for CYP1A2. The activity 
of CYP2E1 and CYP3A4 was only poorly inhibited by XN [133]. An inhibitory effect of XN on 
the CYP1A was also detected in a cell-based assay in H4IIE rat hepatoma cells [36]. 
XN also induced the NAD(P)H:quinone reductase (QR) in murine hepatoma cell Hepa 1c1c7 
[36,134,135]. 
In an in vitro study Viegas et al. [131] determined the mRNA levels of phase I (CYP1A1, 
CYP1A2, NAT2, SULT1A1) and phase II (UGT1A1 and GSTA1) enzymes in HepG2 cells. 
The co-treatment with MelQx and XN led to dose dependent up-regulation of mRNA levels of 
all enzymes except of CYP1A2. The co-incubation with PhlP and XN led to an up-regulation 
of CYP1A2 and a down-regulation of GSTA1 [131]. Ferk et al. [132] did not observe 
differences in the activity of phase I and phase II enzymes in the liver of F344 rats after 
co-treatment with XN and QC [132]. However, it should be considered that in vitro results can 
hardly be compared to in vivo results. 
The mechanism of the QR induction by XN was investigated in several assays by different 
research groups [36,134,135,136,137]. It was found that XN is a monofunctional inducer of 
the QR. XN did not affect the induction of phase I enzymes [36,135]. In brief, Gerhäuser et 
al. [36] transfected Hepa 1c1c7 cells with plasmids that carry selective elements of the QR 
or/and phase I enzymes. The incubation of the transfected cells with XN showed an induction 
solely of the QR element. In another study conducted by Miranda et al. [135], the ability of 
XN to act as a monofunctional or bifunctional inducer was investigated in aryl hydrocarbon 
(Ah) receptor deficient Hepa 1c1c7 cells. XN induced the expression of the QR in the Ah 
receptor deficient cells. Thus it could be concluded that XN acts as a monofunctional inducer 
of the QR [135]. The expression of the QR in Ah receptor deficient cell lines is induced by the 
antioxidant response element (ARE). The transcription factor nuclear factor-erythroid 2 
(NF-E2)-related factor 2 (Nrf 2) is bound to Kelch-such as ECH-associated protein 1 (Keap 1) 
in the cytosol. After an electrophilic reaction of thiol groups of Keap 1 and/or the 
phosphorylation of Nrf 2, Nrf 2 is released to the nucleus. Nrf 2 binds to ARE with the small 
Maf and regulates the transcription of proteins such as the glutathione synthetase (GS), 
HO 1, SOD, QR and UDP-glucuronosyltransferase (UGT) [138] (Figure 1-4). The Nrf 2-
Keap 1 pathway is activated if cells are exposed to chemicals and oxidative stress. 
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Figure 1-4: Nfr2 Keap1 Pathway and the interaction with XN (the pathway is based on the 
information in [138]) 
 
The ability of XN to induce the ARE was investigated using a luciferase assay in HepG2 
cells. XN increased the response of the luciferase assay [134]. In order to investigate the 
effect of XN on the Nrf 2-Keap 1 pathway in detail, the alkylation of the Keap 1 was checked 
by mass spectrometry. XN alkylated the Keap 1 [134,136] and reacted mostly with the 
sulfhydryl group of C151 of the Keap 1 [137]. These results strengthened the theory that a 
Michael like reaction might be responsible for the induction of phase II enzymes. However, 
this might not be the full explanation. Miranda et al. [135] determined the structure-response 
relationship between prenylated and non-prenylated flavanones and chalcones. Flavanones 
without a prenyl group showed no QR induction. Prenylated flavanones led to a weak QR 
induction [135]. 
In a recent study XN was found to induce also the transcription of haeme-oxygenase 1 
(HO 1), which is a phase II enzyme [139]. HO 1 is correlated with anti-oxidative, 
anti-inflammatory and anti-proliferative properties [140]. 
Summing up, XN induces phase II enzymes such as the QR and HO 1 via the Nrf 2-Keap 1 
pathway. XN protects cells from genotoxic damage by HAAs. An inhibitory effect on phase I 
enzymes has to be confirmed in further in vivo experiments. 
1.1.5. (Anti)-oxidative effect 
Reactive oxygen species (ROS) are either radicals or non-radicals. ROS can lead to 
oxidation of substances and harmful reactions. There are also other types of reactive species 
such as reactive nitrogen, reactive chlorine and reactive bromine species [141]. The 
reactivity and harmfulness of radicals is dependent on the radical species. ROS such as 
hydrogen peroxide and superoxide radical anions exhibit a high reaction rate. However, they 
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are less harmful than hydroxyl radicals. Unfortunately there is no scavenger in biological 
systems that react preferentially with hydroxyl radicals [142]. 
In the respiratory chain of mitochondria, oxygen is needed to transfer electrons and build up 
water as well as ATP. During this process ROS can be released. It is for this reason that 
organisms built up defense mechanism in order to scavenge ROS. In a healthy organism the 
production and the scavenging of radicals is in balance. An overproduction of ROS can be 
induced by exogenic factors such as UV radiation and the uptake of toxic compounds such 
as cigarette smoke. In addition, ROS can be released during the response of the immune 
system, which is referred to as “respiratory burst”. Intracellular enzymes, that are known to 
produce ROS, include the cytochrome P 450, xanthine, and the NAPDH oxidase. ROS are 
also produced during the Fenton reaction [143,144]. ROS are correlated with the 
development and promotion of cancer as well as neurodegenerative and cardiovascular 
diseases. Humans exhibit various defensive strategies based on superoxide dismutase, 
glutathione peroxidase, ascorbic acid, α-tocopherol and glutathione. But the capacity of the 
body´s own defense is limited and ingestion of natural phenolic compounds, which exhibit an 
antioxidant activity, is claimed to be beneficial. Quercetin, one of the most potent scavengers 
of the flavonoids, exhibit three important structural characteristics for scavenging activity: the 
catechol structure of the B ring, the 2-3 diene structure and an oxo-structure in position 4 of 
the C ring [145]. 
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Figure 1-5: Quercetin is one of the most potent radical scavengers within the flavonoids. The 
catechol structure of the B ring, the 2-3 diene structure and a keto functionality in position 4 of 
the C ring [145] are important features for the scavenging activity. 
 
Chelation of metal cations, stimulation or inhibition of enzymes and neutralization of radicals 
can also lead to an anti-oxidant effect [142]. The anti-oxidant properties of XN were 
investigated in a variety of assays including the LDL peroxidation assay. The peroxidation of 
LDL is an essential factor for the formation of atherosclerosis. The oxidation of LDL can be 
assessed by the formation of diene and thiobarbituric acid-reactive substances (TBARS) 
[146,147]. 
A structure-response relationship study with 13 chalcones and the corresponding flavonoids 
as well as α-tocopherol was performed. XN showed anti–oxidant activity already at 5 µM. But 
XN`s anti-oxidant activity on the formation of dienes was lower compared to quercetin. 
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However, it was higher than that of the other tested compounds. Interestingly, the inhibition 
of the formation of TBARS was more effective if a combination of XN and α-tocopherol was 
used instead of each compound on its own [146]. 
In another, study the anti-oxidative properties of XN were compared to 12 polyphenolic 
substances in a liver microsomal lipid peroxidation assay and in rat hepatocytes. 
Fe2+/ascorbate, Fe3+-ADP/NADPH, and tert-butylhydroperoxide (TBH) were used as inducers 
for the lipid peroxidation. XN showed an anti-oxidant effect at 5 and 25 µM in the microsomal 
lipid peroxidation assay with Fe2+/ascorbate > Fe3+-ADP/NADPH >TBH. XN also inhibited 
cytotoxic effects induced by TBH in primary rat hepatocytes. In order to investigate the 
underlying mechanism of the protective effects of the compounds, two additional assays 
were performed. In doing so, their influence on the activity of the 
NADPH-cytochrome P 450-reductase and the chelation of iron was investigated. Quercetin 
showed an effect in both assays. XN did not show any activity. Thus XN has to act through 
another mechanism [148]. 
Stevens et al. [147] investigated the scavenging effect of several chalcones and flavonoids. 
In this study the inhibition of the LDL peroxidation, which was induced by 3-morpholino 
sydnonimine (SIN-1), was measured. The prenylated chalcones showed the highest 
anti-oxidant activity [147]. This correlation was also be observed by Miranda et al. [146] and 
Rodriguez et al. [148]. 
In addition to the structure-response relationship study, Stevens et al. [147] also investigated 
the structures of the XN metabolites, which were formed after incubation with SIN-1 and 
peroxynitrite. In the former set-up auronxanthohumol and endoperoxyxanthohumol were 
found to be the main XN metabolites. In the latter set-up solely endoperoxyxanthohumol was 
formed. Based on these results it was discussed that the α,β-unsaturated keto functionality of 
XN is important for the anti-oxidant activity. In addition the prenyl group has an electron 
donating effect, which on his part contributes to the anti-oxidant activity [147]. 
Peroxidation of erythrocytes leads to their immediate shrinkage followed by subsequent cell 
death. As a consequence of this, anemia, vascular injury and metabolic syndrome can occur. 
XN was tested concerning its potential to inhibit the peroxidation of erythrocytes by their 
co-incubation with TBH. XN was an inhibitor of the TBH induced lipid peroxidation [149]. 
In further studies the anti-oxidant activity of XN and XN metabolites were investigated in an 
oxygen radical absorbance capacity fluorescein assay (ORAC). In this assay set up 2,2′-
azobis(2-methylpropionamide) dihydrochloride (AAPH) is used for the generation of radicals 
and fluorescein as the fluorescent dye. The anti-oxidant activity is correlated with the 
inhibition of fluorescence decrease. The results are compared to the anti-oxidant activity of 
Trolox. XN showed lower anti-oxidant activity than ferulic acid and p-coumaric acid. XN 
exhibited 2.3 ± 0.2 Trolox equivalents in a concentration range of 0.25-1.5 µM [150–152]. 
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Ferulic acid exhibited 4.47 ± 0.21 Trolox equivalents in a concentration range of 0.3-1.0 µM 
[153]. These results compared well to the ORAC assay results obtained by Gerhäuser et al. 
[36]. 
Beside this ORAC assay, three more assays were performed in order to determine the 
anti-oxidant activity of XN. In the first assay the fluorescence decrease of β-phycocrythrins 
induced by hydroxyl radicals was studied. The hydroxyl radicals were formed with 
H2O2-CuSO4. This assay yielded 8.9 Trolox equivalents for XN at a concentration of 1 µM. In 
the second assay, the scavenging of superoxide radical anions formed from 12-O-
tetradecanoylphorbol-13-acetate (TPA) by XN was measured in differentiated HL-60 human 
promyelocytic leukemia cells. XN inhibited the superoxide radical anion production with an 
IC50 value of 2.6 ± 0.4 µM. In the third assay the inhibition of the superoxide formation was 
measured in a xanthine/xanthine oxidase assay. XN inhibited the superoxide radical anion 
production with an SC50 value of 27.7 ± 4.9 µM. The detection dye used in the 
xanthine/xanthine oxidase assay was nitro blue tetrazolium chloride (NBT). The 
concentration of NBT was 25 µM [36]. 
Schempp et al. [154] re-evaluated the anti-oxidant activity of XN in the xanthine/xanthine 
oxidase assay. In this study the anti-oxidant activity of XN disappeared at a concentration of 
100 µM NBT. The authors suggested that XN might form radicals upon autooxidation and 
thus scavenge the NBT radicals which are formed by the superoxide radical anions. A 
change of the detection system to cytochrome c confirmed that XN is not a superoxide 
scavenger [154]. 
Hartkorn et al. [155] investigated the ability of XN to affect the oxidation of luminol in vitro. 
The anti-oxidant activity was determined in a xanthine/xanthine oxidase assay. The 
determined IC50 value was 15 µM [155]. Schempp et al. [154] could confirm the results but 
discussed mismatches within the assay. XN can absorb light in wavelength range that 
includes the light emitted by luminol. In addition XN might scavenge the luminal radicals 
[154]. 
In the second part of the study of Hartkorn et al. [155], the influence of XN on the superoxide 
dismutase (SOD), 8-isoprostane, which is a marker for lipid peroxidation and GSH were 
studied under hepatic ischemia reperfusion conditions [155]. The hepatic ischemia 
reperfusion is an accepted model to investigate the anti-oxidant effects of compounds in vivo 
[156]. SOD and 8-isoprostane were positively affected by XN. But no influence on the GSH 
levels under hepatic ischemia reperfusion was observed. In addition NF-κB and Akt as well 
as the anti-apoptotic marker Bcl-xl, the proapoptotic marker caspase-3 and the liver injury 
markers aspartate aminotransferase (AST), alanine aminotransferase (ALT) were 
determined. The NF-κB and Akt level was not significantly decreased, whereas the level of 
the anti-apoptotic marker Bcl-xl was markedly reduced. After the ischemia reperfusion the 
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proapoptotic marker caspase-3 was increased. During the reperfusion period a slightly 
increase of AST, ALT and LDH was determined. A cytotoxic effect of XN in the hepatic 
ischemia and reperfusion system was discussed [155]. 
The production of superoxide radical anion in XN treated cells was also determined by the 
dihydroethidium to 2-hydroxyethidium (DHE) assay and the formation of the thiol disulfide 
GSSG. XN produced superoxide radical anions in dose dependent manner in BPH-1, PC-3, 
LNCaP, SkBr3 and RAW 264.7 cell lines (The EC50 value of maximal superoxide radical 
anion induction were 2.3 ± 0.1 µM to 4.0 ± 0.5 µM, respectively). This effect could not be 
observed in cell free conditions. An involvement of mitochondria within the superoxide radical 
anion production by XN and a correlation within the induction of apoptosis was discussed. In 
order to verify this theory, isolated mouse liver mitochondria were used to perform a DHE 
assay. The production of superoxide radical anion could be confirmed. In addition an effect 
on the respiratory chain, ATP concentration, mitochondrial potential and the cytochrome c 
release was observed at 12.5 µM XN. PARP cleavage was detected [157]. These effects 
were also observed in a T98G human malignant glioblastoma cell line and were associated 
with an activation of mitogen activated protein kinase (MAPK)-pathway/p38 [158]. The 
increased production of ROS by XN was also confirmed in a study conducted by Yang et al. 
[114]. An increase in the ROS concentration of 1509 ± 125% was measured in 3T3-L1 
mouse embryo fibroblasts after 20 min. A cytochrome c release, a diminished mitochondrial 
potential and PARP cleavage were also detected [114]. 
In another study the inhibition of the TBH induced DNA strand break was examined in a 
comet-assay. No scavenging effect of XN could be detected. Nevertheless, a pre-incubation 
revealed significant DNA protection in HepG2 cells. A stimulation of cellular mechanism such 
as phase II enzymes, which lead to a protective effect, was discussed [130]. No scavenging 
activity of XN could be observed in a 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical assay 
[130,134]. 
Summing up the ability of XN to scavenge superoxide radicals should be abandoned, but a 
scavenging of peroxynitrite and hydroxyl radicals appears likely. It must be kept in mind that 
dietary products are transformed to metabolites after ingestion. The investigation of the type 
of XN metabolites revealed metabolites with a catechol substructure in the B ring [159,160], 
which can also contribute to the scavenging of radicals. XN was also found to induce the 
production of ROS that trigger cells into apoptosis (see 1.1.7 Pro-apoptotic mechanism). 
 
1.1.6. Anti-inflammatory effect 
Today it is obvious that chronic inflammation increases the risk for cancer. It is discussed 
that 15-20% of cancer correlated death are induced by inflammation. A chronic inflammation 
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can be caused e.g. by Helicobacter pylori, Barrett´s esophagus, alcoholic liver diseases 
[161]. Beside cancer other diseases such as metabolic syndrome [162], diabetes [163], 
inflammation bowel disease [164] and Alzheimer´s disease [165] are also correlated with 
chronic inflammation. 
Inflammation is, under normal conditions, a temporary reaction and can be induced, for 
instance, by viruses, asbestos, bacteria and tissue injury. Macrophages and neutrophil 
granulocytes are the first inflammatory cells at the site of infection. They segregate 
chemokines, interleukins and ROS to orchestrate the adaptive immune system and induce 
inflammation. This reaction is referred to as innate immune system and causes inflammation 
with dolor, calor, rubor and tumor [166]. Molecular response of the immune system was 
shown to be involved in the carcinogenesis as well as the angiogenesis, metastasis and 
invasion of cancer. ROS can act as bacterial harmful agent but can also induce DNA and 
protein damage in healthy cells. DNA damage itself can cause mutation and can lead to 
cancer. Tumor-associated macrophages and cancer cells can secrete TNF-α, vascular 
endothelial growth factor (VEGF) and chemokine/cytokines, which leads to proliferation, 
angiogenesis and metastasis of cancer cells [34]. The transcription factor NF-κB plays a 
central role in the inflammatory processes in autoimmune diseases [167] as well as the 
tumor initiation and progression [168]. Thus a therapy strategy for chronic inflammatory 
bowel diseases is the inhibition of the NF-κB translocation and the transcription of mRNA 
[167]. There are two major release pathways of NF-κB, the canonical and the non-canonical 
pathway. NF-κB is a dimer which is located in the cytosol and bound to IκB. It is activated by 
a variety of substances including the tumor necrosis factor (TNF), LPS, receptor activator of 
NF-κB ligand (RANKL), UV-C radiation, epidermal growth factor (EGF), and ROS [168]. 
During the activation, the IκB kinase phosphorylates (IKK) the IκB unit of NF-κB/IκB and thus 
allows the degradation by the ubiquitin ligase complex (see Figure 1-6). NF-κB is then 
translocated to the nucleus and advances the transcription and subsequent expression of 
about 200 different proteins [34]. These proteins are involved in the defense of apoptosis 
(Bcl-2), the prostaglandin synthesis (COX-2, 5-LOX), in inflammatory mechanism (i-NOS, 
TNF-α, interleukins (IL)) and in the production of adhesion molecules (ICAM-1) [168]. 
As described above, the inhibition of NF-κB degradation might leads to the suppression of 
tumor cells and the inhibition of autoimmune diseases. 
XN´s influence on the NF-κB pathway was investigated in a variety of studies and showed an 
inhibitory effect in “healthy” and cancer cells [155,169–174,175–177]. The inhibition of NF-κB 
leads to a decrease in the expression of downstream proteins and proinflammatory markers. 
XN inhibited the production of monocyte chemo-attractant protein-1 (MCP-1) in THP-1 
monocytes [178], hepatic stellate cells, primary human hepatocytes [171], RAW 264.7 and 
U937 human monocytes [179]. The production of interleukins such as interleukin-6 (IL-6) 
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[178], mRNA levels of IL-8 and IL-1 [171], IL-2 [176] and IL-1β [172,173,180] as well as 
cytokine TNF [171], TNF-α [172,176] and IFN—γ [176] were decreased by XN. Inflammatory 
modulating enzymes which are regulated through NF-κB were affected by XN also. 
Examples include the cyclooxygenases (COX)-2 and COX-1 [36], N-acetylglucosaminidase 
(NAG) in wistar rats [180] and inducible NO synthase (iNOS) in RAW 264.7 glia cells [181]. 
Interestingly in ionomycin and phorbol 12-myristate 13-acetate activated EL-4 T cells, XN 
increased the production of IL-2 as well as other cytokines via the NF-AT and AP-1. But it 
had no effect on NF-κB [177]. No effect on NF-κB could be also observed in MCF7 cells 
[173]. In addition to these aforementioned effects of XN, proinflammatory factors and 
enzymes as well as angiogenic factors were affected by XN too (see 1.1.9 
Anti-angiogenesis, -metastasis and –invasive properties). 
 
The mechanism of NF-κB inhibition by XN was studied in myeloid and leukemic cells 
[178,182]. XN inhibited the activation of NF-κB, which was induced by TNF, IL-1β, LPS, H2O2 
and okadaic acid. Because XN inhibited the induction of NF-κB independent of the stimulus it 
was concluded that there must be a similar underlying mechanism. The IKK and p65 unit of 
NF-κB were significantly affected by XN. The mutation of specific cysteine residues reversed 
the inhibition and anti-inflammatory effect. XN contains an electrophilic unsaturated carbonyl 
structure that reacts with sulfhydryl groups in a Michael addition. The sulfhydryl groups are 
located in the cysteine 179 of the IKK and the cysteine 38 of p65 [182]. Descriptive studies 
supported this theory. It was shown that IκBα degradation was decreased during the 
co-incubation with XN [169,171,176]. 
In the study of Peluso et al. [178] the influence of XN, XN metabolites and hydrated XN on 
the expression of MCP-1 and IL-6 was investigated in LPS activated monocytic THP-1 cells. 
MCP-1 and IL-6 are downstream signals of the LPS induced NF-κB pathway [168]. 
Hydrogenated XN inhibited the expression of the MCP-1 and IL-6. For this reason it was 
discussed that the α,β-unsaturated carbonyl structure might not be the only explanation for 
the observed effects. The LPS-binding protein associates with LPS, binds to CD14, and 
clusters with Toll-like receptor 4 (TLR4) [166,183]. MD-2 is essential for the initiation of the 
activation of the NF-κB cascade via the TLR4. XN inhibited the expression of TLR4 
[172,178]. The fitting of the tested compounds with the MD-2 unit was calculated in a 
molecular docking simulation. It was shown that the increased inhibition of the MCP-1 and 
IL-6 is correlated with the fitting accuracy to MD-2 [178]. Cho et al. [172] showed an inhibition 
of the MD-2 expression by XN. 
Beside the inhibition via the LPS induced pathway, XN inhibited the IFN-γ activated 
Januskinase/Signal transducers and activators of transcription (JAK/STAT) signaling. IFN-γ 
binds to the IFN receptors thereby leading to a conformation change and 
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auto-phosphorylation of the JAK. The JAK phosphorylates tyrosin residues within the 
receptor thereby creating docking sites for the STAT. The STAT homodimer modulates the 
expression of IRF-1, inflammatory enzymes such as iNOS and adhesion molecules such as 
ICAM-1 [184]. RAW 264.7 cells were stimulated with IFN-γ and showed reduced binding 
activity of STAT-1α and IRF-1, which was revealed by the measurement of decreased mRNA 
levels [172]. 
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Figure 1-6: Postulated mechanism of the anti-inflammatory effect of xanthohumol. (The 
JAK/STAT as well as the LPS and IFN-γ signal transduction through TLR4 is simplified pictured 
from [184]). 
 
Because of the anti-inflammatory effect of XN it was also tested concerning its ability to affect 
osteoarthritis. Examples include a study of the effect of XN and its metabolites on 
IL-stimulated bovine chondrocytes. XN inhibited the hyaluronan export via the ATP-binding 
cassette transporter multi-drug resistance associated protein 5 (MRP5) as well as 
proteoglycan and collagen loss [185]. 
XN was also investigated for the treatment of chronic allergic contact dermatitis and showed 
positive effects in BALB/c mice [177]. 
Of course, not every inflammatory/autoimmune disease initiates cancer and the inflammation 
in the proximity of cancer is not always associated with a bad prognosis. Nevertheless, the 
inhibition of NF-κB by XN showed beneficial effects on the initiation, progression, metastasis 
and invasion of cancer in a variety of cell types (see 1.1.9 Anti-angiogenesis, -metastasis 
and –invasive properties). 
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1.1.7. Pro-apoptotic mechanism 
A balance between cell death and proliferation is indispensable to life. An abnormal cell-life 
time can lead to auto immune diseases, tumor generation and at worst to malignancy. An 
option for the treatment of cancer might be the inhibition of the proliferation by cell death 
induction. Thus the study of the cell death induction by compounds in malignant cells is a key 
for a successful tumor therapy. There are a variety of mechanisms that induce cell death 
such as necrosis, autophagy and apoptosis. Apoptosis is the most regulated mechanism and 
is characterized by a defined cascade of steps towards cell death. The cell fragments 
obtained during apoptosis are recycled. The apoptotic mechanisms are mainly regulated by a 
variety of proteins that is switched “on” and “off”. 
XN was found to trigger death in a broad panel of cancer cell lines. Examples include human 
breast cancer MCF-7 [157,186,187], T47-D [187] and MDA-MB-435 cells [36], as well as the 
leukemic cells B-CLL [188], MM6, U937 [170,174,182], K562 [174], KBM-5 [182], Jurkat and 
HL-60 [36,182]. Furthermore, XN was effective in human colon cancer cells HT-29 [186], 
HCT-15 [189] and HCT116 derived 40-16 cells [190], prostate cancer cells LNCaP (AR+) 
[191], DU145 and PC-3 [175,191,192], benign human cells BPH-1 [157,175], ovarian cancer 
cells A-2780 [186], SKOC3 [189] and OVCAR3 [193], hepatocellular cells HuH-7, HepG2 
[194], AML12, HA22T/VGH, Hep3B [195] and hepatic stellate cells [171], human malignant 
glioblastoma cells T98G [158], fibroblasts HT-1080 [106], dendritic cells [196], medullary 
thyroid cancer cells TT7 [197], cervical cancer cells HeLa [150,151,152], human embryonic 
kidney cells HEK293 [155], adipocyte cells 3T3-L1 [114,116], macrophage microglia 
RAW 294.7 [157], lung cancer cell line A549 and melanoma cells SK-Mel-2 [189]. 
There are several cell death mechanisms of apoptosis which depend on the cell type, 
expressed receptors and modulating factors. In abnormal cells some of this apoptotic factors 
are mutated. In B-cell lymphoma, for instance, the anti-apoptotic protein Bcl-2 is 
over-expressed and leads to an abnormal survival. In 50% of colon cancers, the 
pro-apoptotic protein Bax is mutated [34]. Therefore the triggering of cancer cell apoptosis 
might be an effective tool to combat cancer. The most investigated signal pathways which 
lead to apoptosis are the extrinsic and the intrinsic apoptotic pathways. The intrinsic pathway 
is controlled by the mitochondria. Usually the extrinsic pathway is independent from the 
intrinsic pathway and mitochondria. In some cases however the extrinsic apoptotic signal on 
its own is not sufficient to induce apoptosis. In these cases the intrinsic pathway is induced 
too in order to potentiate the apoptotic stimulus [198]. 
The extrinsic pathway is activated by TNF and Fas ligands. The intrinsic is activated by DNA 
strand break, which can be induced by e.g. UV radiation [199]. In response to an extrinsic 
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signal the caspase cascade is initiated. Caspase is a zymogene protease that exhibits a 
cystein group in the active center and cleaves proteins after an aspartate residue. There are 
two forms of caspases, the initiator caspase and the effector caspase. The caspase cascade 
is started by a signal that activates the initiator caspase. The initiator caspase then activates 
the effector caspase. In the extrinsic pathway caspase-8 is the initiator caspase and 
procaspase-3 the effector caspase [200]. 
As a consequence of an extrinsic and/or intrinsic apoptotic stimulus proteases cleave other 
enzymes such as PARP and thus lead to a fast progression of apoptosis. PARP is therefore 
beside sphingomyelin used as a detection marker of apoptosis [201]. 
The intrinsic pathway is correlated with a release of cytochrome c. Cytochrome c is released 
from mitochondria via Bax. Bax is activated by pro-apoptotic factors of the Bcl-2 family and 
leads to the formation of pores in the mitochondrial membrane. The release of mitochondrial 
proteins activates caspase-9 by aggregation of the proteins with apoptosomes [200]. Cells 
that were treated with XN showed higher levels of the initiator caspase-9 [158,190,191,202] 
and an increased ROS production [114,157,158]. XN generated ROS via the inhibition of 
complex I to III of the respiratory chain and the inhibition of the electron flux between the 
complexes I or II and III [157]. 
During the stimulation of cells with XN a co-activation of the extrinsic and the intrinsic 
pathway could also be observed. Various research groups observed an up-regulation of the 
initiator caspases -8 and -9 and thus concluded that the apoptosis in the investigated 
prostate and human colon cancer cells was induced by the co-activation of the extrinsic and 
intrinsic apoptotic pathway [190,191]. 
In dentritic cells XN induced acid sphingomyelinase, caspase-8 and -3 and led to cell death 
solely via the extrinsic apoptotic pathway [196]. 
Further apoptotic pathways beside the extrinsic and the intrinsic are the endoplasmatic- and 
caspase independent pathway. The caspase independent pathway is correlated with 
apoptosis-inducing factors (AIF) which are excreted by mitochondria. Lust et al. [188] 
investigated the apoptotic mechanism of XN in B-CLL cells. No influence on caspase-3, p38 
and Akt could be detected. Furthermore, XN induced apoptosis is not inhibitable with the 
caspase inhibitor zVAD-fmk [203]. Hence they discussed a caspase/caspase-3 independent 
apoptotic pathway. In addition Delmulle et al. [203] and Strathmann et al. [157] suggested 
autophagy as a further mechanism leading to cell death. Autophagosomes surround 
organelles and proteins. Upon fusion of these vesicles with lysosomes, the content gets 
degraded. The exact cascade of autophagy is not known yet. But it seems clear that 
proteases are also involved in the degradation of the cells by autophagy [34]. 
The induction of apoptosis by the endoplasmatic reticulum (ER) is less investigated. The ER 
is responsible for post translated modification and folding of proteins. ER stress leads to 
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higher misfolded and unfolded proteins which accumulate in the ER and activate the 
unfolded protein response (UDP). As a result the levels of chaperone glucose-regulated 
proteins (GRP) and heat-shock proteins are increased. This in turn leads to regulation of 
proteins such as the transmembrane kinase, which is also a stress responsible protein, 
RNA-activated protein kinase –like ER kinase (PERK), activating transcription factor 6 
(ATF6) and inositol-requiring enzyme 1 (IRE1) transcription factor homologous protein 
(CHOP). The Up-regulation causes an activation of caspase-12 and cleavage of PARP 
[199,204]. XN induced the ER dependent factors such as GRP78, PERK, 
CCAAT/enhancer-binding protein (C/EBP), CHOP and IRE1 [202]. The ER dependent 
apoptosis was discussed by Lust et al [202] and Fribley et al. [205]. Fribley et al. [205] also 
discussed proteasomes as potential initiators. 
Further signals/inducers are the C-Jun N-terminal kinase (JNK), p38, ceramide, granzyme B 
from cytotoxic T-cells, which discharge in the above described pathways [201]. JNK and p38 
are mitogen-activated protein kinases (MAPK) which are involved in the activation of 
apoptosis [206]. The JNK phosphorylates proteins, which trigger the pro-apoptotic protein 
Bax [201]. An activation of ERK1/2 and p38 in a T98G human malignant glioblastoma cell 
line by ROS, which was induced by XN, was discussed [158]. 
Another substance that was determined to be a signaling factor towards apoptosis was 
ceramide. Ceramide is expressed at the cell surface after conversion of sphingomyelin by the 
acid sphingomyelinase (Asm). In addition ceramide is produced by de novo synthesis in 
cellular membranes. Thus the induction of Asm triggers apoptosis [207]. XN was shown to 
induce Asm and apoptosis in dendritic cells [196]. 
The protein kinase Akt is an important survival factor that effects proliferation, angiogenesis 
and apoptosis [34]. Akt is a regulating factor in the NF-κB pathway. Akt phosphorylates IKK 
that regulates the degradation of NF-κB/IκB and leads to a translocation of NF-κB to the 
nucleus. Hence the inhibition of Akt leads to apoptosis. Another pro-apoptotic factor that is 
regulated by Akt is Bad. Bad is a pro-apoptotic protein and belongs to the Bcl-2 family. An 
inhibition of Akt leads to dephosphorylation of Bad and the induction of apoptosis [201]. XN 
was found to be an Akt inhibitor. Deeb et al. [191] and Hartkorn et al. [155] showed an 
inhibition of Akt by XN. XN inhibited Akt in a hepatic ischemia/reperfusion model [155] and in 
a prostate cancer cell line [191]. An inhibition of NF-kB by XN was observed in leukemia cells 
[174]. 
XN triggers cancer cell into apoptosis, but shows rescue ambitions, too. Oxidative stress as 
well as energy exhausting can cause suicidal death of erythrocytes which is also referred to 
as eryptosis. Eryptosis is correlated with an increased activity of Ca2+ and K+ channels. In the 
process potassium chloride is effluxed which leads to a shrinkage of the erythrocytes. XN 
was found to prevent erythrocytes in dose dependent manner from suicidal death [149]. In 
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addition no viability inhibition in primary human hepatocytes at concentrations up to 100 µM 
could be observed [194]. Cancer cells exhibit an abnormal redox balance because of stress 
situations and elevated intercellular ROS levels [208]. This might explain the positive effects 
of XN on healthy cells and the induction of apoptosis in cancer cells. The in this chapter 
described apoptotic pathways that are influenced by XN are summarized in Figure 1-7. 
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Figure 1-7: XN induces apoptosis via different pathways: PI3K-Akt or/and NF-κB, ERK1/2, p38, 
ER dependent, Notch signaling, Autophagy, acid sphingomyelinase, caspase (3) independent, 
extrinsic apoptotic way and mitochondrial dependent. 
 
In principle the apoptotic mechanism depend on the cell type. However, the mechanisms for 
the induction of apoptosis by XN are not fully understood yet. XN induces apoptosis through 
multiple ways and is an extraordinary model compound for cancer treatment through the 
induction of apoptosis. 
 
1.1.8. Estrogen modulating activity 
Secondary metabolites of H. lupulus have been shown to have positive effects in the 
treatment of hormone dependent cancer. Estrogen is a ligand of estrogen receptors α or β 
(ER) which are located at the nucleus and leads to the expression of growth factors. 
Estrogen originates from the aromatization of testosterone and androstenedione. The 
underlying reaction is catalyzed by the aromatase (CYP19). 
A target in the postmenopausal cancer therapy is the inhibition of aromatase in order to 
inhibit the estrogen-induced proliferation of the cancer cells. XN was investigated concerning 
its ability to inhibit the aromatase in choriocarcinoma JAR cells [209,210]. The aromatase 
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was inhibited by XN with an IC50 value of 20.3 µM (95% confidence intervals of 15.3-26.9). 
However no significant influence of XN on the expression of aromatase was observed [209]. 
In addition to the proliferative effect, estrogen can also be converted to different o-quinones. 
The o-quinones can lead to malignance by binding to the DNA. Hemachandra et al. [211] 
investigated the influence of XN and 8-PN on the estrogen-induced expression of 
CYP 450 1B1 and CYP450 1A1 in MCF-10A cells. The expression of the CYP 450 was 
inhibited by 8-PN, but no effect of XN could be observed [211]. 
Estrogen modulates different pathways including those with an alkaline phosphatase 
expression. The alkaline phosphatase might be involved in tumorigenesis [212]. In 
pathological conditions, the alkaline phosphatase level is increased and may point to cancer 
[213,214]. The expression of intestines alkaline phosphatase as well as the proliferation of 
MCF-7 cells was inhibited by XN in mice [212]. 
 
1.1.9. Anti-angiogenesis, -metastasis and –invasive properties 
Cancer is an uncontrolled proliferation of cells and can basically be grouped in two forms, the 
benign and the malignant form. The ability to metastasize, invade and impair organ functions 
is correlated with the malignancy of a cancer type. Hence the inhibition of metastasis, 
invasion and angiogenesis is a key approach in the treatment of malignant cancer. The 
process of metastasis can be divided in several steps such as migration, intravasation, 
transport, extravasation, metastatic colonization and angiogenesis. At first cancer cells have 
to separate from a solid tumor. Thus, the junctions of the tumor cells and the neighbor cells 
(catenin-cadherin junctions) as well as of the extracellular matrix (integrin junctions) have to 
be breached. An alteration in the junctions can lead to independent, cancer cell movement 
and adherence to other extracellular matrices. Mutations in the extracellular domain as well 
as methylation in the promotor section of E-cadherin gene was observed in some cancers. It 
is discussed that E-cadherin acts as a tumor suppressor by the securing of cell-cell junctions 
and suppresses metastasis of tumor cells into other body sections [34]. XN showed an 
anti-invasive effect mainly by growth inhibition and by the adhesion enhancement between 
breast cancer cells via the E-cadherin/catenin in a chicken heart invasion assay. This was 
implicated because the XN effect was abolished if the cells were treated with a monoclonal 
antibody for E-cadherin [187]. 
However other research groups could not observe an anti-invasive effect of XN 
[169,174,215]. 
In a study of Negrão et al. [216] XN was found to affect the proliferation, apoptosis and 
invasion of human aortic smooth muscle cells (HASMC). No effect on the invasion of human 
umbilical vein endothelial cells (HUVEC) could be observed. However an influence on the 
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proliferation and apoptosis could be detected [216]. Thus XNs effect on the cell invasion 
seems to be cell dependent. 
XN was also found to influence enzymes and the expression of proteins that are correlated 
with metastasis. In brief, XN inhibited several matrix metalloproteases that break the 
connection between the extracellular matrix and the intestine in CML, HUVC [170], K562 
CML [174], dermal fibroblasts [217], and HUVECs [169]. 
After the separation of tumor cells from a solid tumor and the extracellular matrix, malignant 
cells can penetrate blood and lymphatic vessels (intravasation) in order to reach the next 
organ. The extravasation is regulated by signals between cancer cells and endothelial cells. 
This process is also referred to as “seed and soil”. During the extravasation cancer cells 
adhere to the endothelium, penetrate the vessels, and infiltrate the intestine. If the cells 
penetrate the vessels from the interior side they can begin to colonize. The maximum 
distance between the cancer cells and the surrounding vessels that allows for the supply with 
oxygen and nutrients is 200 µm. In case of larger distances new vessels are formed 
(angiogenesis). Angiogenesis is a ubiquitous process e.g. during embryogenesis, organ 
development and wound healing. However the formation of blood vessels by endothelial cells 
in order to supply cancer cells with nutrients is fatal. Thus the control of the tumor-associated 
angiogenesis is another key approach in the treatment of cancer. The tumor-associated 
angiogenesis is regulated by a variety of pro-angiogenetic and anti-angiogenetic factors. The 
first include the vascular endothelial growth factors (VEGF) [34]. Imbalance between the 
pro-angiogenetic and anti-angiogenetic factors can cause extended vascularization which is 
also referred to as “sprouting” [218,34]. Sprouting is an effect that orchestrates matured 
endothelial cells in a way that they detach, move and built up new vessels. VEGF are one of 
the main activators that lead to a variety of pro-angiogenetic effects such as an increase in 
the permeability of blood vessels. The expression of VEGF is regulated not only but also by 
MAPK and PI3K/Akt [219]. XN was investigated concerning its ability to inhibit Akt in 
HUVECs which were stimulated with IGF-1 [169]. XN was found to be an Akt and NF-κB 
inhibitor (1.1.6 Anti-inflammatory ). An inhibition of the VEGF production by XN was observed 
in HUVEC, U 937 CML [170] and K562 cells [174]. In addition an inhibition of the VEGF 
production was observed in rats that ingested stout beer supplemented with XN [180]. 
The anti-angiogenetic potential of XN was investigated in a variety of in vitro and in vivo 
models. Examples include MCF7 xenografts in mice [173], a matrigel model and matrigel 
injected in mice [169,216], a wound healing model [180,216] and mice models for 
endometriosis [220]. XN significantly decreased the vascularization [169,173,180,216,220]. 
Additionally, in one of the studies a decreased factor VIII expression was detected [173]. The 
mechanism of the inhibition of the vascularization by XN was discussed from different 
perspectives. On the one hand a significant inhibition of the vascularization was correlated 
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with an inhibition of ROS and VEGF [169,180,220]. On the other hand an induction of 
apoptosis was discussed [173,220]. Dell’Eva et al. discussed a combination of both effects 
[170]. 
Summing up, XN is a potent anti-inflammatory and anti-angiogenetic substance due to the 
inhibition of Akt, NF-κB and correlated signals such as VEGF. The underlying mechanisms 
depend on the cancer cell type, the environment and the concentration of XN. 
 
1.2 Safety studies 
The use of XN as a therapeutic agent requires investigation of the effects on healthy cells 
and organisms in in vitro and in vivo models. Up to now only a few studies are available so 
far that addresses the safety of XN. In the following a short overview of these studies will be 
given. Albini et al. [169] investigated the effect of the supplementation of 200 µM XN in water 
on the health parameters of male nude mice. No effect of XN on the investigated parameters 
could be detected [169]. In another study human bone marrow progenitor cells isolated from 
healthy volunteers were incubated with XN in the colony-forming-unit assay. XN up to a 
concentration of 5 µM did not inhibit the proliferation of the cells [170]. Moreover XN up to a 
concentration of 100 µM showed no effect on the viability of primary human hepatocytes 
[194]. 
However cancer cell lines seem to be more sensitive to XN. A significant difference in the 
viability between normal and malignant astrocytes by XN could be detected. The observed 
lower viability of the malignant astrocytes was attributed to a more pronounced induction of 
apoptosis in the malignant cells [215]. 
In an in vivo safety study in Female Sprague Dawley rats the toxicity of XN on the liver, 
kidney, lung, heart, stomach and spleen was investigated. In this study, the rats obtained a 
XN supplemented starch suspension (1000 mg XN/kg body weight) every day by gavage. 
The feeding period was 28 days. The fed XN induced a slight hepatotoxicity and led to less 
developed mammary glands. Hence during the additionally performed fertility study the XN 
feeding dose was decreased to 100 mg XN/kg body weight per day. In the first as well as in 
the second generation no difference in the fertility was observed. However the sex ratio 
tended towards the female offspring [221]. 
A safety study with BALB/c mice revealed no difference in organ weight, appearance and 
function. The mice were fed with chows supplemented with 0.5% (w/w) XN which equates to 
1000 mg XN/kg body weight [222]. The differences in the studies of Hussong et al. [221] and 
Dorn et al. [222] might be ascribed to the different animal species. In addition different 
analytical methods were used. 
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In another study the influence of XN (100 mg XN/kg body weight per day, 28 days) on the 
enterobacteria of Sprague Dawley rats was investigated. No influence on the flora 
composition could be observed [223]. 
 
1.3 Bioavailability, metabolism and cell uptake 
It is of utmost importance to investigate the bioavailability of XN in order to determine 
suitable XN concentration ranges, which allow achieving the desired effects. The 
bioavailability of a substance is dependent on its liberation, absorption, distribution, 
metabolism and excretion. 
The lipophilic XN was shown to have a low bioavailability after oral administration [224,225]. 
However the results differ depending on the way of ingestion and the sample preparation. 
Avula et al. [224] fed male wistar rats with 10, 20, 50, 100, 200, 400, 500 mg XN/kg body 
weight. Legette et al. [225] fed Sprague-Dawley rats and dissolved the XN in self-emulsifying 
isotropic mixtures of oleic acid, propylene glycol and Tween 80 (0.9:1:1). The oral gavage 
dose was 16.9 mg/kg body weight. Avula et al. [224] could not detect XN in the serum after 
oral application. Legette et al. [225] measured maximal concentrations of 0.42 ± 0.03 µM 
conjugated and unconjugated XN in the serum. A lipophilic solvent was used for the sample 
preparation [225]. Avula et al. [224] used methanol as extraction medium. 
XN as a lipophilic compound adsorb not only at vessels [226] but probably also at proteins 
[227,228]. A high lipophilic elution solvent is necessary to dissolve XN in the extraction 
solutions. Thus the methods used for the quantification of XN can differ in the limit of 
detection (LOD) and limit of quantification (LOQ). 
However the bioavailability can also be a matter of the concentration as Legette et al. [225] 
observed a dependency between the amount of XN in the serum and the ingested amount of 
XN. A double amount of XN fed did not lead to a twofold higher bioavailability of XN [225]. 
In order to give a reliable statement of the behavior of compounds in the organism it is also 
necessary to determine their metabolites. Unfortunately Avula et al. [224] did not determine 
the XN metabolites. Hence a conclusion concerning the non-detected XN in the serum is not 
possible [224]. 
The basic principle of biotransformation is well investigated. The main function of the 
biotransformation is the elimination of compounds from the organism. The enzymes, which 
are involved in the biotransformation, convert lipophilic compounds to more hydrophilic ones 
in order to allow for a fast excretion. The biotransformation takes place mainly in the liver and 
gut, but is also performed in other parts of the organism such as the kidney, muscle, lung, 
skin, spleen and blood. The biotransformation is usually a two step reaction. At first the 
haeme enzymes CYP 450 converts compounds by oxidation, reduction, alkylation and 
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dealkylation to reactive compounds. This process is also referred to as phase I reaction. In 
the phase II reaction, enzymes such as UDP-glucuronosyltransferases or sulfotransferases 
add glucuronic acid or sulfates. The enzymes are located in the mitochondria and cytosol, 
but especially in the endoplasmatic reticulum. Usually the metabolites which are produced 
during the biotransformation lose their activity. However the biotransformation can also lead 
to more reactive substances. This process is also referred to as bioactivation. Examples for 
substances that are bioactivated include HAA, morphine and some glucocorticoides [99,128]. 
Therefore it is of paramount importance to investigate the metabolites of phase I and phase II 
reactions concerning their pharmacological effects. However the pharmacological 
investigation of metabolites in vivo is rather sophisticated, because of their typically low 
concentrations. Hence structure identification studies are often performed in vitro with 
microsomes, microorganisms and the direct transformation with phase I and phase II 
enzymes. This applies also for XN. 
Examples include the co-incubation of XN with human liver microsomes, rat liver 
microsomes, microorganisms and phase II enzymes [103,159,160,229,230,231,232]. 
Yilmazer et al. investigated phase I [159] and phase II metabolites [229]. XN was incubated 
with and without CYP inducers. Xanthohumol C (see Figure 3-1) and three further metabolic 
products were detected. This provided evidence that XN is a substrate for CYPs that are 
located in rat liver microsomes. Three of the metabolites were produced by epoxidation of 
the prenyl chain. The fourth by hydroxylation of the B ring [159]. The hydroxylated B ring of 
the XN metabolites is a catechol structure that might act as a radical scavenger [145] (see 
Figure 1-5). 
In another study conducted by Yilmazer et al. [229] it was observed that glucuronidation is 
the main mechanism (89%) during the metabolism of XN in the phase II reaction [229]. The 
phase II enzymes UDP-glucuronyltransferases and sulfotransferases were not only found in 
the liver but also in the gastrointestinal tract. Hence it was suggested that XN is not only 
metabolized in the liver but with high evidence also in the gastrointestinal tract [230]. 
Unfortunately only few in vivo XN metabolism studies are available so far. One of these 
studies was conducted by Nookandeh et al. [233]. They detected 22 XN metabolites in the 
feces of female SD-rats. However 89% of non-metabolized XN were excreted and only 11% 
metabolites were produced. Several hitherto not reported metabolites such as 
xanthohumol H and 4-Methoxyxanthohumol (see Figure 3-1) were elucidated. XN was 
metabolized mainly by epoxidation of the prenyl chain, hydroxylation, O-methylation and 
O-acetylation [233]. In contrast to the in vitro studies conducted by Nikolic et al. [160] and 
Yilmazer et al. [159], no hydroxylation of the B ring was observed. 
However IXN was detected in one in vivo study [233] as well as in one in vitro study [160]. 
IXN is an isomerization product of XN that is produced in beer during fermentation [9]. The 
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stomach was discussed as a possible place of isomerization. However this could not be 
confirmed in a study conducted by Possemiers et al. [234]. The consensus is a spontaneous 
isomerization of XN to IXN [225,235,236]. 
Another XN metabolite is 8-PN. 8-PN is a phytoestrogen with remarkable estrogenic activity. 
The formation of 8-PN was investigated in the artificial human intestinal microbial ecosystem. 
A dependency between the human gut microflora and the production of 8-PN was observed 
[234]. In further in vitro studies Eubacterium limosum, a resident of the human gut flora, was 
found to O-demethylate IXN to 8-PN. Supplementation of non 8-PN converter feces with 
E. limosum resulted in increased 8-PN levels [235]. The transformation of IXN to 8-PN was 
also observed in in vivo studies. Human microbiota-associated Sprague-Dawley rats 
produced 8-PN, whereas Germ-free Sprague-Dawley rats did not. The IXN concentration in 
the serum of human microbiota-associated rats was found to be higher than in germ-free 
rats. Stability tests with gastric fluids yielded in decreased XN concentrations but no 
production of IXN [236]. 
The conversion of IXN to 8-PN was also observed in humans and thus confirmed the in vitro 
results as well as the in vivo rat experiments. The conversion was found to be mediated by 
the human gut [237] and CYP enzymes [238]. 
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Figure 1-8: Overview of the 8-prenylnaringenin (8-PN) production. Xanthohumol (XN) can be 
spontaneously converted to isoxanthohumol (IXN) and subsequently to 8-PN by gut flora or the 
CYP450. XN can be transformed to desmethylxanthohumol and subsequently to 8-PN. 
 
There are two principle ways for cellular excretion of hydrophobic compounds. One way is 
the aforementioned biotransformation. The second is the immediate efflux [239]. The 
phase II metabolites which are produced during the biotransformation are usually excreted 
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into the bile or the sinusoidal blood by membrane transporters such as multidrug 
resistance-associated proteins Mrp2, Mrp3 and Abcc2 [240]. ABC-transporter are 
ATP-dependent and are located in the cell membrane. The original function of the 
ABC-transporter is the transport of hydrophobic compounds across the cellular membrane 
[239]. The P-glycoprotein is a known transporter and is encoded by the MDR1 gene. It plays 
a major role in drug resistance of cancer cells [34]. 
It is probable that XN metabolites are also excreted by membrane transporters. However the 
mechanism of the XN uptake and excretion is not fully known yet. 
In the uptake study of Rodriguez-Proteau et al. [241] the influence of XN on the uptake of 
digoxin and cyclosporine A was investigated in Caco-2 and Madin-Darby canine kidney 
(MDCKII)–multidrug resistant (MDR) cells. The efflux of cyclosporine A was inhibited by XN. 
Nevertheless the intracellular cyclosporine A concentration was decreased. The efflux of 
digoxin was not impaired by XN. However the intracellular concentration increased. 
Rodriguez-Proteau et al. [241] discussed a competition between XN and cyclosporine A for 
the MDR1. A final conclusion could not be drawn since XN did not affect the efflux of digoxin 
[241]. However a competition might be an explanation, because XN was shown to 
accumulate up to 93% in Caco-2 cells [227] and hepatic cell lines [228] (see also chapter 4). 
An influence of XN on ABC-transporter was also observed by further research groups 
[189,242]. XN was shown to decrease the mRNA levels of ABC-transporter such as the 
ABCB1, ABCC1, ABCC2 and ABCC3 [189]. In addition XN reduced the efflux of cimetidin by 
the P-glycoprotein in Caco-2 and porcine kidney epithelial LLC-PK1 cells [242]. 
Summing up the low bioavailability of XN might be explained by its comparably high 
lipophilicity and the fast and concentrated uptake of XN in different cell lines and cells 
avoiding the penetration into the blood stream, but the exact mechanism of the XN uptake is 
still unrevealed. 
 
1.2. Aims 
XN is a lipophilic compound and exhibits low water solubility. In order to use XN as model 
compound and to measure effects of XN in in vitro assays it was necessary to investigate 
suitable handling and experimental set-ups. 
At first it should be determined which FCS concentration is necessary to achieve a suitable 
recovery of XN under cell culture conditions. Three different FCS concentrations (0, 1 and 
10%) were chosen to mediate the solubility of XN. Because of its lipophilicity XN bind not 
only to proteins but also to different materials used in cell culture work. The dependency 
between the XN concentrations, the FCS amount and cell culture material were investigated 
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and are described in chapter 2. After establishing the experimental set-ups the behavior of 
minor hop chalcones, XN metabolites and related compounds were studied in in vitro assays. 
First the compounds were tested concerning their ability to influence the growth of cancer 
cell lines in chapter 3. MTT assays and CV assays were performed in order to measure the 
influence of the compounds on the cell viability, proliferation and concerning cytotoxic effect 
in three hepatic and one colorectal cancer cell line. The NO production was measured in a 
Griess assay and the iNOS expression with an iNOS activation kit using a fluorescence 
microscope. 
Up to now, little is known about XN´s uptake and intracellular behavior. Therefore the uptake 
of XN was studied in vitro in two hepatic cancer cell lines HuH-7 and HSZ-B, primary hepatic 
cells and Caco-2 cells to mimic a part of the entero-hepatic circulation and is described in 
chapter 4. 
Following the in vitro experiments, the absorption, distribution and metabolism of XN was 
investigated in vivo after oral intake by BALB/c mice and is described in chapter 5. The 
BALB/c mice were fed with 100 mg/kg, 500 mg/kg and 1000 mg/kg body weight of an XN 
enriched extract (73%) for 3 and 7 days. After the feeding period the concentrations of 
conjugated and unconjugated XN were determined in serum, urine, feces, bile and liver. In 
addition the absorption, distribution, metabolism and the XN concentration in dependency of 
the ingested XN amount were determined. Furthermore the influence of the matrix on the 
absorption, distribution and metabolism of XN was investigated on the basis of two different 
chows supplemented with either 98% XN (pure XN) or 73% XN (enriched extract with 
polyphenolic matrix, XE). The BALB/c mice were fed for either 3 or 7 days (1000 mg/kg body 
weight). After the feeding period the serum, liver, urine, feces and bile samples were 
analyzed concerning the amount of unconjugated and conjugated XN. 
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1)
 The data of this chapter is published in: M. Motyl, B. Kraus, J. Heilmann, Pitfalls in 
cell culture work with xanthohumol, Pharmazie 67 (2012) 91–94. 
 
2 Pitfalls in cell culture work with xanthohumol 1) 
2.1 Abstract 
Xanthohumol (XN), the most abundant prenylated chalcone in hop (Humulus lupulus L.) 
cones, is well known to exert several promising pharmacological activities in vitro and in vivo. 
Among these, the chemopreventive, anti-inflammatory and anti-cancer effects are probably 
the most interesting. As XN is hardly soluble in water and able to undergo conversion to 
isoxanthumol (IXN) we determined several handling characteristics for cell culture work with 
this compound. Recovery experiments revealed that working with XN under cell culture 
conditions requires a minimal amount of 10% fetal calf serum (FCS) to increase its solubility 
to reasonable concentration (~50-75 µmol/l) for pharmacological in vitro tests. Additionally, 
more than 50% of XN can be adsorbed to various plastic material routinely used in the cell 
culture using FCS concentrations below 10%. In contrast, experiments using fluorescence 
microscopy in living cells revealed that detection of cellular intake of XN is hampered by 
concentrations above 1% FCS. 
 
2.2 Introduction 
Triggered by the work of Gerhäuser et al. [36] the pharmacological characterization of the 
prenylated chalcone XN (Figure 2-1) strongly advanced in the last decade. It has been found 
that XN, which is the most abundant chalcone in hop (H. lupulus L.) cones, shows among 
others chemopreventive [36], anti-inflammatory [171], cytotoxic [150,192] and 
anti-angiogenic effects [169]. 
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Figure 2-1: Structure of xanthohumol (XN). 
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Mechanistically, it has been observed that XN is able to influence the transcription factors 
NF-κB, NF-AT, Akt and Nrf2 [139,169,177] and to trigger apoptosis [157,191]. Furthermore, 
the modulation of enzymes involved in carcinogen metabolism and detoxification has been 
reported [36,134]. 
Interestingly, it has been noticed that handling of XN is difficult as the water solubility is low 
with only 1.3 mg/l at 23 °C [9], what is always a d rawback for pharmacological in vitro and 
in vivo studies. Moreover, the stability of XN depends on the milieu, leading to the formation 
of the better water-soluble flavanone IXN under the influence of heat and water. Both 
aspects results in low XN contents in beer and consequently, IXN is much more abundant 
after brewing in comparison to XN itself. As the same process is observable for the chalcone 
desmethylxanthohumol, which is converted to the phytoestrogen 8-prenylnaringenin [9], 
stability of chalcones and their conversion to the corresponding flavanones is a topic of 
general importance. 
A very recent study showed that not only brewing processes, but also in vitro assay 
conditions can initiate instability of XN and thus artificially influence the pharmacological 
activity. The presence of FCS is supposed to catalyze the formation of XN dependent 
radicals leading to degradation of XN as well as to radical processes with assay detector 
reagents and thus to false positive results [154]. As a first consequence of this investigation, 
XN cannot longer be classified only as a radical scavenger, but also as an inducer of radical 
producing pathways. This was also supported by very recent in vitro data from cellular test 
systems [157]. These handling difficulties prompted us to further investigate the behavior of 
XN in cell culture to give helpful suggestions for the reliable design of cellular experiments 
with XN. In our investigations, we first determined the solubility of XN in cell culture medium 
(Dulbeccos Minimum Essential Medium, DMEM) containing different concentrations of FCS. 
In a second step, the recovery of XN from medium was determined as a function of FCS 
concentration. Additionally, the recovery of XN from medium supplemented with 10% FCS 
was measured using different plastic materials routinely applied in cell culture like Petri 
dishes, cell culture flasks, centrifuge tubes and 96-well plates. Likewise, the feasible 
conversion of XN to IXN was investigated. As fluorescence microscopy, especially 
fluorescence imaging in living cells, is a tool with increasing importance for cellular studies 
we also analyzed the fluorescence behavior of XN in a cellular system at different 
concentration of FCS. 
2.3 Material and Methods 
XN was provided by NATECO2 (Wolznach, Germany) with a purity >98% determined by 
HPLC as described as stated below. For determination of XN solubility and recovery, the 
same method was applied. All solvents (MeOH/H2O) used were of HPLC quality. DMEM 
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(Gibco, Invitrogen, Grand Island N.Y., U.S.A.) was supplemented with different concentration 
(1-15%) of FCS (Biochrom AG Berlin, Germany) for the solubility and recovery experiments. 
For recovery experiments, stock solution of XN was added to the medium and incubated in 
Petri dishes d 100 x 20 mm, 96 well plates, culture flasks 75 cm2 (all from TPP, Trasadingen, 
Switzerland), culture flasks 25 cm2 (Greiner bio-one, Frickenhausen, Germany), tubes 1.5 ml 
and 2 ml (Eppendorf, Hamburg, Germany) and centrifuge tubes 15 ml (MEUS s.r.l., Piove di 
Sacco, Italy) for 3 or 24 h (37 °C, 5% CO 2, humidified incubator). After addition of two 
volumes (v/v) of acetone, the samples were vortexed and centrifuged at 20,000 g (4 °C). To 
purify the samples, the supernatants were centrifuged through NanoSep centrifugal devices 
(Cat. 5168502 VWR, Darmstadt, Germany) at 20,000 g (4 °C). 
The analytical HPLC system consisted of an Elite La Chrom system (VWR-Hitach, Germany) 
equipped with an L-2455 diode array detector, a thermostated L-2200 autosampler, an 
L-2130 pump and an L-2350 column oven. A Purospher® Star RP-18e (column size: 
250 x 4.0, particle size: 5 µM, Merck, Darmstadt, Germany) was used as column. Detection 
wavelength was 368 nm. The eluents were water/0.1% formic acid (A) and acetonitril/water 
(95/5, B). The injection volume of the sample was 20 µl and the following elution-programm 
was used with a flow rate of 1.0 ml per min (at 30 °C): 0-9 min 57.8-68.2% B 9-14 min 
followed by equilibration to 57.8%. 
Solubility of XN was determined according to the method of Li et al. (modified, [243]). Shortly, 
1 mg XN was continuously vortexed for 3 h or 24 h with 100 µl DMEM containing 1%, 5% or 
10% FCS. Subsequently, 300 µl were filtered through a 0.45 µm Acrodisc® 13 mm syringe 
filter (PALL, Ann Arbor, MI USA) and then extracted as described above. 
Fluorescence imaging experiments were performed using a computer controlled research 
microscope (Carl Zeiss Cell Observer®), consisting of a Zeiss Axio Observer (Carl Zeiss 
Göttingen, Germany) with Software AxioVision 4.8.1 (Carl Zeiss MicroImaging, Germany), 
following the protocol published by Wolff et al. [228]. For imaging of XN, a custom-built filter 
set was used (460/80 FT 475 BP605/40). Quantification of cellular XN fluorescence at 
individual time points was done automatically by the ASSAYbuilder® Physiology Analyst 
software (Carl Zeiss MicroImaging, Germany), using a phase contrast image to determine 
the cell boundaries. Values are presented as mean ± SD as indicated (with n = 3 or 4). 
Comparison between groups was made using one-way ANOVA, followed by Tukey´s 
Multiple Comparison Test as post test. A p value < 0.05 was considered statistically 
significant. For elimination of outliers, the test according to Grubbs was applied. All 
calculations were performed using GraphPad. 
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2.4 Investigation, results and discussion 
The solubility tests for XN in pure DMEM, according to the standard method of Li et al. [243] 
resulted in a solubility of less than 0.05 mg/l (3 h, 37 °C, centrifugation and filtration). This is 
in consideration of the moderately different experimental design in the same range as 
determined by [9] with 1.3 mg/l (water, 4.5 h, 23 °C and centrifugation), underlining again the 
bad solubility of XN in aqueous medium. Addition of FCS resulted in an increase of solubility 
to 2, 5 and 16 mg/l for DMEM containing 1, 5 and 10% FCS (after 3 h). As assays often 
required a longer incubation time, XN solubility was also determined after 24 h (37 °C) 
leading to an increased solubility of 4, 10 and 24 mg/l, respectively (Table 2-1). 
 
Table 2-1: Solubility of XN in DMEM after 3 and 24 h (37 °C, 5% CO 2, centrifuge tubes), and 
effect of FCS supplementation 
Medium Incubation time (h) Solubility (mg/ml) 
DMEM 3 < 0.05 
 24 < 0.05 
DMEM + 1% FCS 3 2 
 24 4 
DMEM + 5% FCS 3 5 
 24 10 
DMEM + 10% FCS 3 16 
 24 24 
 
Accordingly, the maximal solubility of XN under cell culture conditions for 3-24 h (37 °C, 10% 
FCS) can be estimated to be 50-75 µmol/l. Consequently, the application of test 
concentrations clearly higher than 75 µM XN [150,186] renders the results somewhat 
uncertain as the accurate concentration of XN in the assay is not exactly determinable due to 
a clear exceeding of the solubility. In such cellular systems, an equilibration between solved, 
unsolved and intracellular XN can be expected dequalifying for example a determined IC50 
value of a cytotoxicity assay. 
To verify the effective XN concentration in an assay a recovery experiment was performed by 
subjecting 10 µM XN to DMEM supplemented with different FCS concentrations (1-15%). 
After 3 h incubation at 37 °C (in centrifuge tubes)  XN was extracted from the medium and 
quantified by HPLC. As expected, results showed that the measured XN concentration is a 
function of the percentile amount of FCS in medium (Figure 2-2 A). 
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Figure 2-2: A. Recovery of XN (10 µM) after incubation (3 h, 37 °C) in DMEM supplemented with  
-Figure 2-2 continues on page 43- 
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-Continuance of Figure 2-2- 
different concentrations of FCS (1-15%) in centrifuge tubes (n=4). B. Recovery of XN from 
different concentrations (5, 10, 25, 50, 75 and 100 µM) incubated in DMEM supplemented with 
10% FCS (n=4). C. Recovery of XN after incubation of 10 µM XN (3 h, 37 °C) in DMEM 
supplemented with 1, 5 and 10% FCS in different cell culture material like Petri dishes, flasks, 
centrifuge tubes and 96 well plates from different suppliers (n=3). All values in comparison to 
control (XN). 
 
Surprisingly, the measured XN concentration is significantly lower in comparison to the 
applied 10 µM even in FCS concentrations sufficient for an entire solution of the compound. 
A series of recovery experiments with XN concentrations of 5, 10, 25, 50, 75 and 100 µM 
(3 h, 37 °C, 10% FCS) showed that the reduced amoun t of recovered XN is not due to a 
reduced solubility as higher concentrations of dissolved XN can be easily obtained (Figure 
2-2 B). We therefore concluded that most likely also absorption phenomena on plastic 
materials can be obtained for XN under normal assay conditions. This was pursued by 
incubating 10 µM XN (3 h, 37 °C) in DMEM supplement ed with 1, 5 and 10% FCS in different 
cell culture material like Petri dishes, flasks, centrifuge tubes and 96 well plates from different 
suppliers (Figure 2-2 C). Experiments revealed remarkable differences concerning the 
recovery of XN from the medium depending on the used cell culture material. For all 
materials, a satisfying recovery (>90%) of XN requires a minimum of 10% FCS in the 
medium, whereas 1 or 5% FCS resulted in a server loss (~50% or more) of the test 
compound (Figure 2-2 C). 
On the other hand, high FCS concentrations can also hamper results from cellular in vitro 
experiments, as the fluorescence properties of substances can be affected. As shown by 
Wolff et al. [228] the cellular intake of XN into cells can be followed by imaging of XN 
fluorescence. In our experiments, we followed the time dependent cellular intake of 10 µM 
XN in immortalized human hepatic stellate cells [244] with fluorescence microscopy (Figure 
2-3 A) varying the FCS concentrations from 1-10%. 
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Figure 2-3 Measurement of the time-dependents increase of XN fluorescence in human hepatic 
stellate cells by fluorescence microscopy. A. XN fluorescence in hepatic stellate cells 
incubated with 10 µM XN in DMEM containing 1, 2, 3, 4, 10% or no FCS over a period of 60 min. 
Intensity values for all timepoints after XN addition were corrected for background 
fluorescence present at time point 0. Data points represent means of multiple cells ± SD. B. XN 
fluorescence in hepatic stellate cells after 60 min incubation with 10 µM XN in DMEM with 1% 
(upper images) and 10% FCS (lower images). The weak fluorescence present in cells incubated 
with 10% FCS in medium is mostly autofluorescence, which is also present in cells that 
received no XN (not shown). Scale bars: 20 µM. (is published in [226]) 
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Results showed that a reasonable increase was only observable with 1% FCS in medium. At 
higher FCS concentrations, XN fluorescence inside the cells was impaired, probably due to 
quenching or a spectral shift. In cells incubated with 10% FCS in culture medium hardly any 
XN fluorescence was visible (Figure 2-3 B) even though it could be detected and quantified 
via HPLC, as shown by Wolff et al. [228]. 
Likewise, the complete emission of FCS impaired the detectable XN fluorescence inside the 
cells. This may be caused by different factors. On the one hand, increased absorption to the 
culture dish or decreased solubility of XN could alter the available amount of XN to be taken 
up by the cells. On the other hand, binding of XN at least to some proteins contained in the 
FCS could be a premise for its unimpaired uptake into cells. 
The reported conversion of chalcones to flavanones prompted us to look also for the 
appearance of IXN besides XN under the above mentioned cell culture conditions. This 
reaction is not observable after 3 h (DMEM, 10% FCS, 37 °C), whereas the longer incubation 
time (24 h) resulted in the generation of IXN even in non-cellular conditions (data not shown). 
Experiments on the solubility of XN in FCS supplemented DMEM showed that under normal 
cell culture conditions the solved concentration can reach 50-75 µM. The concentration of 
solved XN is further reduced by its absorption to plastic material. The recovery experiments 
clearly revealed that a minimum concentration of 10% FCS in medium is necessary to 
reduce the observed absorption to the plastic to a tolerable value. In contrast, FCS 
concentrations higher than 1% hampered fluorescence measurements with XN rigorously. As 
a general conclusion, we suppose that for several lipophilic natural products a limited 
solubility under assay conditions, absorption to plastic material and a possible interaction 
with FCS in cellular in vitro experiments have to be assumed. A routine determination of the 
maximal FCS concentration seems to be an appropriate parameter for the generation of 
reliable in vitro results. 
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3 Characterization of minor hop compounds, XN 
metabolites and related compounds 
3.1 Abstract 
Xanthohumol (XN, 1) is ingested in human’s diet with beer as well as related chalcones. After 
ingestion, XN (1) is metabolized via biotransformation. The biotransformation might produce 
compounds, which are more active and/or more toxic as the precursor molecules. For this 
reason, the minor hop chalcones, XN (1) metabolites and related compounds were tested on 
their influence on viability and proliferation and thus their induction of cytotoxicity in cancer 
cell lines using the MTT viability assay and crystal violet staining (CV). Furthermore, the 
impact on lipopolysaccharide (LPS)-induced NO production by inducible nitric oxide synthase 
(iNOS) was studied using Griess assay and the influence on iNOS expression was 
determined by immunofluorescence. 
Xanthohumol H (2) lead to lower IC50 in the MTT assay as XN in HuH-7, HSC and Caco-2 
cells. Xanthohumol C (6) and dihydroxanthohumol C 7 were more active in the CV assay. In 
the Griess assay (10 ng/ml LPS as stimulus) the highest activity to inhibit the NO production 
was observed for 3, alpinetin chalcone (18) and helichrysetin (13). In a modified set-up of the 
Griess assay (10 ng/ml LPS and 200 ng/ml IFN-γ as stimulus) the highest activity was 
observed for 6. All compounds showed activity against the iNOS expression with exception 
of 3-OHhelichrysetin (14). The most active compounds were 18, 6, flavokawain B (16), 2 and 
helichrysetin (13). Non-prenylated chalcones and tetrahydropyran chalcones exhibited better 
inhibitory activity against NO production or iNOS expression. 
 
3.2 Introduction 
XN (1) is the main prenylated chalcone in H. lupulus L.. Since the nineteen’s compound 1 
has been intensively investigated. It shows a wide range of effects such as anti-infective, 
anti-inflammatory and anti-cancer activity (see also 1.1 Xanthohumol). In human’s diet 1 and 
minor hop compounds such as prenylated chalcones are ingested with beer. Bioavailability 
studies showed a low disposability [224,225] and substantial metabolism of XN (1, Chapter 
5). The data on pharmacological effects of 1 as well as of phase I and phase II metabolites 
and minor hop chalcones were scarce. The reasons are: 1. The low concentration of minor 
hop compounds and XN (1) metabolites in hops, body fluids and organs; 2. The low amount 
of body fluids and organs available for extraction; 3. The lack of synthesis routes for 1 
phase II metabolites to provide sufficient amounts for in vivo and in vitro testing. 
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However, XN metabolites and structural derivatives might have distinct pharmacological 
effects compared to 1 itself. Thus, a thorough evaluation of their properties is highly 
desirable. 
 
3.2.1 Minor hop compounds, XN metabolites and related compounds 
The minor hop compounds, XN metabolites and structurally related compounds, which were 
investigated in this chapter, are summarized in Figure 3-1. 
XN (1) was isolated for the first time from H. lupulus L. by Power et al. [80]. The minor hop 
compounds xanthohumol C (6), dihydroxanthohumol C (7), desmethylxanthohumol (5) and 
flavokawain C (17) were identified by Stevens et al. [12,82]. 
In order to investigate the metabolism of 1 a variety of in vitro and in vivo studies were 
performed [159,160,233]. The in vivo study performed by Nookandeh et al. revealed several 
XN metabolites such as xanthohumol H (2), 4-acetoxyxanthohumol (3) and 
4-methoxyxanthohumol (4) in feces of female SD-rats [233]. 
Flavokawain A (15) and flavokawain B (16) [245], alpinetin chalcone (18) [246,247], 
helichrysetin (13) and 3-OHhelichrysetin (14) were included in this study in order to look for 
structure response relationship studies. Compounds 15 and 16 were found in 
Piper methysticum but occur also in other plants [245]. Compound 13 is a genuine chalcone 
from Helichrysum heterolasium and was isolated by Bohlmann et al. [248]. A synthesis route 
for 13 and 14 was developed by Vogel et al. [150]. 
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-Continuance of Figure 3-1-  
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Figure 3-1: Structures of the investigated minor hop compounds, XN metabolites and related 
compounds. 1: Xanthohumol (XN), 2: Xanthohumol H, 3: 4-Acetoxyxanthohumol, 4: 
4-Methoxyxanthohumol, 5: Desmethylxanthohumol, 6: Xanthohumol C, 7: 
Dihydroxanthohumol C, 8: Acetylchroman, 9: Prenylacetophenon, 10: 
Tetrahydroxanthohumol C, 11: Dihydrohelichrysetin, 12: Dihydroflavokawain C, 13: 
Helichrysetin, 14: 3-OHhelichrysetin, 15: Flavokawain A, 16: Flavokawain B, 17: Flavokawain C, 
18: Alpinetin chalcone. 
 
3.2.2 Biological effects of XN metabolites 
Diseases such as the metabolic syndrome [162], diabetes [163], inflammation bowel disease 
[164], Alzheimer´s disease [165] and cancer [161] are correlated with chronic inflammation. 
The expression of proinflammatory proteins is modulated amongst others by the transcription 
factor NF-κB. NF-κB plays a central role in the inflammatory process and is correlated with 
oncogenic activation in cancer [34]. It has been observed that the inhibition of the 
transcription factor leads to apoptosis [182]. NF-κB is a dimer, which is located in the cytosol 
and bound to IκB. During activation, the IκB kinase phosphorylates (IKK) the IκB unit of 
NF-κB/IκB and thus allows the degradation by the ubiquitin ligase complex (see 1.1.6 
Anti-inflammatory effect). NF-κB is then translocated to the nucleus and leads to 
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expression of about 200 different proteins, which are involved in the prevention of apoptosis 
[34]. Examples include Bcl-2, enzymes of the prostaglandin synthesis (COX-2, 5-LOX), 
proteins involved in inflammatory mechanisms (inducible nitric oxide synthase (iNOS), 
TNF-α, interleukins (IL)) and adhesion molecules (ICAM-1) [168]. 
In the study of Peluso et al. [178] they investigated the effect of different compounds such as 
1, 5 and 17 on the expression of MCP-1 and IL-6. MCP-1 and IL-6 are downstream signals of 
the LPS induced NF-κB pathway [168]. Both cytokines were inhibited by 1, 5 and 17 at 
20 µM. 17 exhibited the highest inhibitory activity on MCP-1. IL-6 was comparably inhibited 
by 1 and 17. Interestingly, the dihydro compounds and the flavanones showed also activity in 
both, the NO and the MCP-1/IL-6 assay systems [178,181]. It seems that the α,β-unsaturated 
structure is not absolutely required for the NF-κB inhibition. Peluso and co-workers [178] 
proposed an interaction with the MD-2 and Toll-like receptor 4 (TLR4). The fitting of the 
tested compounds with the MD-2 unit was calculated in a molecular docking study. It has 
been shown that the increase in the inhibition of the MCP-1 and IL-6 is correlated with the 
fitting accuracy to MD-2 [178]. MD-2 is needed for the induction of the NF-κB cascade by 
LPS. Compound 1 was shown to reduce the expression of the TLR4 [172,178] and MD-2 
[172]. 
 
The expression of iNOS has been reported to correlate with chronic inflammation found in 
bowel disease [164] and diabetes mellitus [249]. The iNOS produces NO in micromolar 
amounts by L-arginine depletion and L-citrullin production (Figure 3-2) [250]. 
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Figure 3-2: The NO production by iNOS. iNOS catalyze the NO production through L-arginine 
depletion to L-citrullin with O2 and the coenzyme NDPH. 
 
It is controlled by the transcription factors NF-κB and STAT-1. The iNOS expression is 
induced by LPS via the NF-κB pathway and by the cytokine IFN-γ via the JAK/STAT 
pathway. The expression of iNOS is calcium/calmodulin independent and it is constitutively 
expressed. The LPS-binding protein associates with LPS, binds to CD14, and clusters with 
Toll-like receptor 4 (TLR4) [166,183]. MD-2 is essential for the initiation of the NF-κB 
cascade via the TLR4. In the JAK/STAT pathway, IFN-γ binds to the IFN receptors thereby 
leading to a conformation change and auto-phosphorylation of the JAK. The JAK 
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phosphorylates tyrosin residues within the receptor thereby creating docking sites for the 
STAT. The STAT homodimer modulates the expression of IRF-1, inflammatory enzymes 
such as iNOS and adhesion molecules such as ICAM-1 [184]. 
High concentrations of NO can lead to the formation of reactive nitrogen species (RNS). RNS 
can nitrate proteins and DNA, trigger apoptosis and mutagenesis, and maintain cancer 
[250,251]. Studies showed that iNOS activation leads to survival of colorectal cancer [252]. 
The correlation between the iNOS expression and survival was also observed in human 
gastric cancer. The investigation revealed a correlation between the angiogenesis, COX-2 
and tumor progression. The expression of both enzymes, iNOS and COX-2, led to a worse 
prognosis and was correlated with angiogenesis. The prognosis gets better if only one or 
none of the two enzymes was expressed [253]. In ameloblastoma higher iNOS levels were 
correlated with higher VEGF concentrations [254]. However, iNOS seems to have beneficial 
effects, too. NO showed antibacterial effects [255]. In addition, a beneficial interaction with 
cancer was discussed. IFN-γ stimulated leukemia cell lines could be triggered to apoptosis 
by the induction of NO and caspase-3 [256]. In human pancreatic cancer, the induction of 
iNOS led to a higher apoptotic index [257]. The effects of the expression of iNOS are 
controversial discussed in the literature. The outcome depends probably on the molecular 
status of cancer and the NO concentration [250]. Beside the dichotomy of the iNOS, the 
iNOS can be used for the screening of compounds and their ability to influence the 
expression pathways. 
Zhao et al. [181] investigated the effect of chalcones and flavanones on the NO production in 
LPS and IFN-γ stimulated RAW 264.7 cells. The production of NO was inhibited by 
compound 1 and tetrahydroxanthohumol (10) at 5 µM, but the effect was more pronounced 
for 1. The underlying mechanism was not investigated [181]. 
Flavokawains and 18 were tested on their activity to inhibit iNOS, for instance. Compound 15 
has been shown to influence a variety of pro-inflammatory proteins. Compound 16 inhibited 
the expression of iNOS, COX-2, the production of NO and PGE2 as well as the secretion of 
TNF-α in LPS stimulated RAW 264.7 macrophages and mice [258]. Compound 16 inhibited 
the expression of COX-1 [259]. Zhou et al. [260] investigated the influence of 16 on NF-κB in 
TNF-α stimulated human hepatoma HepG2 cells and cervical carcinoma HeLa cells. 
Compound 16 influenced NF-κB mostly in hepatocytes. Decreased levels of free IκBα units, 
a decreased transcriptional activity of NF-κB and decreased nuclear translocation were 
observed. An either direct or indirect inhibition of IKK by 16 was discussed [260]. An IKKβ 
inhibition by 15 but not by 16 could be observed in an in vitro kinase assay. However 15 and 
16 inhibited the TNF-α induced NF-κB transcriptional activity in a luciferase assay. The 
inhibitory mechanism of both flavokawains was based on the inhibition of the IκB degradation 
and the translocation of the subunits p50 and p65 of NF-κB [261]. Compound 18 that carries 
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one O-methoxy group at the C-6´ and a non-substituent B ring, was found to lead to 
remarkable NO inhibition in LPS stimulated RAW 264.7 cells. The IC50 value of 18 was 
1.5 µM (without a SD) [262]. The inhibitory mechanism seems to be similar to that of 16. Qin 
et al. described an inhibition of the IκB degradation [263]. Lee et al. and Israf et al. showed 
an inhibition of the NF-κB translocation induced by 18 [262,264]. 
The IKK is regulated by the Akt. Compound 18 inhibited the Akt and thus the IKK. In addition 
18 indirectly inhibited the transcriptional activity as well as the phosphorylation of RelA/p65. 
Thus, the expression of NF-κB down-regulated enzymes such as iNOS and COX-2 were 
inhibited [262] but without a loss in activity [264]. The production of thromboxane and 
prostaglandins is mainly catalyzed by the COXs. Hence the synthesis of thromboxan B2 and 
prostaglandin E2 was inhibited by 18 in LPS activated blood monocytes [265]. An inhibition of 
the COX--2 was also observed in BV2 [266] and myeloma cells [263]. However an effect of 
18 on the degradation of NF-κB/IκB and the COX-2 expression in THP-1 and RAW 264.7 
cells could not be observed [262–265,267]. 
 
In order to orchestrate the immune response macrophages and neutrophil granulocytes 
segregate chemokines, interleukins and ROS. This leads to an inflammation that is 
characterized by rubor, calor, tumor and dolor, which are the cause of an enhanced 
permeabilization of the vascular system and the infiltration of fluids. In order to orchestrate 
the adaptive cells, endothelial cells produce selective lectins, chemokines and integrins 
(adhesion molecules) on their surface. The adaptive cells can then roll, be activated, adhere, 
and infiltrate the tissue. The whole process is termed homing. The last step of the homing is 
the diapedese and is correlated with a loss of connectivity between the endothelial cells. 
Diapedese allows the entry of the immune cells. Homing is associated with three digit postal 
codes, every cell needs a proper code in order to roll, be activated and adhere to the 
endothelium [268]. Endothelial cells express the adhesion molecule integrin ICAM-1. The 
expression of the adhesion molecule is non-constitutive and is induced by IL-1 and TNF-α 
[166]. A variety of research groups established the ICAM assay, which assesses the 
inhibition of ICAM-1 by different compounds [269,270]. Compound 1, 2, 3, 4, 6, 13 and 14 
were investigated in the ICAM assay in order to determine their influence on the ICAM-1 
production in human microvascular endothelial cells (HAMEC-1) [152]. Compound 14 
showed the highest inhibition of the expression of ICAM-1. Compound 1, 2, 4 and 6 were the 
most ineffective compounds but nevertheless inhibited the ICAM-1 expression. 
 
Beside the anti-inflammatory properties of 1, minor hop chalcones and related compounds, 
they were investigated concerning their cytotoxicity in a few cancer cell lines. However the 
underlying mechanism of the proliferative, inhibitory and cytotoxic effects of XN metabolites 
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and related compounds, with exception of 17 and 18, were not investigated so far. 
Compound 1, 2, 3, 4, 5, 6, 7, 13, 14 and 17 were found to be cytotoxic in Hela cells. The 
cytotoxicity was observed in a lower micromolar range, between 5.2 µM ± 0.8 µM (13) and 
19.2 ± 1.2 µM (17) [150,151,152]. In another study the cytotoxicity of 1, 5 and 6 in human 
breast cancer cells MCF-7, colon cancer cells HT-29 and ovarian cancer cells was 
investigated. 1 was the most active one followed by 5 and 6 (all 10 µM with SE pointed in 
diagram) [186]. 
There are also a few studies available concerning the cytotoxicity of XN (1) related 
compounds. 15-17 were investigated concerning their cytotoxic activity in L-02 and HepG2 
cells [260,271,272]. In the study of Li et al. [271] compound 15 showed no cytotoxicity in both 
cell lines. 16 and 17 were equally toxic in HepG2 cells (IC50 of compound 16: 
62.38 ± 5.04 µM and 17: 59.48 ± 2.72 µM). In L-02 cells 16 showed higher cytotoxic activities 
(IC50 of compound 16: 35.15 ± 2.56 µM and 17: 57.04 ± 2.32 µM) [271]. 
Compound 16 also influenced the growth of human oral squamous carcinoma HSC-3, 
human melanoma (A-2058), oral adenosquamous carcinoma (Cal-27), human non-small-cell 
lung cancer (A-549) [273]; wild type and p53-/- human colon cancer (HCT116), A-549, mouse 
fibroblast (NIH3T3), human fibroblast (HFW) [274]; androgen receptor(AR)-negative 
hormone-refractory prostate cancer (HRPC) DU145 and PC-3 as well as AR-positive HRPC 
LAPC4 and LNCaP cells [275]. Compound 16 triggered cells to regulated cell death by the 
MAPK (ERK, JNK and p38) signaling [260], mitochondrial dependent pathway [274], 
mitochondrial dependent and independent pathways [275] as well as the ER dependent 
pathway [273]. All cited studies discussed the possibility that the apoptotic ways were 
induced by ROS because the addition of NAC [273,274] and GSH [260] prevented apoptosis. 
Additionally cell death via autophagy was also discussed [274]. Interestingly, compound 16 
was studied in vivo in Balb/c mice and exhibited a hepatotoxic effect (16: 25 mg/kg body 
weight for 1 week) which was abolished by GSH [260]. 
The influence of 15 on cellular mechanism was analyzed in urinary bladder cancer cell lines 
such as p53 wild type RT4 and mutated T24 [276], UMUC3, TCCSUP, 5637, 
HT1376-HT1197 [277] and Ej [276]. Zi and co-workers [276] investigated the effect of 15 and 
16 on the cell proliferation and the underlying mechanism of 15 induced apoptosis. The p53 
mutated urinary bladder cell lines were 3 to 4 times more sensitive to 15 than the wild type. 
Compound 15 showed the weakest inhibitory effect on the proliferation and 16 was the most 
potent proliferation inhibitor. The incubation with flavokawains led to typical apoptotic signs 
such as cell shrinking, rounding up, blebbing, nuclear fragmentation and condensation. The 
compound 15 was shown to influence apoptotic factors such as Bax and caspase-3/9. Zi et 
al. [276] determined the influence of 15 on the tumor growth in in vivo xenografts (Ej) 
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NCR-nu/nu mice. Mice were fed with 50 mg/kg 15 for 25 days. A tumor growth inhibition of 
57% was observed [276]. 
The compound 18 is a simple chalcone which carries a non-substituted B ring and an 
O-methoxy group in the A ring (Figure 3-1). A viability inhibition of a human colon cancer cell 
line SW-480 by 18 was detected. The IC50 value was 35 µM (without SD) [278]. The inhibition 
mechanism was studied in more detail in vitro [52] and in vivo [279]. Compound 18 induced 
apoptosis via the in- and extrinsic pathway by the up-regulation of the death receptor 5. The 
up-regulation of the death receptor 5 was discussed to be correlated with the NF-κB 
inhibition [52]. In the in vivo studies of Yadav et al. [279] the up-regulation was correlated 
with an increased ROS production. Furthermore, 18 was shown to inhibit TNF-α mediated 
cell death in L929 cells at an IC50 value of 7 µM (without a SD) [280]. 
Summing up, the minor hop compounds 5, 6 and 17 were investigated concerning their 
antioxidant and cytotoxic activity so far. The XN metabolites and other minor hop ingredients 
were less or not investigated concerning cytotoxic, hepatotoxic, proliferative, and 
inflammatory properties with the exception of 15, 16 and 18. Furthermore, a 
structure-response relationship study with the metabolites, minor hop substances and 
structure related flavokawains, unprenylated chalcones (13, 14) and dihydro compounds was 
not performed, yet. 
 
3.3 Aims of the study 
XN (1) is ingested in human’s diet with beer as well as related chalcones. After ingestion, 
biotransformation might produce compounds, which are more active and/or more toxic as the 
precursor molecules. For this reason the minor hop chalcones, XN metabolites and related 
compounds were tested on their capability to influence viability and proliferation in cancer cell 
lines using the MTT and CV assay. Furthermore, the ability of the compounds to inhibit NO 
production by iNOS was determined by Griess assay. Expression of iNOS was analysed 
using immunofluorescence combined with fluorescence microscopy and image analysis.  
 
3.4 Material 
3.4.1 Chemicals 
Chemicals Compounds 2, 3, 4, 6-9, 13, 14, 15-17, 18 were obtained by synthesis (University 
of Regensburg) [150,152]. XN (1) was provided by the Nookandeh Institut (Hamburg, 
Germany) and exhibited a purity of 98%. The hydrogenations of 7, 13, 17 were performed by 
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Petr Jirásek (Pharmaceutical Biology, University of Regensburg) using a method described 
by Mori et al. [281] to obtain the compounds 10-12. The purities of the tested compounds 
were between 86-99% (3.6.1 Purity degree, lipophilicity and structure determination). Ethanol 
(Order no. 8006) was bought from J.T. Baker (Deventer, Netherlands). Deuterated acetone 
and chloroform were obtained from the Deutero GmbH (Kastellaun, Germany). 
Crystal violet (Order no. 1190210), tri-sodium citrate dihydrate (Order no. 1.06448.1000), 
dimethyl sulfoxide (DMSO) (Order no. 1.02931.1000), ortho-phosphoric acid (Order no. 
1.00573.1000), sodium dodecyl sulfate (SDS) (Order no. 1.02931.1000), acetone (Order no. 
1.00014.2511), formic acid (Order no. 1.00264.1000), glacial acetic acid (Order no. 
1.00063.1000), sulfuric acid (Order no. 1.00731.1000), acetonitrile (Order no. 1.00030.2500), 
methanol (Order no. 1.06035.2500), sodium nitrite (Order no. 1.06549.0500) and HPTLC 
plates silica gel 60 F254 (charge HX109045) were purchased from the Merck KGaA 
(Darmstadt, Germany). 
Anisaldehyde (Order no. A8, 810-7), naphtyletyhlene diamine dihydrochloride (NED) (Order 
no. N-5889), sulfanilamid (Order no. S-9251), 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) (Order no. M-2128), trypan blue (Order no. T-0887), 
lipopolysaccharide (LPS) from Escherichia coli 055:B5 (LPS) (Order no. L-2880) and 
Interferon-γ (IFN-γ) mouse recombinant expressed in E. coli (Order no. I-4777) were obtained 
from Sigma-Aldrich (Steinheim, Germany). 
Ethyl acetate (Order no. 232110025) and cyclohexane (Order no. 176810010) were 
purchased from Acros Organics (Geel, Belgium). 
Deionized water (18 mS/cm) was obtained using a Millipore Milli-Q UF Plus equipment. 
 
3.4.2 Cell lines and culture materials 
Cell lines. The immortalized activated human hepatic stellate cell line (HSC) was obtained 
from the University Hospital of Regensburg, Department of Internal Medicine I [244]. The 
human hepatoma cell line (HepG2) (ATCC®-number HB-8065TM) and the murine macrophage 
cell line (RAW 264.7) (ATCC®-number TIB-71TM) were obtained from the American Typ 
Culture Collection (ATCC, USA). The human colorectal cell line (Caco-2, ATCC®-number 
HTB-37TM) was a gift from the Institute of Virology, Helmholtz Zentrum München, Germany. 
The human hepatoma cell line (HuH-7, HSRRB-number JCRB0403) was obtained from the 
Health Science Research Resources Bank (HSRRB) of the Japan Health Sciences 
Foundation (JHSF, Japan). 
Media and supplements. Roswell Prak Memorial Institute 1640 (RPMI 1640) medium 
without phenol red (Order no. F 1275), RPMI 1640 medium with phenol red (Order no. 
F 1215), Dulbecco’s modified eagle medium (DMEM) with phenol red (Order no. FG 0415), 
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L-glutamine (Order no. K 0283), non essential amino acids 100 x (NEAA, Order no. K 0293), 
fetal calf serum (FCS, Order no. S 0115), phosphate buffered saline (PBS, Order no. 
L 1825), sodium pyruvate 100 mM (SP, Order no. L 0473) and trypsin 10 x (Order no. 
K 2135) were purchased from the Biochrom AG (Berlin, Germany). 
DMEM without phenol red (Order no. 41965) and DMEM with phenol red (Order no. 31053) 
were bought from Invitrogen, GIBCO (Grand Island N.Y., U.S.A.). 
Material for routine cell culture work and experiments. 96 well plates (Order no. 92096), 
cell scrapers (Order no. 99003), culture flasks 75 cm² (Order no. 90076) and 150 cm² (Order 
no. 90151) were purchased from TPP (Trasadingen, Switzerland), safe lock tubes 1.5 ml 
(Order no. 0030.102.002) and 2 ml (Order no. 0030 120.094) from Eppendorf (Hamburg, 
Germany) and centrifuge tubes 15 ml (Order no. 17020) from MEUS s.r.l. (Piove di Sacco, 
Italy). The Cellomics® iNOS activation kit (Order no. 8403802) was purchased from Thermo 
Scientific (Bonn, Germany). 
 
3.5 Methods 
3.5.1 Purity analysis 
The purity of the used compounds was analyzed by HPLC. The HPLC-system consisted of 
an organizer Elite Lachrom, diode array detector L-2455, autosampler L-2200, pump L-2130 
and a column oven L-2350 (all from VWR-Hitachi, Breda, Netherlands). A Purosphere® Star 
RP-18e 250 x 4.0 mm 5 µm column form Merck (Darmstadt, Germany) was used. The 
analytes were dissolved in acetone at a concentration of 10 mM and diluted to a final 
concentration of 10 µM in 50% acetone. A sample of 20 µl was injected and separated using 
a gradient program. Eluent A consisted of water supplemented with 0.1% formic acid. Eluent 
B was acetonitrile. UV-detection was performed at a wavelength of 368 nm. The gradient 
started with 55% eluent B and reached 85% after 27 minutes. During the following 3 min the 
initial conditions were reestablished and hold for 10 min. The HPLC was operated at a flow of 
1.0 ml/min and a temperature of 30 °C. 
The purity of the compounds was calculated as percent of the total peak area. 
 
3.5.2 Comparison of lipophilicity by high performance thin layer 
chromatography (HPTLC) 
The lipophilicity of the compounds was rated by HPTLC analysis (CAMAG, Muttenz, 
Switzerland). It was performed with a twin through chamber 200 x 100 mm, a Linomat 5 
applicator, an ADC 2 automatic developing chamber and a Reprostar 3. 7.5 µl of 500 µM 
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solutions were applied in 1 cm lines on HPTLC plate Silica gel 60 F254. The first/last 
compound and the start line had 1 cm distance from the respective borders of the silica plate. 
The solvent system was hexan:ethyl acetate:methanol 70:20:10 + 0.1% formic acid. After 
11 min of separation, the compounds were heated up to 110 °C on a heatplate 
Thermoplate S (Desaga, Sarstedt AG & Co., Nümbrecht, Germany). After 5 min, the HPTLC 
plate was dipped into Naturstoff reagent (5 g/l in methanol). Then the HPTLC plate was 
dipped into macrogol 400 (50 g/l in methanol). 
 
3.5.3 Hydrogenation and NMR analysis 
The hydrogenation of 7, 13 and 17 was performed by Petr Jirásek using a method described 
by Mori et al. [281]. The molecular structures were confirmed by NMR using a Bruker Avance 
spectrometer (400 MHz). 1H NMR spectra were recorded at ambient temperature. For this 
purpose, 10 and 12 were dissolved in deuterated chloroform. Compound 11 was dissolved in 
deuterated acetone. 
 
3.5.4 FCS heat inactivation 
FCS was inactivated in a water bath at 56 °C for 30  min. The FCS was cooled down to room 
temperature, and aliquoted in 50 ml portions. The aliquots were stored at -20 °C until used. 
 
3.5.5 Cell cultivation and harvesting 
HSCs, HuH-7 and HepG2 cells were cultivated in DMEM with phenol red from Invitrogen, 
GIBCO (Grand Island N.Y., U.S.A.), which was supplemented with 10% heat-inactivated 
FCS. Caco-2 cells were cultivated in DMEM with phenol red from Biochrom AG (Berlin, 
Germany), which was supplemented with 10% heat-inactivated FCS, 1% SP and 1% NEAA. 
The cells were cultivated in 150 cm2 culture flasks and kept in a New Brunswick scientific cell 
incubator (Edison, N.J., U.S.A.) at 37 °C and 5% CO2 in a humidified atmosphere. Once a 
week the cell lines were split and after four days the growth media were exchanged. For 
splitting, the exhausted media were aspirated and the confluent cells were carefully washed 
with 13 ml PBS. After aspiration of PBS, 2 ml of trypsin (1 x in PBS) were added to the 
culture flasks with confluent cells. The adherent cells were incubated for approximately 4 min 
at 37 °C. After carefully beating at the underside of the culture flask wall, cells were detached 
from the bottom of the culture flask. 5 ml medium were added to the trypsin/cell suspension 
to stop the trypsination. 
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Mouse macrophages RAW 264.7 were cultivated in RPMI 1640 medium supplemented with 
10% heat-inactivated FCS and 1% L-glutamine. Three times a week RAW 264.7 were 
splitted. In order to detach RAW 264.7 from the culture flasks bottom, the cells were 
scrapped off with a cell scraper. For this, the exhausted growth medium was discarded and 
5 ml medium were added to the adherent mouse macrophages. The cell suspension of each 
cell line was transferred to a 15 ml centrifuge tube. In order to remove dead cells and debris, 
the cell suspension was centrifuged in a centrifuge Megafuge 1.0 R (Heraeus Sepatech 
GmbH, Osterode, Germany) at 700 rpm for 5 min. The supernatant was discarded and the 
cells were resuspended in 5 ml medium. HSCs, HuH-7 and Caco-2 cells were diluted 1:10. 
HepG2 and RAW 264.7 cells were diluted 1:20. 
 
3.5.6 Cell counting 
The cell suspensions were counted in a Neubauer cell counting chamber and seeded in 
96 well plates (TPP, Trasadingen, Switzerland) to determine the viability, proliferation, NO 
production and iNOS expression. Therefore, a small amount of the cell suspension (3.5.5 
Cell cultivation and harvesting) was diluted with 0.4 mg/ml trypan blue PBS. 10 µl of the 
trypan blue cell suspension were pipetted under the glass lid of the Neubauer cell counting 
chamber. Cells in 4 large-scale quadrates were counted and the cell number was calculated 
by the following equation (Equation 3-1). 
 
 
 
 
 
Equation 3-1: Calculation of the cell numbers. Cells were counted with a Neubauer cell 
counting chamber. 
 
3.5.7 Dilution of test compounds 
Prior to use the compounds were dissolved either in DMSO or in ethanol yielding either 
100 mM or 10 mM stock solutions. In the next step, the stock solutions were diluted with 
medium without phenol red to their test concentrations. DMEM without phenol red was used 
for HSC, HuH-7, HepG2 and Caco-2 cells. RPMI 1640 medium without phenol red was used 
for RAW 264.7 cells. The dilutions were used for 3.5.8 Viability assay, 3.5.9 Proliferation 
assay, 3.5.10 Nitric oxide , and 3.5.11 iNOS . 
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The end concentrations of solvent were kept below 0.1% (DMSO) and 1% (ethanol) 
respectively. 
3.5.8 Viability assay 
The MTT viability assay was performed according to Mosmann et al. [282] with the following 
modifications. Each incubation step was performed in an incubator at 37 °C and 5% CO2, in 
humidified atmosphere. Each well of a 96 well plate was filled with 100 µl medium with 
phenol red containing 5.000 HSC cells or 15.000 HuH-7 cells or 7.500 HepG2 cells or 15.000 
Caco-2 cells or 5.000 RAW 264.7 cells (medium see 3.5.5 Cell cultivation and harvesting). 
The outer wells were filled only with medium (blank value). The whole pipetting scheme is 
summarized in Figure 3-13. The cells were kept for 24 h at 37 °C to allow sedimentation and 
adherence on the culture flask bottom. Afterwards the exhausted growth medium was 
aspirated and 100 µl of medium with the test compounds in different concentrations were 
added. 
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Figure 3-3: Pipetting scheme of a 96 well plate used for viability testing. The outer wells (light 
gray) were filled with medium (blank value). 3 wells of column 2 and 11 were filled with either 
100 µl medium without compounds (control abbreviation c) or with 100 µl medium with the 
highest solvent concentration (solvent control abbreviation s.c.). The interior wells from row B 
to G and column 3 to 10 were used for IC50 determinations of two compounds. Eight different 
concentrations of compound 1 and compound 2 were measured. The rows B, C and D were 
filled with compound 1. E, F and G with compound 2. The compounds were diluted to their test 
concentration of 10, 20, 30, 40, 50, 60, 80 and 100 µM (see 3.5.7 Dilution of test compounds). 
Each well was filled with 100 µl. 
 
After 24 h incubation, the compound solutions were aspirated. Shortly before use, 4 mg/ml 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT)) in PBS were 1:10 diluted in 
medium (RPMI for RAW 264.7 and DMEM for the other cell lines). 100 µl of 0.4 mg/ml MTT 
solution were filled in each well followed by incubation for 3 h. 
After conversion of MTT to formazan crystals by mitochondrial dehydrogenases (Scheme 
3-1), the MTT solution and the medium of the outer wells (blank value) were removed and 
100 µl of a 10% SDS solution were pipetted into the wells to solve the formazan crystals. 
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Scheme 3-1: Reaction of the tetrazolium salt MTT to formazan catalyzed by succinat 
dehydrogenase. 
 
After 24 h, the formazan crystals were dissolved in SDS. The absorption A was measured 
with the microplate reader SpectraFluor Plus (TECAN, Hombrechtikon, Switzerland) at 
560 nm. 
For each compound, the determination was performed in 3 different experiments with 
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different passage numbers. For all compounds, the viability was determined with Equation 
3-2. 
 
 
 
Equation 3-2: Calculation of cell viability in % referring to untreated control cells. 
 
3.5.9 Proliferation assay 
To analyse the influence of the test compounds on proliferation, cells were stained with 
crystal violet (CV, structure is depicted in Scheme 3-2). CV as a cationic dye intercalates in 
the histone free areas of the DNA. The crystal violet staining assay (CV) was adopted from 
[283]. 
At the beginning of the experiments cells were seeded into three 96 well plates. After 24 h 
cultivation one 96 well plate was stained with CV solution in order to determine the initial cell 
density prior to the addition of the test compounds. The two remaining 96 well plates were 
used to analyse the influence of the substances on cell proliferation. One of the remaining 
96 well plates was handled as described in 3.5.8 Viability assay up to the removing step of 
the compound solution. The third 96 well plate only received culture medium in order to 
determine the 48 h blank values of untreated cells. 
 
C
N N
Cl
N
 
 
Scheme 3-2: Structure of crystal violet. 
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After the aspiration of the compound solutions the staining was performed with 50 µl 0.5% 
CV dissolved in 20% methanol for 10 min. After the removal of the CV solution, stained cells 
were washed 3 times with 250 µl deionized water in order to completely remove unbound 
CV. The plates were air-dried at room temperature. Subsequently, 100 µl of a 0.05 M sodium 
citrate/ethanol (1:1, v/v) solution were added to each well in order to dissolve the bound CV. 
Afterwards the absorption was measured with a SpectraFluor Plus microplate reader 
(TECAN, Hombrechtikon, Switzerland) at 560 nm. 
For each compound the experiment was performed three times with different passage 
numbers. The control value of untreated cells after 48 h was defined as 100% proliferation. 
Inhibition of the proliferation was defined as the part of the values that were found in between 
the 24 h and the 48 h control values. Cytotoxicity was defined as the part of the values found 
below that one of the 24 h control. 
 
3.5.10 Nitric oxide assay (Griess assay) 
The nitric oxide assay was performed in order to determine the influence of the test 
compounds on the NO production by iNOS. The test method was adopted from [284]. 
For this assay, 100 µl RPMI 1640 medium with phenol red containing 8 x 104 RAW 264.7 
cells were seeded in 96 well plates and cultured for 24 h. Then the media were aspirated and 
100 µl of a mixture of 50 µl of the test solutions in concentrations that showed no effect on 
the cell viability and 50 µl of 20 ng/ml LPS (yielding a final concentration of 10 ng/ml LPS per 
well) were pipetted in each well. The plates were cultivated for another 24 h. The complete 
pipetting scheme is depicted in Figure 3.4. 
Usually the used concentrations in both assays were 2, 5, 8, 10 and 15 µM. Desm XN was 
used up to 30 µM, A-chroman and P-acetophenon up to 50 µM.  
In the second set-up of the nitric oxide assay the same pipetting scheme was used, but the 
testing solutions were supplemented with 20 ng/ml LPS plus 400 ng/ml IFN-γ yielding a final 
concentration of 10 ng/ml LPS and 200 ng/ml IFN-γ per well. 
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Figure 3-4: Pipetting scheme of a 96 well plate used in the nitric oxide assay. The columns 1 
and 12 (light gray) were filled with medium. Four wells of column 2 and 11 were filled with 
100 µl medium without compounds (control), the other four wells in column 2 and 11 were filled 
with 100 µl medium supplemented with the highest solvent concentration (s-control). The 
interior wells of rows A to D in columns 3 to 6 were used to determine the influence of 
compound 1 on the nitric oxide. Usually the compound concentrations were 2, 5, 8, 10 and 
15 µM. 100 µl were pipetted in each well. In order to check the appropriate stimulation the cells 
in row A and H were not stimulated. 
 
The intracellularly generated NO is released into the culture medium where it gets oxidized to 
nitrite. In order to determine the concentration of the accumulated nitrite in the supernatants, 
a 9 point nitrite calibration curve (serial dilution started with 100 µM) was prepared in 
RPMI 1640 without phenol red using a 100 µM sodium nitrite stock solution solved in 
RPMI 1640 without phenol red. After an incubation time of 24 h, 50 µl of each supernatant 
were transferred to a new 96 well plate. 50 µl Griess reagent were added to the supernatants 
and the nitrite solutions followed by incubation for 15 min.  
The Griess reagent was composed of 0.1% naphtyletyhlene diamine dihydrochloride (NED, 
Sigma-Aldrich, Steinheim, Germany) and 1% sulfanilamide (Sigma-Aldrich, Steinheim, 
Germany) in 50 mM ortho-phosphoric acid (85%, Merck, Darmstadt, Germany). For easier 
dissolution of the components, the reagent was prepared in a hot waterbath, and then cooled 
down before use.  
The Griess reagent reacts with nitrite to form an azo dye. The underlying reaction scheme is 
depicted in Scheme 3-3.  
The absorbance of the colored solutions was measured at 560 nm using a SpectraFluor Plus 
microplate reader (TECAN, Hombrechtikon, Switzerland). 
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Scheme 3-3: Griess reaction. The nitrite reacts with the amino group of sulfanilamide. A 
diazonium cation is formed which binds to naphtyletyhlenediamine and builds an azo dye 
[285]. The absorbance of the colored solutions is measured at 560 nm. 
 
For each compound the experiment was performed 3 times with different cell passage 
numbers. The nitrite content of the samples was calculated using the prepared calibration 
curve. Control c, which was incubated with medium and stimuli, was defined as 100% NO 
production. 
 
3.5.11 iNOS protein expression 
In order to determine if an inhibition of nitric oxide formation by the compounds was based on 
a reduced expression of iNOS protein, expression was analyzed by immunofluorescence 
using the Cellomics® iNOS Activation Kit (Thermo Scientific, Bonn, Germany). For this, 
1 x 104 RAW 264.7 cells were seeded, incubated and stimulated as described in 3.5.10 Nitric 
oxide assay. Most of the compounds were tested at concentrations of 5 and 10 µM. The 
dihydro compounds were also tested at 15 µM. Compounds 16–18 were also analysed at 
2 µM. 5 and 9 were used up to 40 µM and 8 up to 50 µM. After incubation with the test 
compounds, immunostaining was performed as described in the kit instructions. Briefly, the 
cells were fixed and blocked. Staining the iNOS protein with the primary antibody and the 
staining solution the cells were permeabilized. 
Fluorescence imaging was carried out with a computer-controlled Cell Observer® system 
consisting of a Zeiss Axio Observer (Carl Zeiss, Göttingen, Germany) with software 
AxioVision 4.8.1 (Carl Zeiss, MicroImaging, Munich, Germany), motorized scanning stage, 
AxioCam HRm and HXP 120 light source. Images were aquired using a 10x/0.3 Ph1 M27 EC 
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Plan-Neofluar objective (Carl Zeiss AG, Oberkochen, Germany). Image analysis was 
performed with the ASSAYbuilder® Physiology Analyst software. The valid object count 
(number of cell cores detected by the software) and mean ring spot total intensity were the 
parameters used for calculation. With the mean ring spot total intensity a ring is 
superimposed on the cell without the cell core and the intensity is measured by the software. 
For each compound the experiment was performed 3 times with different cell passage 
numbers. 
 
3.5.12 Statistical analysis and calculations 
The statistical analysis was performed with Graph Pad Prism 4. Significant different averages 
(p value < 0.05) were evaluated statistically with one-way ANOVA followed by Tukey’s 
Multiple Comparison Post Test. 
The IC50 values were calculated with Graph Pad Prism 4. Therefore a sigmoidal 
dose-response were calculated with a variable hillslope, fixed bottom and top. 
The results were expressed as mean ± standard deviation (SD). Results were checked for 
outliers using Grubbs test. 
 
3.6 Results 
3.6.1 Purity degree, lipophilicity and structure determination 
The investigated compounds were analyzed by HPLC in order to determine their purity. The 
purity was 94 to 99% with exception of 5 (see Table 3-1: Purity and lipohilicity), which had a 
purity of 86%. 
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Table 3-1: Purity and lipohilicity of the investigated compounds. 
No. Compound IUPAC name Rf-values 
Purity 
% 
1 Xanthohumol (XN) 
 
2’,4’-Dihydroxy-6’-methoxy- 
3’prenylchalcone 
0.15 99 
2 Xanthohumol H 2’,4’,4-Tri(hydroxy)-3’(3’’-hydroxy-3’’- 
methylbutyl)-6’-methoxychalcone 
0.08 97 
3 4-Acetoxy-
xanthohumol 
4-Acetoxy-2’,4’-dihydroxy-6’-methoxy-3’- 
prenylchalcone 
0.25 96 
4 4-Methoxy-
xanthohumol 
2’,4’-Dihydroxy-4,6-dimethoxy-3’- 
prenylchalcone 
0.29 96 
5 Desmethyl-
xanthohumol 
2‘,4,4‘,6‘-Tetrahydroxy-3‘- prenylchalcone 0.09 86 
6 Xanthohumol C 2’’,2’’-Dimethylpyrano[2’’,3’’:3’,4’]-2’,4- 
dihydroxy-6’-methoxychalcone 
0.33 97 
7 Dihydroxanthohumol
 C 
2’’,2’’-Dimethyl-3’’,4’’-dihydro-(2H)- 
pyrano[2’’,3’’:3’,4’]-2’,4-dihydroxy-6’- 
methoxychalcone 
0.35 98 
8 Acetylchroman 2,2-Dimethyl-5-hydroxy-7-methoxy- 
acetylchroman 
0.36 94 
9 Prenylacetophenon 2,4-Dihydroxy-3-prenyl-6- 
methoxyacetophenon 
0.69 98 
10 Tetrahydroxanthohu
mol C 
Dihydro 
2’’,2’’-Dimethyl-3’’,4’’-dihydro-(2H)-pyrano[
2’’,3’’:3’,4’]-2’,4-dihydroxy-6’- 
methoxychalcone 
0.39 87 
11 Dihydro-helichrysetin Dihydro 
2’,4,4’-Trihydroxy-6’-methoxychalcone 
0.15 88 
12 Dihydro-
flavokawain C 
Dihydro 
2’,4-Dihydroxy-4’,6’-trimethoxychalcone 
0.28 94 
13 Helichrysetin 2’,4,4’-Trihydroxy-6’-methoxychalcone 0.14 99 
14 3-Hydroxy-
helichrysetin 
2’,3,4,4’-Tetrahydroxy-6’- 
methoxychalcone 
0.07 98 
15 Flavokawain A 2’-Hydroxy-4,4’,6’-trimethoxychalcone 0.49 99 
16 Flavokawain B 2’-Hydroxy-4’,6’-dimethoxychalcone 0.56 94 
17 Flavokawain C 2’,4-Dihydroxy-4’,6’-trimethoxychalcone 0.25 99 
18 Alpinetin chalcone 2’,4’-Dihydroxy-6’-methoxy-chalcone 0.31 99 
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Furthermore, the lipophilicity of the compounds was estimated by HPTLC in order to identify 
a possible relationship between the lipophilicity and the biological activity of the used 
compounds. The results of the HPTLC are depicted in Figure 3-5 and the Rf-values are in 
Table 3-1, starting with the most lipophilic 9 > 15 > 14 > 10 > 8 > 7 > 6 > 18 > 4 > 12 > 17 = 3 
> 1 = 11 > 13 > 5 > 2 > 14. 
 
 
 
A  B  C D  E   F G  H    I J K  L M N  O P  Q  R  S  
 
 
Figure 3-5: The lipophilicity of 18 compounds was estimated by HPTLC. A: Flavokawain A (14), 
B: Flavokawain B (15), C: Flavokawain C (17), D: Alpinetin chalcone (18), E: Pinostrobin, F: 
4-Acetoxyxanthohumol (3), G: Dihydroxanthohumol C (7), H: Xanthohumol C (6), I: 
Xanthohumol H (2), J: 4-Methoxyxanthohumol (4), K: Helichrysetin (13), L: 3-OHHelichrysetin 
(14), M: Xanthohumol (1), N: Desmethylxanthohumol (5), O: Acetylchroman (8), P: 
Prenylacetophenon (9), Q: Dihydro-Flavokawain C (12), R: Tetrahydroxanthohumol C (10), S: 
Dihydro-Helichrysetin (11). The solvent system consisted of hexan:ethyl acetate:methanol 
(70:20:10) + 0.1% formic acid. The HPTLC plates were derivatized with Naturstoff reagent and 
macrogol. 
 
In the majority the inhibition of the NF-κB pathway is attributed to the Michael system. In 
order to analyze if the Michael system is solely responsible for the iNOS inhibition, 7, 13 and 
17 were hydrogenated to obtain 10-12. The hydrogenation reaction was verified by 1H NMR 
spectroscopy. The 1H NMR spectra confirmed the complete hydrogenation (see Figure 9-1). 
 
3.6.2 Effect on the cell viability and proliferation 
Compounds 1-4, 6, 7, 13 and 14 (3.2.1 Minor hop compounds, XN metabolites and related 
compounds) were tested in two cell based assays, the cell viability MTT assay and the 
proliferation assay CV. The compounds were tested concerning their effects in 3 hepatoma 
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HSC, HepG2, HuH-7 cell lines, and a colon carcinoma Caco-2 cell line as well as 
immortalized mouse macrophages RAW 264.7. 
IC50 values determined in MTT and CV assay. In order to determine IC50 values for the 
viability and proliferation data, the different cell lines were incubated with the compounds at 
concentrations of 10, 20, 30, 40, 50, 60, 80 and 100 µM. Based on the concentration 
response curves, the IC50 values were calculated for both assays as mean ± SD (three 
different experiments). The IC50 values are summarized in five diagrams in Figure 3-6. In 
A-D, the IC50 proliferation and viability values of 1-4, 6, 7, 13 and 14 are depicted for HSC, 
HepG2, HuH-7 and Caco-2 cells. In Figure 3-6, the IC50 viability values for RAW 254.7 cells 
concerning the above mentioned eight substances plus additional derivatives are 
summarized. 
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-Continuance of Figure 3-6- 
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Figure 3-6: IC50 values of the compounds determined from off dose response proliferation (█) 
and viability curves (█). No IC50 value could be calculated for the compound 4 (#) and 
compound 14 (*). Compound 14 (*) showed no toxicity up to the highest tested concentration of 
100 µM (1)). A: HSC, B: HepG2, C: HuH-7, D: Caco-2, E: RAW 264.7. Mean ± SD n ≥ 4.  
 
The IC50 values of 14 (*) and 4 (#) could not be calculated for the cell lines (A-D) in both 
assays (MTT/CV). The hydrophilic compound 14 showed no effect on the cell viability, cell 
proliferation or cell behavior up to a concentration of 100 µM (1) display the upper 
measurement concentration see Figure 3-6). However, compound 4 caused a measurable 
effect in both assays but no IC50 value could be determined. In almost all cell lines 20 µM of 4 
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induced a decrease in the viability, a proliferation inhibition and exhibited cytotoxicity. The 
effects of 4 were very similar at concentrations between 20-100 µM (see Figure 3-7). Hence, 
no IC50 value of 4 could be calculated. 
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Figure 3-7: The behavior of 4-methoxyxanthohumol (4) in the MTT (A) and CV (B) assay in four 
cell lines. The first light grey bar displays the HSC, the second darker grey bar the HepG2, the 
third dark grey bar the HuH-7 and the fourth white bar the Caco-2 cells. Abbreviation c. and 1 c. 
display the control of untreated cells after 24 h incubated with medium 2. c. Control of 
untreated cells after 48 h of incubation. 
 
Nevertheless, compound 4 showed a strong effect, but not a sigmoidal behavior (Figure 3-7). 
A low activity on the cell viability and proliferation was detected for compound 13. The IC50 
values (MTT) of 13 were 33.0 ± 8.6 µM (E: RAW 264.7), 93.0 ± 9.5 µM (C: HuH-7), 
96.7 ± 1.6 µM (A: HSC) and >100 µM (B: HepG2, D: Caco-2) (Figure 3-6). Summing up 13 
showed marginal and 14 no biological activity in all cell lines and both assays. 
The compound (concerning prenylated chalcones and those with tetrahydropyran ring 
annuleted to the A-ring) 2 reached the lowest IC50 value in HuH-7, HSC and Caco-2 cells 
determined with MTT assay. Compound 2 showed IC50 values of 49.4 ± 6.1 µM (A: HSC), 
47.7 ± 2.3 µM (C: HuH-7) and 60.1 ± 16.2 µM (D: Caco-2). Only in HSC cells a significant 
difference could be measured between 2 and the other prenylated chalcones. The 
compounds 2 and 7 (IC50 of 55.4 ± 3.7 µM) were the compounds which reached significantly 
the lowest IC50 values in the MTT assay. The highest IC50 values in HSCs reached 6 and 3. 
The compound 6 showed IC50 value of 69.1 ± 3.3 µM and 3 of 74.5 ± 6.8 µM (A: HSC). Quite 
the opposite direction for 3 was determined in HepG2 cells. Compound 3 reached the lowest 
IC50 values of 39.8 ± 6.6 µM, but a significant difference in the values could be only 
measured between 3 and 6 (52.6 ± 2.2 µM). The other chalcones such as the prenylated and 
tetrahydropyran-chalcone exhibited an IC50 value of 46.0 ± 2.1 µM (XN, 1), 50.2 ± 2.2 µM (2) 
and 50.0 ± 5.3 µM (7 (A: HSC)). 
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In the macrophages cell line RAW 264.7 16 showed the lowest IC50 value of 16.0 ± 4.7 µM. 
Not only 16 exhibited remarkable IC50 values in RAW 264.7, also the structural related 
chalcones 17 (24.1 ± 10.0 µM) and 18 (20.6 ± 11.7 µM). In the group of the prenylated 
chalcones 2 (19.4 ± 0.3 µM) and 10 (22.9 ± 4.0 µM) reached the lowest IC50 values. 
In the CV assay a quite opposite behavior was measured for 2 and 7 as well as for 6. The 
compound 2 showed the highest IC50 values concerning the proliferation e. g. >100 µM (A: 
HSC), 98.4 ± 10.5 µM (B: HepG2), 93.3 ± 21.9 µM (C: HuH-7) and >100 µM (D: Caco-2). 
Compound 7 showed the lowest IC50 values of 55.1 ± 6.8 µM (A: HSC), 45.2 ± 9.1 µM (C: 
HuH-7) and 41.7 ± 5.4 µM (D: Caco-2). Compound 7 was significant different from compound 
2 in HSC and Caco-2. A similar trend was observed for 6. In HSC (73.8 ± 8.5 µM), HuH-7 
(50.4 ± 21.8 µM) and Caco-2 (42.4 ± 8.4 µM) cells the IC50 values of 6 were higher as for 7 
but lower compared to the other compounds. In HepG2 cells 6 reached the lowest IC50 value 
of 40.2 ± 10.2 µM. 
Sensitivity of the cells incubated with the compounds. Already low concentrations of the 
investigated compounds led to a cell viability decrease in RAW 264.7 macrophages. The IC50 
value of 2 was 19.4 ± 0.3 µM compared to 49.4 ± 6.1 µM in HSC, 47.7 ± 2.3 µM in HuH-7 
and 60.1 ± 16.2 µM in Caco-2 cells. HSC and Caco-2 were the most unsusceptible cell lines. 
The HSC and Caco-2 cells were robust against incubation with high concentrations of all 
tested chalcones except of Heli. 
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3.6.3 Nitric oxide assay 
All compounds were screened concerning their ability to inhibit the NO production using a 
Griess assay. Two different stimuli were used to induce the NO production and thus allow for 
the measurement of the influence of the tested compounds on the NO production. One of the 
stimuli was 10 ng/ml LPS. The second was a combination of 10 ng/ml LPS and 200 ng/ml 
IFN-γ. The results of the Griess assay are summarized in Table 3-2. 
 
Table 3-2: Influence of 18 compounds (1-18) on the NO production by iNOS in RAW 264.7 cells 
determined by Griess assay. NO formation was induced either with LPS or with a combination 
of LPS and INF-γ. The compounds were tested at their non-toxic concentration. In the table the 
remaining NO production in % from the control is depicted. 
 10 ng/ml LPS 10 ng/ml LPS and 200 ng/ml IFN-γ 
Compound 
Concentration in 
µM 
% remaining NO 
production 
Concentration in 
µM 
% remaining NO 
production 
 
    
1 10 65.4 ± 12.0 15 84.1 ± 6.0 
2 5 65.4 ± 17.3 15 78.3 ± 3.0 
3 10 74.0 ± 8.1 no inhibition 
4 5 75.5 ± 7.5 no inhibition 
5 15 25.6 ± 21.4 15 87.8 ± 3 
6 2 72.1 ± 4.1 5 84.7 ± 5.3 
7 5 62.3 ± 16.7 8 76.8 ± 10.5 
8 30 49.9 ± 2.8 no inhibition 
9 50 55.1 ± 5.8 no inhibition 
10 no inhibition 8 87.5 ± 2.1 
11 no inhibition no inhibition 
12 no inhibition no inhibition 
13 2 77.7 ± 2.3 8 80.5 ± 0.5 
14 2 91.2 ± 3.8 10 87.2 ± 6.3 
15 15 23.7 ± 15.7 no inhibition 
16 5 40.0 ± 13.4 8 80.9 ± 7.6 
17 5 38.4 ± 4.3 8 80.1 ± 10.5 
18 2 70.2 ± 1.6 10 66.8 ± 15.6 
     
 
After induction with 10 ng/ml LPS, 18, 6 and 13 showed the highest inhibition of NO 
formation followed by 14 (all at 2 µM). At 5 µM 16 and 17 showed a significantly higher 
inhibitory activity than 4 (p<0.05). 7, 2 and 4 were less active in inhibiting the NO production 
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than the aforementioned compounds. At 10 µM XN (1) and 3 exhibited a significant higher 
inhibitory activity than 15 and 5. The compound 8 and 9 showed an inhibitory effect on the 
NO production at 30 µM and 50 µM. No inhibition was observed for the dihydro-chalcones. 
In order to compare the results of the Griess assay with those of the iNOS protein expression 
assay, it was necessary to conduct both experiments under the same conditions. A second 
version of the assay was conducted with 10 ng/ml LPS and 200 ng/ml IFN-γ as stimuli. No 
inhibitory activity on the NO production could be observed for 3, 4, 8, 9, 11, 12, and 15 under 
these conditions. At 2 µM a significant NO inhibition of the compounds 18, 6, 13 and 14 could 
be already detected during the activation with solely 10 ng/ml LPS. Using 10 ng/ml LPS and 
200 ng/ml IFN-γ, the first inhibitory activity was observable at 5 µM for compound 6. At 8 µM 
an inhibitory effect was also observed for 7, 17, 13, 16 and 10. The statistical analysis 
revealed no significant difference between these compounds. 18 and 14 inhibited the NO 
production at 10 µM. At 15 µM no significant difference could be observed between 1, 2 and 
5. 
 
3.6.4 iNOS protein expression 
The nitric oxide assay only reveals whether a compound is able to inhibit the NO production 
or not. It gives no information about the underlying mechanism. Reduction of NO formation 
can for example be caused by reaction of NO with the test compounds, by inhibition of iNOS 
enzym activity or by reduction of iNOS protein expression. 
Thus, the purpose of this study was to also determine if the inhibition of the NO production is 
caused by a decrease in iNOS expression. iNOS expression was analyzed with a 
fluorescently labeled antibody (Cellomics® iNOS Activation Kit). The positive control 
(activated cells without test compound) acted as a 100% reference point in order to allow for 
a comparison of the tested compounds. The results are summarized in Table 3-3. 
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Table 3-3: Influence of compounds 1-18 on iNOS expression determined by fluorescence 
immunostaining. The compounds were tested at their non-toxic concentration. In the table the 
remaining iNOS expression in % from the control is depicted 
 10 ng/ml LPS and 200 ng/ml IFN-γ 
Compound Concentration in µM % remaining iNOS expression 
   
1 10 18.2 ± 8.9 
2 5 39.6 ± 12.5 
3 5 56.0 ± 11.0 
4 no inhibition 
5 no inhibition 
6 5 35.2 ± 2.6 
7 10 16.8 ± 14.6 
8 50 76.3 ± 7.7 
9 no inhibition 
10 10 65.4 ± 9.1 
11 10 62.3 ± 16.8 
12 5 72.1 ± 8.3 
13 5 41.1 ± 17.9 
14 no inhibition 
15 10 30.2 ± 6.7 
16 5 35.5 ± 12.5 
17 10 22.9 ± 9.0 
18 5 10.7 ± 6.6 
   
 
All compounds except of 4, 5, 9 and 14 showed an inhibitory effect on the iNOS expression. 
The compounds were tested in concentrations without an effect on the cell viability. The most 
active chalcones at 5 µM were 18, 6, 16, 2 and 13 followed by 3 and 12. At 10 µM 7, 1 and 
15 showed the highest inhibition of the iNOS expression followed by 11 and 12. At 50 µM 8 
reduced the iNOS expression to a remaining level of 76.3 ± 7.7%. 
 
3.7 Discussion 
3.7.1 Effect on the cell viability and proliferation 
The effect of minor hop compounds, XN (1) metabolites and structure related chalcones on 
the viability, proliferation and the cell survival was investigated in HuH-7, HepG2 and HSC, 
RAW 264.7 and Caco-2 cells. 
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The murine macrophage cells RAW 264.7 were much more sensitive to the tested 
compounds than the other cell lines. The defense and the activation of further immune-cells 
against toxic products and harmful organisms is their main function in the body. In contrast to 
the macrophages, hepatic stellate cells were not less sensitive to the tested compounds. 
Hepatic stellate cells are non parenchymal cells and located in the liver. Under healthy 
conditions, they store vitamin A. Under pathologic conditions, they start to build up 
extracellular matrix and lose vitamin A storage. This process is in many cases correlated with 
alcohol abuses and viral infections. The production of extracellular matrix causes a partial 
loss of the liver function and can lead to reversible fibrosis and at worst to necrosis and 
organ failure [286]. Therefore, HSC are more resistant to toxic substances than other cells, 
which was also confirmed in this study. HSC, colon cancer Caco-2 cells were also less 
sensitive to the compound exposure. The same non-sensitive behavior was observed in the 
sulforhodamine assay performed by Miranda and co-workers [186]. They incubated human 
breast cancer MCF-7, colon cancer HT-29 and ovarian cancer A-2780 cells with different 
chalcones for 48, 96 and 144 h. The ovarian cancer cell line was the most sensitive followed 
by human breast and the colon cancer cells. Interestingly, the cytotoxicity was more 
pronounced in HT-29 and A-2780 cells after 48 h compared to 96 h of incubation. It was 
discussed that the cells became less sensitive to the chalcones because of the detoxification 
process and/or the efflux by P-glycoproteins [186]. In further studies it was shown that 1 
inhibit P-glycoprotein transport in Caco-2 [242] and MDCKII cells [241]. Furthermore, 
compound 1 inhibited the mRNA levels of the efflux transporter genes, too [189]. 
Nevertheless, the influence of 1 on the P-glycoprotein transporter is not fully understood yet 
[241] (1.3 Bioavailability, metabolism and cell uptake). However, compound 1 and other 
chalcones can be biotransformated and lose their cytotoxic effects. Thus, proliferation and 
cytotoxicity assays should be performed time-resolved in order to reach a more significant 
conclusion on the effect of the substances. 
This may also explain the different behavior of HeLa cells in the studies conducted by Vogel 
et al. [150-152] and this study. In the latter, the HeLa cells were incubated with the minor 
hops compounds and XN metabolites for 72 h in the MTT assay. 13 showed the strongest 
viability inhibition (IC50 value 5.2 ± 0.8 µM) followed by 2 > 1 > 6 > 14 > 7 = 4 > 3 > 5 and 17 
[150-152]. In this study, a partially different behavior was observed probably because of the 
different cell types. 13 and 14 were found to be the compounds with the least cytotoxic 
effects. Compound 2 exhibited in this study the lowest IC50 value (Figure 3-6: A, C and D). 
The incubation time in this MTT assay was 24 h. 
A correlation between the lipophilicity of the tested substances and their cytotoxicity could be 
partially observed. The HPTLC study revealed that 5, 2, 13 and 14 were the most hydrophilic 
among the investigated compounds (see Table 3-1). The compound 13 and 14 were found to 
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have the lowest cytotoxicity. In contrast the lipohilic 16 exhibited the lowest IC50 values in 
RAW 264.7 cells in the MTT assay. This is also in agreement with a study conducted by Li 
and co-workers [271]. In their study 15 showed the weakest effects on the viability of 
RAW 264.7. Compounds 16 and 17, which are more lipophilic, were more potent. Further 
examples include a local anesthetics study [287] and a study with heat shock proteins [288]. 
The studies showed that lipophilic chemicals exhibit higher cytotoxicity in human 
T-lymphoma cells [287] or induce heat shock proteins [288]. 
The lipophilicity plays not only an important role for the cytotoxicity of substances, but has 
also been shown to provide protection against in vitro LDL oxidation. Lipophilic compounds 
were more potent in the inhibition of the LDL oxidation due to the physical capability to 
approximate to the LDL particles [146]. The same effect was observed for proteins. Lipophilic 
compounds can approximate to and interact with lipophilic centers of enzymes [288,289]. 
Compound 1 can interact with mitochondrial proteins, induce the release of ROS and thus 
lead to apoptosis [157]. In addition 1 can change the membrane fluidity [290]. This process 
might lead to a faster infiltration and a higher cytotoxicity. Compound 1 was found to 
penetrate the cell membrane of different cell lines but the exact access mechanism are still 
unknown [227,228]. It seems that 1 might affect the transport by ABC-transporters [189,241]. 
As aforementioned a correlation between the lipophilicity and cytotoxicity of the investigated 
substances could only be partially observed in this study. Compound 2 as an outlier showed 
a high inhibitory activity concerning the viability, but only weak effects on the proliferation and 
cytotoxicity. Compound 2 however was determined to be as hydrophil as 14. The prenyl 
chain of 2 might be an explanation for this behavior. Prenyl chains were shown to lead to a 
variety of effects. For example compounds with a prenyl chain showed a higher antioxidant 
capability in oxidative injury models [148]. In addition, prenylated compounds possessed 
noteworthy activity against gram-negative bacteria [19], exhibited antimicrobial effects [291] 
and induced phase II enzymes [135]. Furthermore, they were shown to inhibit beta-side APP 
cleaving enzyme 1 (BACE1) [292], the invasion of cancer cells [187] as well as their 
proliferation and 5-LOX activity [289]. In addition, prenylation of apigenin and liquiritigenin 
has been shown to increase their cytotoxicity in different cell lines [293]. This correlation was 
also observed in a cytotoxicity study of prenylated isoflavonoids from Bituminaria morisiana 
(PIGNATTI & METLESICS) GREUTER. The prenyl chain in C-8 position enhanced the cytotoxicity 
of the pterocarpans [294]. 
The lipophilicity of compounds increases with the number of prenyl groups. However, 
lipophilicity can not only be attributed to prenyl groups. As aforementioned compounds with 
prenyl groups were usually more active compared to those without prenyl groups, but 16 was 
the most active compound in the MTT assay in RAW 264.7 cells and possesses no prenyl 
-77- 
 
 
 
group. Thus, neither the lipophilicity nor the number of prenyl groups is solely responsible for 
the inhibition of the viability and the proliferation of cancer cells by a substance. 
In the present study, the mechanisms which induce cytotoxicity were not investigated in 
detail, but two distinct assays were used to get some hints. The MTT assay measures an 
increase or decrease in the cell viability, which can be caused by a drop of the cell count 
and/or a decrease in mitochondrial activity. The CV assay is only based on the cell count. 
With increasing concentrations 2 first inhibited the viability and then the cell count (Figure 3-6 
A, B, C and D). This might point to an involvement of the mitochondria. Compounds 6 and 7 
showed the opposite behavior. First, a decrease in the cell count was observed, which was 
then followed by a decrease in viability. Thus, 6 and 7 might induce cell death via a different 
mechanism. The behavior of 1, 3 and 13 depends on the used cell line. It is known that 
compound 1 induces apoptosis by different pathways depending on the cell type. This 
includes the intrinsic, extrinsic, and the endoplasmatic reticulum- and NF-κB dependent 
pathway (1.1.7 Pro-apoptotic mechanism). XN (1) was shown to induce the ROS production 
which triggers cells into apoptosis [157,154]. In this study 1 showed moderate effects on the 
cell viability and proliferation of the investigated cell lines. Thus the mechanism that are 
influenced by XN (1) might be different from those influenced by 2, 4, 6, and 7 and should be 
studied in more detail in order to reveal which cell death mechanism are responsible for the 
observed effects. 
 
3.7.2 Nitric oxide assay and iNOS protein expression 
The tumor initiation and promotion is correlated with chronic inflammation [161]. The 
expression of iNOS was correlated with lower chance of survival depending on the type of 
cancer and chronic inflammatory diseases (see 3.2.2 Biological effects of XN metabolites). In 
the present study the inhibition of the NO production and iNOS by the minor hop chalcones, 
XN metabolites and related compounds was investigated concerning the structure-response 
relationship. 
All compounds except of the dihydro compounds 10, 11 and 12 showed a significant 
inhibition of the NO production in the performed Griess assay (10 ng/ml LPS). It is discussed 
in the literature that, the inhibition of the NO production might be mediated by endogenous 
electrophils via an α,β-unsaturated carbonyl moiety [181,295]. Compounds without this 
moiety led to no or only little decreases in the NO production [181]. In the present study, the 
same was observed in the nitric oxide assay using 10 ng/ml LPS as stimuli. 
In order to compare the data from the Griess assay with that of the iNOS expression the 
assay was additionally performed with 10 ng/ml LPS and 200 ng/ml IFN-γ. In this case 10 
showed a significant inhibitory effect on the NO production at 8 µM. The observed inhibition 
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of NF-κB regulated factors by dihydro compounds is in agreement with the study of Peluso et 
al. [178]. In their study monocytic THP-1 cells were stimulated with LPS and co-incubated 
with or without prenylated and non-prenylated chalcones as well as with flavanones. The 
influence on the MCP-1 and IL-6 production was investigated. Dihydroxanthohumol 
compared to 1 showed a higher inhibition of the IL-6 and the MCP-1 production. MCP-1 and 
IL-6 are cytokines which are regulated by the NF-κB pathway [178]. In the present study, the 
inhibition of NF-κB regulated factors by dihydro compounds could not be detected solely 
using 10 ng/ml LPS as stimulus, but it could be confirmed in the assay version with 
10 ng/ml LPS plus 200 ng/ml IFN-γ as stimuli. Possibly the compounds are more potent to 
inhibit the NO production via the JAK/STAT pathway compared to the NF-κB pathway. It is 
discussed and pruposed in the literature that 1 inhibits the NF-κB pathway via its 
α,β-unsaturated moiety [169,171,176] and there is no such moiety in the dihydro compounds. 
XN (1) was also shown to influence the JAK/STAT pathway but a clear mechanism is not 
known, yet and thus hinders a comparison with the dihydro compounds (1.1.6 
Anti-inflammatory effect). 
A correlation between the inhibition of NF-κB or related proteins and tetrahydropyrans (A ring 
of 6 and 7) has, not been discussed in the literature, yet. Compound 6 significantly inhibited 
the NO production irrespective of the used stimuli. The compound 8 showed higher inhibitory 
effects compared to 9. The compound 10 inhibited the NO production in case of the 
stimulation of the cells with 10 ng/ml LPS and 200 ng/ml IFN-γ. This effect could also be 
observed during the determination of the iNOS expression. Compound 6 belongs to the 
effective iNOS inhibitors in this study. Therefore it is suggested that the A ring with the 
tetrahydropyran is conducted for the inhibition of the NO production and iNOS expression 
independent regardless of the used stimuli. 
In the study of Zhao et al. [181] the prenylation was not found to enhance the inhibition of the 
NO production. This was also confirmed in the present study. Prenylated chalcones mostly 
exhibited a lesser inhibition of iNOS expression than non-prenylated chalcones with the 
exception of 2. Compound 2, which possesses a hydroxylated prenyl chain, was the most 
active chalcone in the group of prenyl chain carrying chalcones. Compound 5 however, also 
a prenylated chalcone, showed the weakest effect. One reason might be the lower purity of 
86% of 5. In the study of Peluso et al. [178] 5 also was less active compared to 1 and 16. 
In the group of prenylated chalcones the ability to inhibit the NO production was also 
dependent on the substituent of the B ring. Compounds exhibiting a free hydroxyl group 
inhibited the NO production more efficient than an O-methoxylated or an O-acetylated one. 
Peluso et al. observed an increase in the IL-6 and MCP-1 inhibition with an increasing 
number of prenyl groups and an O-methoxylation of the A ring (LPS stimulated THP-1 cells) 
[178]. IL-6 and MCP-1 are regulated via the NF-κB pathway. This could not be observed in 
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this study. One reason might be the used cells or the factors which were determined in the 
study of Peluso et al. [178]. 
Compound 13, a non-prenylated chalcone, exhibited the highest inhibitory effect on NO 
production and iNOS protein expression. In general, the non-prenylated and the 
tetrahydropyran-chalcones showed a higher inhibitory activity in the NO production and the 
iNOS expression. Compound 18 does not contain a hydroxyl group in the B ring, but it was 
as active as 13 in the Griess assay with 10 ng/ml LPS stimulation and the iNOS expression 
assay. In the second version of the NO assay with 10 ng/ml LPS and 200 ng/ml IFN-γ as 
stimuli, 18 showed a lesser inhibition of the NO production than 13. The iNOS expression is 
stimulated by LPS via the NF-κB pathway and by IFN-γ via Jak/STAT signaling (1.1.6 
Anti-inflammatory effect). The compound 18 might be more potent in the inhibition of the NO 
production via the NF-κB pathway. One hydroxyl group in the non-prenylated chalcones 
seems to lead to a more effective inhibition of the NO production and the iNOS expression 
than two or no hydroxyl groups. A similar correlation was also observed for the flavokawains. 
The compound 16 and 17 were more potent than 15 with an O-methoxy group at the B ring. 
Interestingly, 16 was more potent to inhibit the iNOS expression. One outliner is 14. 
Compound 14 showed inhibitory effects in the NO assays but no effect on the iNOS 
expression. There was no correlation between the lipophilicity of the compounds and the NO 
production as well as the iNOS expression. 
 
3.8 Summary 
In the present study, the influence of XN (1), minor hop constituents and XN metabolites 
concerning their influence on cell viability and proliferation was analyzed using MTT assay 
and CV. Compound 2 exhibited the lowest IC50 value in the cell viability and 6 and 7 in the 
proliferation assay. The higher lipophilicity of 6 and 7 might be one explanation. However 2 is 
more hydrophilic than XN (1) but exhibited stronger anti-viability effects. Thus these XN 
metabolites and related compounds are possible candidates for advanced studies in order to 
reveal the underlying mechanism that led to the cell death. 
The influence of the compounds on the NO production and iNOS expression was determined 
by Griess assay and the iNOS immunostaining. iNOS expression was induced with 
10 ng/ml LPS and 200 ng/ml IFN-γ as stimuli. The NO formation was stimulated with 
10 ng/ml LPS and 200 ng/ml IFN-γ stimuli to compare the effects in the iNOS expression 
assay and with 10 ng/ml LPS to evaluate the efficiency of inhibition and the possible 
pathways. In the first version of Griess assay (10 ng/ml LPS), the dihydro compounds did not 
inhibit the NO production. In the second version of the assay (10 ng/ml LPS and 
200 ng/ml IFN-γ as stimuli) however, 10 inhibited the NO production. The 
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tetrahydropyran-chalcones 6 and 7 as well as the non-prenylated 13 were the compounds 
with the highest inhibitory activity on NO production and iNOS expression. In addition, 
non-prenylated chalcones with one hydroxyl group seem to be more effective in inhibiting the 
NO production and the iNOS expression compared to those with two or no hydroxyl groups. 
The prenyl chain seems to be less importance for this effect. In the iNOS assay all 
compounds, with exception of 14, showed an inhibition of the iNOS expression on the protein 
level. 
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 The data of this chapter is pulished in: H. Wolff, M. Motyl, C. Hellerbrand, J. Heilmann, B. 
Kraus, Xanthohumol uptake and intracellular kinetics in hepatocytes, hepatic stellate cells, 
and intestinal cells, J. Agric. Food Chem 59 (2011) 12893–12901. 
 
4 In vitro uptake of xanthohumol in hepatic and colorectal 
cancer cell lines and primary hepatocytes 2) 
4.1 Abstract 
Xanthohumol (XN), a prenylated chalcone found in hops, has been reported to show 
anti-inflammatory and anti-infective properties. In addition, it possesses anti-cancer activity, 
affecting all development stages of cancer cells including cancer initiation, promotion and 
progression. In order to achieve these activities in vivo adequate XN concentrations have to 
be reached. Different studies revealed a low bioavailability of XN and in Caco-2 cells a fast 
and high cellular uptake has been reported. The exact uptake mechanism as well as the 
uptake in hepatic cell lines and primary hepatocytes has not been investigated yet. For this 
reason, we studied the cellular uptake and accumulation of XN in different hepatic and 
colorectal (cancer) cell lines and primary hepatocytes. Caco-2, HuH-7, HSC and primary 
hepatocytes were incubated with medium supplemented with 10 µM XN.  
In order to determine the XN amount per cell a calibration curve was prepared. The 
calibration curve was based on the ratio between the protein amount per HuH-7, HSC and 
Caco-2 cells. 
This study revealed that HuH-7 cells had the lowest protein concentration per cell. HSC had 
the highest. HuH-7 was the weakest uptaker followed by HSC, Caco-2 and primary 
hepatocytes. HSC, Caco-2 and primary hepatocytes accumulated a 52, 63 and 47 fold higher 
XN amount compared to the outer medium. However, the exact uptake mechanism is still not 
known and should be a topic of further studies. 
 
4.2 Introduction 
XN is one of the ingredients in hops and shows a wide range of effects such as 
anti-inflammatory, anti-cancer and anti-infective activity. The exact cell uptake mechanism of 
XN is not completely investigated, yet. Four studies investigated the absorption and/or 
protein binding or transporter interference for XN in different cell models [227,228,241,242].
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In the study of Pang and co-workers [227] the absorption of XN was determined in Caco-2 
monolayers. The permeability of XN was measured in two directions from the AP to BL and 
from the BL to AP. The permeability coefficient of XN was similar to that of the low 
permeability marker sucrose (AP to BL, XN 1.33 ± 0.03 10-7 cm/s, sucrose 1.96 ± 0.5 10 -
 7
 cm/s). After 1 h the amount of XN was 0.8 ± 0.1% of 10 µM on the acceptor side, from the 
AP to the BL direction at 37 °C. Interestingly, 73. 0 ± 2.3% of XN accumulated in the Caco-2 
cells. Quantification showed that 94 ± 1.0% of the intracellular accumulated XN was located 
in the cytosol. In order to determine the time course of the XN uptake, Caco-2 cells were 
incubated with 10 µM XN at 37 °C for 10 min. During  the first minutes, XN was fastly 
absorbed. After the XN concentration decreased in the donor side the absorption stagnated 
[227]. In the same study a XN uptake depending on the XN concentration in the surrounded 
medium and the temperature was observed. Thus, investigation was performed in order to 
determine the type of transport. The treatment with various transporter inhibitors revealed a 
non-facilitated and energy-independent transport. In addition during the incubation with the 
transporter inhibitors the XN uptake increased 2 to 3 fold compared to the uptake of XN in 
the medium. This implicates that under normal conditions XN is actively moved out of the 
Caco-2 cells. Efflux of drug and xenobiotics from cells is correlated with ABC-transporters 
(1.3 Bioavailability, metabolism and cell uptake). Lee et al. [189] showed an influence of XN 
on the mRNA levels of ABC-transporters [189]. Taur et al. [242] showed that XN as well as 
quercetin, naringenin and genistein reduced the transport of the P-glycoprotein and 
increased the cimetidine absorption but did not influence the cimetidin uptake on organic 
cation transporters [242]. In another study of Rodriguez-Proteau et al. [241] the influence of 
XN on the uptake of cyclosporine A and digoxin in Caco-2 and MDCKII cells was measured. 
There was a quite different behavior of XN on the uptake of the substances. The efflux of 
cyclosporine A was inhibited, but the intracellular concentration was decreased whilst the 
opposite was observed for digoxin [241]. 
It is known that XN interacts with proteins such as Keap 1 [137,139], NF-κB [176,182] and 
IKK [182], most likely via its α,β-unsaturated carbonyl structure that can react with thiols 
[137]. Thus, it seems not surprising that studies showed a bounding of XN to proteins. Pang 
et al. [227] determined the capability of XN to bind to isolated cytosolic native or denaturized 
proteins. XN bound 20 fold higher to native cytosolic proteins compared to the denatured 
proteins. This was confirmed by the observations of Wolff et al. [228] investigating the 
movement of XN with fluorescence recovery after photobleaching (FRAP). It was observed 
that XN moves like a heavier molecule with a mean size of 27 kDa. It seems that XN bound 
to proteins. After bleaching XN movement was not only detected in the cytosol but much 
more interesting in the nucleus, too [228]. This might explain the effect of XN on the 
regulation of transcription. 
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4.3 Aim 
The exact uptake mechanism of XN is not fully understood yet. The uptake has to the best of 
our knowledge never been investigated in hepatic cancer cell lines and primary hepatocytes. 
In order to determine the amount of XN that is taken up per mg of cell proteins two hepatic 
cancer cell lines and primary hepatocytes were incubated with XN supplemented medium. 
Simultaneously calibration curves and cell volumes were determined in order to calculate the 
absorbed XN per cell. 
 
4.4 Material 
4.4.1 Chemicals 
Chemicals Xanthohumol was provided by the Nookandeh Institut Hamburg with a purity of 
98%. Ethanol (Order no. 8006) was bought from J.T. Baker (Deventer, Netherlands). 
Dimethyl sulfoxide (DMSO) (Order no. 1.02931.1000), sodium dodecyl sulfate (SDS) (Order 
no. 1.02931.1000), acetone (Order no. 1.00014.2511), formic acid (Order no. 1.00264.1000) 
and acetonitrile (Order no. 1.00030.2500) were purchased from Merck KGaA (Darmstadt, 
Germany). The Bradford reagent was obtained from Bio-Rad (Munich, Germany). Bovine 
serum albumin (BSA) (Order no. A-6003) was purchased from Sigma-Aldrich (Steinheim, 
Germany). 
Deionized water (18 mS/cm) was obtained from Millipore Milli-Q UF Plus equipment. 
 
4.4.2 Cell lines and culture materials 
Cell lines The immortalized activated human hepatic stellate cell line (HSC) was obtained 
from University Hospital of Regensburg, Department of Internal Medicine I [212] The human 
hepatoma cell line (HepG2) (ATCC®-number HB-8065TM) was obtained from the American 
Type Culture Collection (ATCC, USA). The human colorectal cell line (Caco-2) 
(ATCC®-number HTB-37TM) was a gift from the Institute of Virology, Helmholtz Zentrum 
München, Germany. The human hepatoma cell line (HuH-7) (HSRRB-number JCRB0403) 
was obtained from the Health Science Research Resources Bank (HSRRB) of the Japan 
Health Sciences Foundation (JHSF, Japan).  
Human liver tissue samples are obtained and experimental procedures were performed 
according to the guidelines of the charitable state controlled foundation HTCR (HUMAN 
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TISSUE AND CELL RESEARCH, Gemeinnützige Stiftung bürgerlichen Rechts), with the 
informed patient's consent. Isolation of primary human hepatocytes was carried out at the 
Center of Liver Cell Research, University Hospital of Regensburg.  
Medium and supplements Dulbecco’s modified eagle medium (DMEM) with phenol red 
(Order no. FG 0415), L-glutamine (Order no. K 0283), non essential amino acids 100 x 
(NEAA) (Order no. K 0293), fetal calf serum (FCS) (Order no. S 0115), phosphate buffered 
saline (PBS) (Order no. L 1825), sodium pyruvate 100 mM (SP) (Order no. L 0473) and 
trypsin 10 x (Order no. K 2135) were ordered from Biochrom AG (Berlin). 
DMEM high glucose without phenol red (Order no. 41965) and DMEM high glucose with 
phenol red (Order no. 31053) were obtained from Invitrogen, GIBCO (Grand Island N.Y., 
U.S.A.). 
Material for cell culture 96 well plates (Order no. 92096), cell scrapers (Order no. 99003), 
culture flasks 75 cm² (Order no. 90076) and 150 cm² (Order no. 90151) were purchased from 
TPP (Trasadingen, Switzerland), safe lock tubes 1.5 ml (Order no. 0030.102.002) and 2 ml 
(Order no. 0030 120.094) from Eppendorf (Hamburg) and centrifuge tubes 15 ml (Order no. 
17020) from MEUS s.r.l. (Piove di Sacco, Italy).  
 
4.5 Methods 
4.5.1 FCS heat inactivation 
FCS was inactivated in a water bath at 56 °C for 30  min. Then FCS was cooled down to 
room temperature, and portioned into 50 ml aliquots. The aliquots were stored at -20 °C until 
use. 
 
4.5.2 Cell cultivation and harvesting 
HSC, HuH-7 and Caco-2 were cultivated and harvested as described in chapter 3 (3.5.5 Cell 
cultivation and harvesting). 
Primary hepatocytes (PH) were isolated in the Center of Liver Cell Research, University 
Hospital of Regensburg. 5 x 106 PH cells were seeded in 100 mm collagen coated 
BIOCOAT® culture dishes (Becton Dickinson labware, Bedfrod, MA, U.S.A.). The cells were 
cultivated as described in [296,297]. In Brief, the cells were for 24 h with and the next 24 h 
with FCS. After that the cells were incubated with XN to determine the XN uptake (4.5.3 
Measurement of XN uptake). 
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4.5.3 Measurement of XN uptake 
6 x 106 HuH-7, 1 x 106 HSC or Caco-2 were seeded in Petri dishes d 100 x 20 mm in 6 ml 
DMEM with phenol red and were cultivated for 36 h. The medium of HuH-7, Caco-2, HSC 
and PH was aspirated and replaced with DMEM without phenol red supplemented with 
10 µM XN for 3 h. The supplemented XN medium was aspirated and the cells were washed 
three times with 6 ml PBS. Subsequently, the cells were incubated with 1 ml trypsin (1 x in 
PBS) for approximately 4 min at 37 °C. After carefu lly beating at the underside of the culture 
flask wall, cells were detached from the bottom of the culture flask. 5 ml medium were added 
to the trypsin cell suspension to stop the trypsination. The suspension was transferred into 
centrifuge tubes and was centrifuged at 700 rpm for 5 min. The supernatant was discarded 
and the cell pellet was resuspended in 5 ml PBS. 80 µl of the resuspended PBS suspension 
were taken and homogenized with 50 µl glas beads (0.75-1.0 mm). After the homogenization 
one equivalent amount (v/v) of acetone was added. The homogenized cells were spin down 
at 1,000 rpm for 4 min at 4 °C. After the centrifug ation step, the supernatant was transferred 
in NanoSep centrifugal devices (catalog no. 5168502, VWR, Darmstadt, Germany) and were 
centrifuged at 14,800 rpm and 4 °C for 20 min. Subs equently, the purified solution was 
analyzed by HPLC. 
 
4.5.4 Quantification of XN 
Quantification of XN was performed with a LaChrom Elite system (Hitachi) equipped with a 
Purosphere® Star RP-18e column (5 µm 250 x 4 mm) column with a precolumn 
(LiChroCART 4-4). The HPLC system (VWR Hitachi, Breda Netherlands) was composed of 
an organizer Elite Lachrom, diode array detector L-2455, autosampler L-2200, pump L-2130 
and a column oven L-2350. The mobile phase A consisted of water with 0.1% formic acid 
and B of pure acetonitrile. The detachment of 20 µl sample was performed with a flow rate of 
1 ml/min and a column oven temperature of 30 °C. In  order to separate and to quantify the 
XN amount, the following gradient course was used: 0-9 min, 35-65% B; 9-11 min, 65%-35% 
B. After 11 min the column was equilibrated to 35% B. 
The quantification was performed with DAD at a wavelength of 368 nm. A calibration range 
of 0.1-100.0 µM; typical retention time for XN was 10.7 min. Calibration curves for the 
quantification of XN were measured with 11 different concentrations (n=6 for every 
concentration) resulting in a R2 of 0.9999. 
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4.5.5 Determination of protein content per cell 
In order to determine the protein amount per cell, cells were treated as described in 4.5.3 
Quantification of XN. In contrast to the determination of the uptake, the cells were not 
stimulated with XN. 
After 3 h the cells were harvested and the cell count as well as the protein amount was 
determined. The cell count was determined as described in 3.5.6 Cell counting. The protein 
amount was determined with the Bradford reagent. In order to develop a BSA calibration 
curve, 10 mg/ml BSA were weighed out and were dissolved in PBS. The BSA calibration 
curve was performed in serial dilution with 6 concentrations, 1.0, 0.75, 0.5, 0.25, 0.125 and 
0 mg/ml BSA solved in PBS. The measurement was performed in a 96 well plate. 2.5 µl of 
the BSA solution was added to 125.5 µl Bradford reagent. After 5 min the absorption was 
measured with a microplate reader SpectraFluor Plus (TECAN, Hombrechtikon, Switzerland) 
at 590 nm. 
 
4.5.6 Determination of the cell volumes 
The cell volumes were determined as described by Wolff et al. [228]. 
 
4.5.7 Calculation and statistical analysis 
The statistical analysis and the calculation of results were performed with Graph Pad 
Prism 4. Significant different averages (p value < 0.05) were evaluated statistically with 
one-way ANOVA followed by Tukey’s Multiple Comparison Post Test. The results are 
expressed as mean ± standard deviation. The test according to Grubbs was applied to 
remove outliers. 
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4.6 Results 
At first the XN uptake per mg protein was determined in HuH-7, HSC, Caco-2 and PH cells. 
The highest XN uptake was found in HSC and Caco-2 cells, followed by PH and HuH-7 
(Table 4-1). The uptake measurements were performed in 9, 8, 6 and 2 independent 
experiments for HSC, HuH-7, Caco-2 and PH cells respectively. 
Table 4-1: The XN uptake in HuH-7, HSC, Caco-2 and PH cells. Data are shown as mean ± SD. 
The concentration of XN was determined per cell and per protein content. In order to determine 
the concentration per cell the cell volume was measured with a fluorescent microscope as it is 
described in the paper of Wolff et al. [228]. 
 Cell type 
 
HuH-7 HSC Caco-2 
Primary 
hepatocytes 
XN per cell (pg/cell) 0.03 ± 0.02 0.83 ± 0.22 0.72 ± 0.13 0.39 ± 0.26  
XN per protein (µg/mg) 0.21 ± 0.18 1.49 ± 0.39 2.13 ± 0.38 0.56 ± 0.07 
Cell volume (pL) 3.53 ± 0.84 4.88 ± 1.42 4.25 ± 2.39 2.04 ± 0.27 
XN per cell (µM) 25 ± 6 511 ± 132 625 ± 132 469 ± 149 
approximated accumulation (fold) 3 52 63 47 
 
In order to determine the XN concentration per cell calibration curves for the protein content 
were recorded. The calibration curves describe the correlation between the protein content 
and the cell number allowing the determination of the average protein content per cell (see 
Figure 4-1). The HSC (A) contained the most protein per cell followed by Caco-2 (A) and 
HuH-7 (B) cells (see Figure 4-1). A calibration curve for the PH could not been generated, 
because of the different protein amounts per cell. The amount of XN per PH cells was 
determined directly. After the harvesting of the PH cells the cell count as well as the protein 
concentration was determined. The HuH-7, HSC and Caco-2 calibration curves were 
prepared with data of at least 3 independent measurements. 
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Figure 4-1: Correlation of protein content with the cell number for HSC, Caco-2 (A) and HuH-7 
cells (B). 
 
The coefficient between cell number and protein content was between 0.9484 and 0.9782. 
HSC which have the highest ratio between protein amount and cell count exhibit the best 
correlation coefficient (0.9782). 
The cell volume was determined by fluorescence microscopy as it is described in the paper 
of Wolff et al. [228]. The XN concentration even for single cells could be calculated. For the 
uptake investigations the cell lines and the PH´s were incubated with 10 µM XN in DMEM for 
3 h. HuH-7 cells exhibited a concentration of 25 ± 6 µM XN and were the weakest uptaker. 
HSC, Caco-2 and PH cells accumulated 52, 63 and 47 fold higher XN concentrations 
compared to the medium (see Figure 4-2). 
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Figure 4-2: XN uptake in HuH-7, HSC, Caco-2 and PH cells in µM. The cells were incubated with 
10 µM XN in DMEM for 3 h. HuH-7 was the weakest uptaker. HuH-7 cells exhibited 3 fold higher 
XN concentrations if compared to the outer medium. HSC, Caco-2 and PH exhibited 47 to 63 
fold higher XN concentrations. The XN uptake was determined in 9, 8, 6 and 2 independent 
experiments for HuH-7, HSC, Caco-2 and PHs respectively. 
 
The uptake of XN in HuH-7 differs significantly from that of HSC, Caco-2 and PH. No 
significantly different intracellular XN concentration was observed comparing the HSC, 
Caco-2 and PH. 
 
4.7 Discussion 
In order to determine the amount of XN that was taken up per cell and protein, cell volumes 
and protein contents of the different cell lines were determined. HuH-7 had the lowest protein 
amounts per cell and HSC the highest. Because the protein amount per cell differs 
depending on the patients, no average protein content per cell was determined for the PH. 
The XN concentration per cell was determined using the cell volume [228]. The 
measurements revealed a weaker XN uptake in HuH-7 cells. HSC, Caco-2 and PH exhibited 
a 52, 63 and 47 fold higher XN concentration compared to the XN concentration in the 
medium. HuH-7 cells exhibited only a 3 fold higher XN concentration compared to the 
medium. 
The reason for different XN up-take is most likely the varying density and type of 
ABC-transporters in HuH-7 cells compared to HSC, Caco-2 and PH. For example the uptake 
of cyclosporine A in co-stimulation with XN was found to differ in Caco-2 and MDCKII-MDR 
cell lines. MDCKII-MDR cells took up cyclosporine in a dose dependent manner. In Caco-2 
cells the cyclosporine A uptake decreased in case of co-incubation with XN [241]. A stronger 
activation and different types or densities of ABC-transporters might lead to a higher efflux of 
XN out of HuH-7 cells. Furthermore, studies also revealed that XN influences the mRNA 
values of multidrug proteins [189] and the efflux of cimetidine by P-glycoproteins [242]. The 
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effects of XN on ABC-transporter seem to be complex and are not fully investigated yet. 
Another reason for the different XN uptake in HuH-7 cells might be the existence of other 
transporters which are involved in the XN uptake. Pang et al. [227] incubated Caco-2 cell 
with transporter inhibitors such as dipyramidamole, sodium azide, oligomycin and rotenone. 
The experiment revealed an increased uptake of XN [227]. 
The lower XN uptake might also be the cause of a higher metabolism of XN in HuH-7. It is 
known that XN is metabolized in high quantities. However in this study this was rather not the 
case. The quantification of XN was performed by HPLC (4.5.3 Measurement of XN). This 
method had the advantage that metabolites with similar chromophor could be detected. As 
phase II metabolites are more hydrophilic compared to their precursor they eluted earlier on 
a reversed phase column. But at early retention times the chromatograms of the extracts of 
HuH-7 did not differ from the ones of the HSC. 
Uptake and movement studies showed that XN binds to proteins [227,228]. Wolff et al. [228] 
showed with FRAP measurements that XN moved slowly in the cell such as a molecule with 
a mean size of 27 kDa. In another study it was shown that XN bound rather to native 
cytosolic proteins (94%) than to cellular membranes or organelles, with sizes bigger than 
10 kDa [227]. HuH-7 showed a lower amount of proteins per cell compared to HSC and 
Caco-2. If the protein amount per cell is lower, XN is possibly faster excreted via higher efflux 
and absorbed in smaller quantities. 
 
4.8 Summary 
This study revealed that hepatic cancer cell lines as well as primary hepatic cells absorb XN 
in high concentrations. But there was a clear dependency on the cell type. HuH-7 cells 
exhibited only 3 fold higher intracellular concentrations of XN compared to the medium. This 
might have different reasons such as different ABC-transporters, other protein amounts per 
cell and different transporter densities, but the clear mechanism of XN´s uptake is not known, 
yet. The understanding of the uptake mechanism might lead to new approaches to increase 
the bioavailability of XN and structure related compounds. Moreover, a thorough 
investigation could explain whether a XN metabolite is able to reach his target in humans 
compared to his precursor. 
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after oral application in mice – manuscript in preparation 
 
5 Influence of dose and phenolic congeners on absorption 
and distribution of the hop chalcone xanthohumol after 
oral application in mice 3) 
5.1 Abstract 
Hop cones contain several structurally related chalcones with xanthohumol (XN) being the 
most abundant. We elucidated the dose dependent absorption of XN in mice after oral 
application with regard to its phase II metabolism and its distribution in serum, liver, urine, 
bile and feces. A matrix effect on the absorption of XN was addressed by feeding pure XN in 
comparison to a phenolic hop extract highly enriched with XN. 
Application of 0.5% XN in diet for 3 and 7 days resulted in biologically relevant 
concentrations of XN phase II metabolites in all excretes and investigated tissues. The 
concentrations of XN phase II metabolites in serum did not show a linear relationship to 
dose, as escalating plasma levels were observed with highly enriched XN diet (0.5%). 
Results showed a high concentration of XN conjugates in bile and pointed to a possible 
relevance of the entero-hepatic circulation. Feeding of a XN enriched phenolic extract 
derived from hops (XE) showed that absorption of XN is positively influenced by its 
congeners. HPLC-HRMS analysis revealed the presence of several minor chalcones and 
flavanones in the XN enriched extract. 
Data indicate that phase II metabolites are the biologically relevant compounds after oral 
consumption of XN. For the use of XN as a functional nutrient application of a standardized 
extract is recommended instead of pure compound. 
 
5.2 Introduction 
Since the Middle Ages the female inflorescences (cones) of the plant (Humulus lupulus L. 
Cannabaceae) have been an essential ingredient in beer brewing, and about 95% of 
worldwide cultivated hop is used for brewing purposes with the rest largely utilized for the 
production of phytomedicines and dietary supplements [298]. There are basically three 
classes of secondary metabolites present in hop cones: prenylated acylphloroglucinols 
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(so-called bitter acids) represented by e. g. humulon and lupulon, essential oil components 
and phenolic compounds with xanthohumol (XN, Figure 5-1) being the most abundant 
prenylated chalcone in hops. 
 
O
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Figure 5-1: Structure of xanthohumol (XN); observed glucuronidation and sulphatation 
positions are indicated with arrows. 
 
Recently much attention has been paid to the polyphenolic content of hops, and especially, 
XN has been identified as a compound with multiple biological activities [299]. Limited 
availability of the more than 10 minor chalcones like demethylxanthohumol or xanthohumol C 
which occur at 5-1,000 fold lower concentration relative to XN [82] resulted in less 
pharmacological information on these compounds [150,151]. Most of the chalcones contain a 
free 2`-hydroxy group, and thus, also the corresponding flavanones like isoxanthohumol, 
6-prenylnaringenin and 8-prenylnaringenin are present in hop cones, extract and beer [82]. 
Of special importance is the conversion of XN to the flavanone isoxanthohumol during the 
brewing process [9] making isoxanthohumol the quantitatively predominating prenylated 
flavonoid in beer. Furthermore, hops contain significant amounts of flavonol glycosides and 
proanthocyanidines [300,301]. 
The bad solubility of XN in aqueous solutions together with the conversion into 
isoxanthohumol results in relatively low contents in beer. For example, Stevens et al. 
reported on XN contents ranging from 0.009 to 0.69 mg/l [84]. Nevertheless, XN is a 
pharmacologically extremely interesting compound mainly due to its reported 
chemopreventive and anti-cancer activity [36,169] and thus a candidate of product 
development in the functional food domain. Several in vitro studies have been done on the 
metabolism of XN using microorganisms [232] and liver microsomes [160], leading to the 
identification of a couple of phase I metabolites like 3-hydroxyxanthohumol and 
xanthohumol H. Furthermore, the production of xanthohumol-4-O-glucuronide and 
xanthohumol-4´-O-glucuronide as phase II metabolites and the conversion to 
isoxanthohumol have also been reported in vitro and in vivo [159,233]. Very recently, the role 
of human intestinal bacteria on the in vivo metabolism of XN has been addressed in 
germ-free and human microbiota-associated rats by Hanske et al. [236]. 
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Still, little is known about the in vivo absorption and metabolism of XN, particularly after oral 
administration. A previous study in rats indicated that the bioavailability of XN is low. Avula et 
al. determined the XN concentration in rat plasma, urine and fecal samples after a single i.v. 
or oral application of pure XN [224]. Choosing a HPLC method with a detection limit of 
0.013 µg/ml, XN was not detectable in urine and feces. The authors also addressed the 
matrix effect no absorption by feeding one rat with hop extract containing either 20 or 
50 mg/g XN, but no difference was observed between application of pure XN and the hop 
extract. However, the authors did not investigate phase II metabolites by direct quantification 
of the glucuronides and sulphates or indirect quantification via addition of glucuronidases and 
sulphatases and subsequent determination of entire XN. Furthermore, several studies in 
flavonoids can be strongly source dependent and both are often significantly different 
comparing various extracts or the application of a pure compound with a food product (e.g. 
vegetables, fruits and beverages) containing the same amount accompanied by other 
secondary metabolites [302–304] reviewed in [305]. The plasma levels of flavonols and their 
phase II metabolites are sometimes reported to be lower after application of the pure 
compound in comparison to the applied food product [303,305]. As the epidemiological 
impact of flavonols in the diet (especially in the case of quercetin glucosides) is supposed to 
be very high, studies on absorption and metabolism focused in the last years on the 
consumption of flavonols from several edibles and not on the application of pure compounds 
[305,306]. 
 
5.3 Aim 
The aim of our study was to elucidate the absorption of XN with regard to its distribution in 
liver, urine, bile, feces and serum, its phase II metabolism, as well as to investigate the 
influence of other hop phenolics on the absorption and metabolism of XN. To find the optimal 
dose for the feeding experiments, different concentrations of a XN enriched phenolic hop 
extract (73%, XE) were mixed with the diet to yield 0.05, 0.25 and 0.5% of XN and fed to 
BALB/c mice. To evaluate the influence of a short time as well as a more continuous 
polyphenol intake on metabolism and absorption, mice were fed for 3 and 7 days with XE, 
and the resulting concentration of XN and its quantification before and after addition of 
glucuronidase and sulphatase. To investigate a possible effect of phenolic congeners on the 
absorption, also pure XN (>98%) was mixed with the diet in the most applicable 
concentration of XN and its metabolites in liver, serum, bile and feces were also measured 
after 3 and 7 days in comparison to the respective extract group. 
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5.4 Material and Methods 
5.4.1 Chemicals 
Glucuronidase (bovine liver, Type B-10, G0501) and sulphatase (from Helix pomatia, Type 
H-1 S9626) were obtained from Sigma-Aldrich (Deisenhofen/St. Louis, MO, USA). XN was 
from Alexis Biochemicals (Lausen, Switzerland) or from Nookandeh Institute (Homburg/Saar, 
Germany) with a purity ≥ 98%, determined by HPLC. 
XN-enriched phenolic hop extract (XE) was a gift from NATECO2 (Wolnzach, Germany) and 
contained 73% XN determined by HPLC with UV detection. The extract was obtained after 
extraction of dried hop cones with supercritical CO2 (300 bar, 50-60 °C) to remove the 
essential oil and the bitter acids. After wards the residue was extracted again with 
supercritical CO2 (600-900 bar, 60-90 °C) to obtain a polyphenolic e xtract with 10-30 °C XN 
content. Further enrichment of XN and polyphenols resulted from pH-dependent precipitation 
and filtration of the associated compounds. Data sheet on extract information can be 
obtained via NATECO2. For better characterization of the secondary metabolite spectrum in 
XE, the extract was fractionated on Sephadex LH-20 (MeOH) and resulting fractions were 
analyzed by TLC, HPLC-DAD and HPLC-HRMS (Figure 5-8: HPLC chromatogram of fraction 
8. Solvent A: 5 mM NH4OOCH, solvent B: acetonitrile/water 95/5; column: Purospher® Star 
RP-18e (size: 250 x 4.0, particle size: 5 µm); flow: 0.8; 0-15 min 40 to 100% B, 15-22 min 
100% B; detection wavelength: 368 nm.Figure 5-7, Figure 5-8, Figure 5-9). Analysis revealed 
the presence of several hydroxyl cinnamic acids, prenylated chalcones and flavanols 
according [307]. 
 
5.4.2 Animals, animal treatment and sample asservation 
Female BALB/c mice were purchased from Charles River Laboratories (Sulzfeld, Germany) 
at 6 weeks of age and housed in a 22 °C controlled room under a 12 h light-dark cycle with 
free access to food and water. After 1 week of acclimatization, mice were divided into 
different groups (4-5 mice per group). The groups were fed for 3 and 7 days either with a diet 
supplemented with three different concentrations of XE leading to a 0.05, 0.25 and 0.5% 
(w/w) content of XN or supplemented with an equivalent dose of pure XN (0.5%), Afterwards 
the 0.5% content diets were fed in the main experiment to a second group (8-10 mice) for 
both XE and pure XN under the same conditions. Both chows were prepared by Ssniff 
(Soest, Germany) and are based on the Ssniff® R/M-H chow (Cat. V1534-0). At the end of 
the experimental time, mice were killed by heart puncture under ketamine/xylazine (2:1) 
anaesthesia, and blood samples and organs were collected for further analyses. Liver tissue 
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sections were frozen in liquid nitrogen immediately after organ explantation and stored at 
-80 °C. For serum analysis, blood was centrifuged a t 2,000 g to remove cellular components. 
Serum (supernatant) was used immediately for further analysis or stored at -80 °C- As 4-5 
(8-10 in the second experiment) mice lived in one cage, the feces was first pooled and than 
divided into 4-5 (8-10) samples to generate in overall average for each group in a cage. 
Urine and bile were collected by puncture of the bladder and gall bladder, respectively, under 
deep anaesthesia, and stored at -80 °C until proces sing for further analysis. 
 
5.4.3 Sample preparation 
For HPLC analysis of XN content in liver, tissue samples (~200 mg) were thoroughly 
homogenized in 800 µl of 2 M sodium acetate buffer (pH 4.7) containing 10 mg/ml ascorbic 
acid at 4 °C using a MICCRA D1 homogenizer (ART Pro zess- & Labortechnik GmbH & Co. 
KG, Müllheim, Germany). Afterwards the samples were homogenized with an ultrasonic 
homogenized in 1 ml buffer. Urine (5 µl) and bile [5 µl, pooled from 5 (8-10) animals of one 
cage as one gives not enough volume for sample preparation] samples were diluted with 
buffer to 25 µl. Serum (45 µl) samples were used undiluted. For enzymatic hydrolysis of 
conjugated XN-metabolites an aliquot of the samples were spiked with an equivalent volume 
of sodium acetate buffer containing β-glucutonidase and sulphatase). Resulting sample were 
incubated in sealed vials for 3 h at 37 °C with con tinuous shaking (400 rpm). After addition of 
an equivalent amount (v/v) of acetone the processed samples were vortexed and 
centrifugated at 20,000 x g; 4 °C) using NanoSep ce ntrifugal devices (Cat. 5168502 VWR, 
Darmstadt, Germany). Recovery of XN in the samples was reproducible and at 90-105% 
(Table 5-1). 
 
5.4.4 Analytical methods 
Quantification of XN was done by HPLC in analogy to [230]. The analytical HPLC system 
consisted of an Elite La Chrom system (VWR-Hitachi, Germany) equipped with a L-2455 
diode array detector, a thermostated L-2200 autosampler, a L-2130 pump and a L-2350 
column oven. A Purospher® Star RP-18e (column size: 250 x 4.0, particle size: 5 µm, Merck, 
Darmstadt, Germany) was used as column. Detection wavelength was 368 nm. The eluents 
were water/0.1% formic acid (A) and acetonitrile (95/5, B). The injection volume of the 
sample was 20 µl and the following elution-program was used with a flow rate of 1.0 ml per 
min (at 30 °C): 0-9 min 57.8%-68.2% B, 9-14 min up to 100% B and equilibration to 57.8%. 
Typical retention time for XN was 11.0 min. Calibration curves for the quantification of XN 
were measured with 11 different concentrations (n=6 for every concentration) resulting in a 
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R2 of 0.9999. For validation of the extraction process raw samples of the used tissues and 
excretes were spiked with different XN concentrations and extracted. Performance 
parameters of the method (e. g. LOD, LOQ and recovery) are given in Table 5-1. 
 
5.4.5 Statistical analysis 
Values are presented as means ± SD. Comparison between groups was made using 
ANOVA, followed by Tukey´s Multiple Comparison Test as post test. A p value < 0.05 was 
considered statistically significant. For elimination of outliers the test according to Grubbs 
was applied. All calculations were performed using GraphPad Prism 4. 
 
5.5 Results and Discussion 
To obtain valid information concerning the concentrations of unconjugated XN as well as of 
its phase II metabolites the concentration of XN with and without supplements of 
β-glucuronidase and sulphatase was determined. We started with the method of Wang and 
Morris [308], developed for the quantification of quercetin conjugates, to optimize the 
deconjugation process. Experiments with random liver and serum samples resulted in a 
β-glucuronidase concentration of 10 U/µl, a sulphatase concentration of 1 U/µl and an 
incubation time to 3 h to guarantee a quantitative hydrolysis of the conjugated compounds 
and a uniform working procedure (Figure 5-2). A further increase of the enzyme 
concentrations or incubation time respectively did not result in higher deconjugation 
efficiency of XN (Figure 5-2). Legette et al. [225] also used the same time (3 h) and 
temperature (37 °C) for the deconjugation process. 
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Figure 5-2: Hydrolysis of the conjugated XN metabolites by β-glucuronidase and sulphatase. 
Optimization of incubation time and enzyme concentration in random liver (black column) and 
serum (white columns) samples. A XN concentration depending on the incubation time (1, 2 
and 3 h) for two different enzyme activities (glucuronidase/sulphatase activity: 5/0.5 and 
10/1 U/µl). B XN concentration depending on the variation of enzyme activity at a constant 
incubation time of 3 h (glucuronidase/sulphatase 5/ 0.5, 10/1; 15/1.5, 20/2.0 U/µl). Values are 
expressed as mean ± SD from 3 different experiments. 
 
For further work it was necessary to determine the recovery rate of the external standard XN 
in the sample matrix. In doing so the target was to reach a low LOD and LOQ and to achieve 
a recovery of ± 10%. Blank serum, urine, bile, feces and tissue like liver were used to spike 
XN into the samples and to determine the LOD, LOQ, and the recovery. In addition the 
coefficient of the determination (R2) was calculated. The results are summarized in Table 
5-1. 
 
Table 5-1 Performance parameters of the HPLC method for the quantification of xanthohumol 
(XN) 
Tissue/excretion LOD (µM) LOQ (µM) 
Recovery 
(%) 
Calibration range 
recovery (µM) R
2
 (calibration line) 
 0.006* 0.02*   0.9999 
Serum   90-112 2.5-25 0.9971 
Liver   92-105 0.31-59 0.9999 
Urine   90-108 0.08-270 0.9986 
Bile   89-94 1.25-1000 0.9991 
Feces   88-112 6.25-313 0.9954 
*Calibration range: 0.001-3 µM 
 
R2 was between 0.9954 and 0.9999. It should be noted that the calibration curve, depending 
on the sample matrix, is processed over a range of 0.08 µM to 1000 µM. The recovery rate 
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was ± 12%. Avula et al. [224] reached a LOD of 0.04 µM and a LOQ of 0.1 µg/ml using 
methanol for the sample extraction. In this study we showed that using methanol as the 
extraction solvent only a 50% recovery of XN could be reached (Figure 5-3). Avula et al. 
[224] determined a recovery rate of 98.5%. Unfortunately, it is not clear if this result was 
obtained for all calibration points. In the study of Legette et al. [225] the relative standard 
deviation was 12% or better, the accuracy was between 90% and 110% and the LOQ 
0.4-0.5 nM. In their study the XN quantification was performed with MS. For this reason the 
LOQ is lower than the one obtained in this study. 
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Figure 5-3: Sample extraction 
 
The poor solubility of XN in aqueous solutions prompted us to supplement the diet and not 
the water with XN and XE, respectively. XN content in diet samples was analyzed by HPLC 
to ensure a sufficient stability as well as a homogenous XN distribution during the chow 
preparation (data not shown). Mice were fed for 3 and 7 days with different concentrations of 
XE (0.05, 0.25 and 0.5% XN) in the chow. Food consumption did not vary significantly 
between the different experimental groups, and in line with our previous safety study on XN 
no signs if toxicity were observable in the mice with the highest XE/XN concentration used 
[222]. Feeding of different concentrations of XE did neither after 3 nor after 7 days led to a 
linear increase of the serum and urine concentrations of XN or its conjugated metabolites 
(Figure 5-4). 
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Figure 5-4: Concentration of conjugated (white columns) and unconjugated (grey columns) XN 
in A serum and B urine after feeding of diet enriched XE equivalent to 0.05, 0.25 and 0.5% (w/w) 
XN for 3 (plain columns) and 7 (shaded columns) days. Values are expressed as mean ± SD 
obtained from 4-5 animals in each group. 
 
For example, after 7 days serum levels of conjugated XN in the 0.25% group reached 
0.5 ± 0.1 µM in comparison to 2.2 ± 0.9 µM in the 0.5% group. Thus, the highest 
concentration applied led to an over proportional increase of the serum and urine XN levels. 
A similar trend was observed by Legette et al. [225]. However no further body fluids or 
tissues were investigated. Interestingly, they gavaged the feed in liquid form which led to a 
similar pattern of XN in the sera. However to the best of our knowledge the distribution of XN 
in the urine, bile, feces as well as the liver after oral ingestion of chow was not investigated 
so far. 
The comparability and reproducibility of in vivo studies concerning the bioavailability of 
further chalcones should be supported by the realization of a pilot experiment to evaluate the 
dose dependent absorption behavior of the respective compound. Interestingly, several 
studies on the bioavailability of other more widespread polyphenols did not address this 
problem as only a single dose was applied. The existing data concerning the 
dose-dependent investigation of flavonoid bioavailability point to the fact that there is a 
dose-dependent absorption for the main flavonols, but probably heterogeneous absorption 
behavior among the different classes of polyphenols. Egert et al. [309] reported on a dose 
dependent increase of quercetin concentration in plasma, and Barve et al. [310] found the 
same for orally administered kaempferol. However, for the main tea catechin 
epigallocatechin-3-O-gallate (EPCG) a linear dose relationship to the plasma concentration is 
only observable for lower dosing, whereas higher doses resulted in a dose-independent 
plateau of EPCG plasma level [311]. Furthermore, Ullmann et al. [312] reported in line with 
our results on XN a dose escalating effect for the plasma levels of EPCG after repeated 
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application of higher EPCG doses. Based in the food intake the daily intake of XN in mice fed 
with 0.05, 0.25 and 0.5% diet can be translated to approximately 100, 500 and 1000 mg/kg 
body weight, respectively [222]. 
Mechanistically, a variation of XN absorption depending on the applied dose and escalating 
plasma levels with the highest XN concentration dependent transport mechanisms. In 
contrast to the report of Avula et al. [224] detectable concentrations of free, unmetabolized 
XN were present not only in the urine, but also in serum in our setup. This can be likely 
explained by the continuous XN intake over several days or the higher dose of XN used, 
whereas Avula and colleagues investigated a single dose design. Furthermore, the extraction 
of biological samples with MeOH chosen in [224] is not suitable to recover low concentration 
of XN quantitatively (Figure 5-1). Nevertheless, also in our study the concentration of free XN 
in serum was very low and did not exceed 1 µM in all groups. Interestingly, in contrast to the 
phase II metabolites the concentrations of free XN in serum did not significantly increase with 
the time or a higher dose of applied XN (Figure 5-4, Figure 5-5). 
-101- 
 
 
 
A 
Liver
0.05 0.25 0.50
0.0
2.0
4.0
6.0
8.0
10.0
12.0
XN (%) in diet
XN
 
(µ
M
)
B 
Bile
0.05 0.25 0.50
0.0
2.5
5.0
7.5
10.0
XN (%) in diet
XN
 
(m
M
)
                                 C 
Faeces
0.05 0.25 0.50
0
50
100
150
200
XN (%) in diet
XN
 
(µ
M
)
 
Figure 5-5: Concentration of conjugated (white columns) and unconjugates (grey columns XN 
in A liver, B bile and C feces after feeding of diet enriched with XE equivalent to 0.05, 0.25 and 
0.5% (w/w) XN for 3 (plain columns) and 7 (shaded columns) days. Values are expressed as 
mean ± SD obtained from 4-5 animals in each group. As the bile value resulted from a pooled 
sample no standard deviation is given. 
 
Figure 5-5 shows the amount of pure XN and XN metabolites present in liver and bile after 3 
and 7 days feeding of XE at different concentrations. In all groups hepatic concentrations of 
conjugated XN were found to be significantly higher than corresponding serum 
concentrations as we found that the bile is highly enriched with XN containing mmolar 
concentrations. In line with serum and urine concentrations of XN and its phase II 
metabolites in liver and bile did not linearly increase with higher intake of XN. An enrichment 
of XN-conjugates in liver was observable for all groups irrespective of the time span of XN 
intake and increase with higher XN content in the diet (Figure 5-6 A). A comparison of the 3 
and 7 days groups revealed a remarkable decrease of conjugated XN after linger application 
of XE (e. g. containing 0.5% XN from 8.1 ± 2.2 µM to 6.7 ± 2.4 µM). This result was 
confirmed with statistical significance in the second experimental setup comparing the 
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application of 0.5% XN in the XE group (Figure 5-6 C, 11.5 ± 2.3 µM in the 3 days group vs. 
5.6 ± 1.6 µM in the 7 days group) with the 0.5% pure XN group. 
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Figure 5-6: Concentration of conjugated (white columns) and unconjugated (grey columns) XN 
in A serum, B urine, C liver, D bile after feeding of diet enriched with 0.5% (w/w) pure XN or XN 
in XN in XE for 3 (plain columns) and 7 (shaded columns) days. Values are expressed as 
mean ± SD obtained from 8-10 animals in each group. Bile is given without SD as it was pooled 
from all animals due to the low volume. * Significant on the p < 0.05 level, ***significant on the 
p < 0.001 level. 
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In the bile the enrichment of XN-conjugates was more heterogeneous (Figure 5-5 B). For 
animals fed with 0.05% XN there is no significant difference between the 3 and the 7 days 
group. In the case of the 0.25 and 0.5% groups we observed some differences depending on 
the feeding time, however, results are not conclusive. Further, as compared to serum, urine 
and hepatic tissue concentration of conjugated XN in bile showed a quite high variation of XN 
in the two 7 days groups (Figure 5-5 B, Figure 5-6 D, 10.0 mM in the dose finding set up vs. 
2.9 mM in the XE/pure XN comparison set up) that received the XE diet with 0.5% XN, a 
phenomenon for which we do not have a plausible explanation up to now. However, there 
appears to be a dose dependent increase of XN concentration in the bile, at least comparing 
mice fed with 0.05% XN diet and the 0.25 and 0.5% groups, respectively. Most impressive is 
the extremely pronounced content of XN conjugates in bile, which can be likely explained by 
the very good solubilization of the lipophilic XN and its amphiphilic glucuronides by bile acids. 
Furthermore, it points to the existence of an entero-hepatic circulation of XN and its 
metabolites. Similar to the other specimen the analyzed concentration of free XN in bile was 
low in comparison to the concentration of phase II metabolites in all groups (micromolar 
range). These results underline, in accordance with several publications on other 
polyphenols [313–315], that for studies on absorption of XN (and most likely also for other 
chalcones) the determination of phase II metabolites is indispensable. 
 
Based on these data the gut and the liver appear as favorable organs to use the 
chemopreventive and anti-cancer activity of XN. Naturally, intestinal epithelial cells are 
exposed to the highest XN concentrations after oral application. In addition, also hepatic 
concentrations are higher than in other organs since after oral application XN concentrations 
in the portal circulation are higher than in the systemic circulation, and enterohepatic 
circulation of the bile further augments this situation. 
The shape of the concentration curve of XN excreted with the feces is closely coupled to the 
bile concentration to the bile concentration with the highest concentration of XN and its 
phase II metabolites after 7 days and a feeding concentration of 0.5% (m/m) XN in XE 
(Figure 5-6). As no metabolic cages were used a defined mapping of feces to single mice 
was not possible. In contrast to the other investigated samples the excreted XN belonged 
mainly to the free XN content and the phase II metabolite concentrations were generally 
lower. A comparatively high concentration of phase II metabolites was observable 7 days 
application of 0.5% XN in both experimental setups (Figure 5-5, Figure 5-6). The increasing 
content of phase II metabolites in these samples in comparison to the 3 days measurement 
and the 0.25% XN concentration after 7 days, gives striking evidence that XN undergoes an 
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induced excretion to bile especially after application of higher doses and a longer oral intake 
of XN, respectively. 
 
In order to investigate the effect of the extract on the absorption of XN also pure XN was fed 
to mice for 3 and 7 days with a concentration of 0.5% XN in the same chow as used for the 
feeding experiments applying XE. Figure 5-6 shows that absorption of XN is positively 
influences by extract application (and likely the polyphenolic congeners) as the concentration 
in the serum is significantly lower after application of the same amount of pure XN. The 
concentration in the serum is significantly lower after application of the same amount of pure 
XN. The concentration of conjugated XN metabolites decreased from 5.1 ± 2.0 µM (in case 
of XE diet) to 3.5 ± 0.8 µM (in case of XN diet) after 3 and from 5.2 ± 2.7 µM (XE diet) to 
2.8 ± 0.9 µM (XN diet) after 7 days. In contrast, the concentration of overall (conjugated and 
free) XN in the feces samples (Figure 5-6) was significantly higher after the application of 
pure XN in comparison to the extract. After 3 days the group fed with 0.5% XN in XE 
revealed an entire (conjugated + unconjugated) level of 115.9 ± 24.9 µg XN per mg feces, 
whereas the group fed with 0.5% pure XN showed a value of 135.1 ± 62.2 µg/mg. After 
7 days the extract-group revealed an entire concentration of XN 129.8 ± 29.5 µg/mg feces in 
comparison to 185.4 ± 77.1 µg/mg in the pure XN group. It is of general importance and in 
line with the XN content in feces that the distribution of XN and its metabolites is also 
influenced as the concentration of XN in bile is dramatically increasing after feeding of pure 
XN in the 3 and 7 days groups the interpretation is difficult to explain as we have no results 
for the single individuals. Urine and hepatic concentration of XN were not significantly 
different in the animals receiving the extract or the pure XN diet neither after 3 nor after 
7 days (Figure 5-6). The positive influence on the absorption of pharmacologically active 
metabolites by other polyphenolic compounds has been also reported in the case of 
Hypericum perforatum extracts for hypericin [316] and was explained by better solubilization 
of lipophilic compounds by the polyphenolic congeners [317]. As XN reveals also relatively 
high lipophilicity this is plausible explanation for the better absorption of XN, too. 
Nevertheless, also several other factors modulating absorption and degredation of flavonoids 
can be discussed for the positive effect after XE application. Congeners with antioxidant 
activity are able to protect XN from oxidative degradation, the degree of microbial 
degradation by the gut can be structure- and concentration-dependently modulated [318], or 
the number of bacteria in the gut and thus the activity of the microbial flora can be influenced 
[319]. 
As several compounds of the overcritical CO2 hop extract are polyphenols according the 
TLC, HPLC/DAD and HPLC/HRESIMS analysis (Figure 5-7, Figure 5-8, Figure 5-9) the 
increased absorption of XN from the extract suggests that application of a spectrum of 
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multiple phenolic substances contribution to an increased XN bioavailability. Contribution of 
polyphenols to pharmacokinetic parameters has been reported by Moon and Morris [320], 
who showed increased bioavailability, reduced clearance and induced entero-hepatic cycling 
of biochanin A after co-administration of quercetin and EPCG. 
 
5.6 Summary 
Summing up, our results show that biologically relevant concentration of XN phase II 
metabolites could be obtained in all excretes and investigated tissues of mice in the case of 
both application schemes, pure XN and a XN-enriched phenolic hop extract (XE), after 3 and 
7 days, whereas the concentration of unconjugated XN was significantly lower. An 
enrichment of XN and its phase II metabolites was detected in the liver and particularly in the 
bile. A dose dependent absorption for XN was not observable as escalating plasma levels for 
XN with highly enriched XN diet (0.5%) were measured. Furthermore, with the latter dose an 
induced entero-hepatic circulation of XN can be observed. The ongoing research, using LC 
coupled to high resolution ESI-MS/MS analyses as well as isolation, will focus now on the 
extract characterization of the metabolic spectrum after the application of pure XN and XE to 
clarify whether there is not only a quantitative, but also a qualitative variation of the XN 
metabolism caused by the application matrix. This question is of special interest as a recent 
publication of Jirasko et al. [321] reported on hitherto unknown phase II metabolites of XN 
derivatives after modification in a phase I reaction after the application of a XN containing 
hop extract. Another question of relevance is the variable conversion of XN into 
isoxanthohumol and also the recently reported conversion to the demethylation product 
8-prenylnaringenin by human bacteria [236,322]. This is of pharmacological relevance as 
isoxanthohumol often showed markedly lower effects in pharmacological assays, whereas 
8-prenylnaringenin showed significant estrogenic effects. Also an influence on human P450 
enzymes by hops secondary metabolites has been reported [133] and should be investigated 
after application of XE. Furthermore, the synthesis, pharmacological characterization of XN 
phase II metabolites as well as investigation on their transport behavior on cellular levels is 
absolutely necessary to address the biological importance due to their high content in the 
investigated tissues. As the metabolism of polyphenols can be quantitatively and qualitatively 
different between rodents and humans in vivo studies in man are still a lacking brick in the 
investigation of XN metabolism. 
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5.7 Appendix 
 
 
Figure 5-7: TLC chromatogram of the main fractions obtained from CC of XE 73% (1.7 g) on 
Sephadex LH-20 (155 g, L 53 cm Ø 3.5 cm) with MeOH as mobile phase. 190 fractions (5 ml, 
combined after TLC analysis). TLC conditions: silica gel (Merck), mobile phase: CHCL3/MeOH 
90:6, detection: 366 nm; dark spots belong mainly to prenylated chalcones and flavanones; 
main spot fraction 9 and 10: xanthohumol. 
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Figure 5-8: HPLC chromatogram of fraction 8. Solvent A: 5 mM NH4OOCH, solvent B: 
acetonitrile/water 95/5; column: Purospher® Star RP-18e (size: 250 x 4.0, particle size: 5 µm); 
flow: 0.8; 0-15 min 40 to 100% B, 15-22 min 100% B; detection wavelength: 368 nm. 
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Figure 5-9: UV- and HRESIMS spectra of selected polyphenols in fraction 8 (XE 73%). Data 
(lambdamax and [M+H]+) points to the presence of several prenylated chalcones as congeners of 
xanthohumol. UHD Accurate Mass Q-TOF LC/MS System; with Ultra-High-Definition Q-TOF, 
JetStream-Technology, MS-ESI (Agilent). 
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6 Discussion 
XN is a small molecule with a prenyl chain and belongs to the huge family of polyphenols 
and the subgroup of chalcones. In comparison to other chalcones such as 
hydroxysafflor yellow A and isoliquiritin, XN exhibits no sugar moiety. XN is a lipophilic 
compound that is poorly soluble in water and medium [82,226] with a solubility of 
< 0.05 mg/ml XN in cell culture medium after 3 h incubation time [226]. A low solubility was 
also observed for other flavonoids such as silymarin [323]. In order to use the prenylated 
chalcones as reference substances in pharmacological studies, it is necessary to establish 
appropriate experimental set-ups in order to reach the requested XN concentrations in the 
medium. There are different methods to enhance the solubility of compounds e.g. by 
complexation, micellization, cosolvency [324], adjustment of the pH [325] and BSA 
optimization [326]. In this thesis the solubility of XN was adjusted with FCS. FCS is a 
complex solution of different proteins and factors [327]. With higher FCS concentrations the 
solubility of XN increased in a dose dependent manner. A minimum FCS concentration of 
10% was necessary in order to reach XN concentrations of 10 µM. The absorption of XN to 
proteins was shown in different studies [227,228]. Pang et al. [227] investigated the ability of 
XN to bind to native isolated cytosolic proteins. The ability of XN to bind to proteins was also 
studied in cells by FRAP measurements [228]. Moreover XN was also shown to interact with 
proteins such as Keap 1 [137,139], NF-κB [176,182] and IKK [182], but the proteins which 
are responsible for the mediation of the solubility are not identified yet. But high FCS 
concentrations might also lead to interference with detection methods such as fluorescence 
measurements [226] (Chapter 2). FCS contains different proteins and factors [327] which 
might quench the fluorescence or induce a spectral shift. However, XN adsorb not only to 
proteins but also to cell culture materials. In Greiner culture flasks, TPP culture flasks and 
Petri dishes but not in centrifuge tubes and 96 well plates the required XN concentration of 
10 µM could be reached using 10% FCS. The adsorption of small molecules to culture 
materials was also shown in other studies. The adsorption of different small molecules was 
examined, for instance, on different UV-ozone treated materials such as poly(methyl 
methacrylate), polysterne, polycarbonate, poly(dimethylsiloxane) and cyclic olefin 
copolymers. It was shown that the treatment of thermoplastics with UV-ozone reduced the 
adsorption of the compounds on some of the thermoplastics [328]. The required 
experimental set-up for lipophilic compounds should be checked at the beginning of in vitro 
as well as in vivo experiments. The supplementation of pure water without any solubilizers 
with XN is inadvisable for in vivo studies [169,220]. The supplementation of chow might solve 
the solubility problem of XN in in vivo studies (see also Chapter 5). Summing up it is 
-109- 
 
 
 
necessary to determine the effective concentration of lipophilic compounds in the used media 
at the beginning of the experiments. 
 
XN exhibits a low bioavailability. Only a few studies were performed that investigate the XN 
uptake in vitro. Pang et al. [227] determined the XN uptake in Caco-2 cells. Wolff et al. [228] 
(see also Chapter 4) investigated the time course and manner of the XN uptake in hepatic 
and colorectal cancer cell lines as well as primary hepatocytes. In addition the XN 
concentration per cell was determined. Both studies detected a fast and concentrated uptake 
of XN. XN absorption reached a steady state between 30 and 60 min in HSC, HuH-7, PH 
[228] and Caco-2 cells [228,227]. 
In order to determine the XN concentration per cell in this thesis, the XN amount per protein 
was measured and a correlation curve that describes the ratio between the protein per cell 
and the cell volumes prepared for each cell line as well as the PH. The measurements 
revealed that HSC, Caco-2 and PH took up 52, 63 and 47 fold higher XN concentrations 
compared to the XN supplemented medium. In HuH-7 the uptake was only 3 fold higher 
compared to the medium (see Chapter 4) [228]. Reasons for the low XN uptake in HuH-7 
cells might be the existence of different transporter types and densities in the cell lines. 
ABC-transporters are ATP-dependent and are located in the cell membrane. A function of 
the ABC-transporters is the transport of hydrophobic compounds across the cellular 
membrane [239]. XN was shown to influence ABC-transporters and reduce their mRNA 
levels [189] as well as the efflux of compounds mediated by P-glycoproteins [242,241,227]. 
Pang et al. [227] incubated Caco-2 cells with transporter inhibitors and detected an increased 
uptake of XN. However a clear mechanism is not known yet. 
Another possible reason of the low XN uptake in HuH-7 cells would be a higher phase I or 
phase II metabolism of XN in HuH-7 cells. The detoxification of XN and metabolites was also 
discussed in the study of Miranda et al. [186]. They determined the cytotoxic effects of XN 
and metabolites in different cell lines. The cells were incubated with the compounds for 48, 
96 and 144 h. The longer the incubation time the lower was the observed cytotoxicity. In this 
thesis a higher metabolic rate in HuH-7 cells might be not the mode of action. The 
intracellular concentration of XN was determined by HPLC. This method had the advantage 
that metabolites with a similar chromophor could be detected and observed during the XN 
quantification (see Chapter 5). Rather no difference concerning the phase II metabolism was 
observed between the cell lines. The exact mechanism for the low XN uptake in HuH-7 is not 
known. 
Nevertheless XN, showed a fast and comprehensive up-take by the liver cells. This fact 
might also lead to a low bioavailability. E.g. Avula et al. [224] did not detect XN after oral 
application of 10, 20, 50, 100, 200, 400, 500 mg XN/kg body weight and XN enriched hops 
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extract in rat’s serum. Legette et al. [225] detected 0.42 ± 0.03 µM conjugated and 
unconjugated XN after a single oral gavages dose of 16.9 mg/kg body weight. In this thesis 
BALB/c mice were fed with two different chows. In a first experiment the chow was 
supplemented with 73% XN (27% phenolic matrix). BALB/c mice were fed with 
100 mg XN/kg, 500 mg XN/kg and 1000 mg XN/kg body weight of the 73% XN chow for 3 
and 7 days. After the feeding period the serum, liver, urine, feces and bile samples were 
analyzed concerning their XN content (unconjugated and conjugated XN). The 
concentrations of unconjugated XN were between 0.01 and 0.12 µM (see Chapter 5). The 
slight differences between the studies might be attributed to different experimental designs. 
The concentration of unconjugated XN in serum is generally low and a suitable lipophilic 
solvent had to be chosen in order to effectively extract XN from the matrix. Different solvents 
might lead to different recoveries from serum with differing LOQs and varying results. Apart 
from the optimal extraction solvent, the detection method is also relevant. Legette et al. [225] 
worked with a LOQ of 0.4-0.5 nM, Avula et al. [224] with 0.04 µM. In this thesis a LOQ of 
0.02 µM was achieved. Legette et al. [225] determined the XN amount with MS and probably 
for this reason reached lower LOQ [225]. Furthermore, in comparison to the study of Avula et 
al. [224], Legette et al. [225] determined the sum of unconjugated and conjugated XN. In our 
study the unconjugated, conjugated and the sum of XN was determined. The ratio between 
unconjugated and conjugated XN was between 21 and 163 (see Chapter 5). This might be 
one reason why Avula et al. [224] did not detect XN, because the phase II metabolites were 
not determined. The investigation of phase II metabolites is of great importance. After oral 
ingestion the flavonoids can be absorbed in the small intestine and the colon as aglycones 
and in some cases also as glycosides [329–331]. After the uptake they are transported to the 
liver by the venous gastrointestinal blood. Metabolism such as glucuronidation and 
deglucuronidation can take place in the small intestine and/or in the liver [332–334]. One 
example for deglucoronidation in the liver is the toxic metabolite mycophenolate mofetil acyl 
glucuronide, which is deglucuronidated in the liver by α,β hydrolase domain containing 10 
[332]. The precursor flavonoids and their metabolites can reach the bile and colon after they 
passed the liver and may be absorbed again (entero-hepatic circulation). The complex 
mechanism of the metabolism of flavanoids is not fully understood and is still under 
investigation. However metabolites can spread higher, lesser or the same activity compared 
to their precursors. Thus phase II metabolites should always be investigated in order to 
determine the bioavailability and behavior of polyphenols in vivo. The concentrations of 
unconjugated XN ranged between 0.01 and 0.12 µM in serum (see Chapter 5). Thus the 
bioavailability of unconjugated XN was low, but a high phase II metabolism rate was 
observed. Similar results were described for quercetin (single oral dose of 350 mg/kg body 
weight). No free quercetin was detected but a metabolite concentration of 30.0 ± 3.8 µM after 
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24 h [335]. The same high phase II metabolism was also observed for further lipophilic 
flavonoid aglyca in a Caco-2 cell model. This study revealed a good permeability of 
aglycones and a comprehensive metabolization to their glucuronic acid and sulfate 
derivatives [336]. Similar behavior was observed for XN in cellular uptake and in in vivo 
studies. XN showed a rapid uptake in hepatic cancer cell lines, Caco-2 and PHs [227,228] 
(see also Chapter 4). The fast and high uptake might be an explanation for the low 
bioavailability and absorption of XN [224,225] (see also Chapter 5). 
In our study the dose dependent distribution of unconjugated and conjugated XN was 
investigated in serum, bile, urine, feces and liver 3 and 7 days after daily intake with the 
chow. In all samples of the body fluids, secretions and tissues the concentration of 
unconjugated and conjugated XN was not linearly increasing with the ingested amount of 
XN. A similar pattern was also observed in the study of Legette et al. [225] for XN and in the 
study of Yang et al. [337] for epicatechin-3-gallate (ingestion of 1.5, 3.0 and 4.5 g 
decaffeinated green tea solids). In contrast a linear correlation between the ingested dose 
and the absorption was described for other flavonoids like isorhamnetin [338]. The 
determination of the bioavailability on the basis of only one dose as it was performed in 
different studies e.g. [335,339] might lead to only limited conclusions. Thus it seems to be 
beneficial to investigate the dose dependent absorption rather than conducting single dose 
experiments.  
In our study the concentration of XN metabolites in the liver was lower after 7 days of 
administration compared to 3 days, but higher in bile and feces (1000 mg/kg body weight). 
No difference in the XN metabolite concentrations depending on the feeding period was 
observed for serum and urine samples. Interestingly, the XN concentration was highest 
(unconjugated and conjugated) in the bile followed by feces, urine, liver and serum. This 
pointed to an entero-hepatic circulation. Quercetin metabolites were also found to be 
excreted through the bile [340]. Compounds with a molecular weight of less than 300 Da are 
commonly excreted via the urine. Molecular weights above 300 Da commonly lead to an 
excretion via the bile [99]. 
Noteworthy is also the high concentration of conjugated XN in the serum. Only a small 
amount of unconjugated XN reaches the systemic circulation (ratio of 
conjugated/unconjugated XN ranges between 21-163). 
 
In the second part of the study the influence of the matrix on the bioavailability and uptake 
was studied, because it was shown in the literature that compounds are better ingested with 
matrix as without [303,341,342]. One group of BALB/c mice was fed with a diet 
supplemented with 98% XN (XN). The second group was fed with a diet supplemented with 
73% XN (XE) (27% phenolic matrix). The feeding period was either 3 or 7 days (1000 mg/kg 
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body weight). After the feeding period the serum, liver, urine, feces and bile samples were 
analyzed for the amount of unconjugated and conjugated XN. It was observed that with the 
ingestion of XE significantly more conjugated XN was found in the systemic circulation. 
Furthermore, the excretion of conjugated XN via the bile and feces was higher for the XN diet 
compared to XE. The same trend was observed for the urine but could not be statistically 
confirmed. The observed effects were attributed to the remaining matrix in the XE diet. Matrix 
effects on the absorption of compounds were also observed in other studies about 
flavanoids. E.g. the bioavailability of polyphenols (e. g. epigallocatechin-3-gallate) was 
increased in case of the ingestion with decaffeinated green tea [341]. Wiczkowski and 
co-workers [303] discussed matrix effects as a possible explanation for a higher uptake of 
quercetin in shallots. Matrix effects were also discussed by Egert et al. [342]. They 
determined the uptake of quercetin in cereal bars and quercetin powder-filled hard capsules 
[342]. There are many different explanations for the higher absorption and bioavailability 
which are observed in case of ingestion of substances with matrix. One explanation might be 
the regulation of the efflux or influx of the compounds by transporters e.g. ABC-transporter 
by the matrix [343,344]. Another explanation might be lower metabolism of polyphenols 
caused by the matrix. Chen et al. [341] investigated the absorption of polyphenols (e. g. 
epigallocatechin-3-gallate) with decaffeinated green tea matrix or without in rats. The results 
pointed to higher absorption of polyphenols with matrix as without. They discussed a 
competition of matrix tea polyphenols with the metabolism enzymes such as glucuronosyl- 
and sulfotransferase. This might lead to higher concentration of polyphenols and lower 
elimination [341]. Flavonoids can be also absorbed in the colon [329,330] and are 
transformed by the colon microflora. The matrix might also prevent the molecule against 
destruction and oxidation by the microflora [318]. Another explanation might be the higher 
solubility of a polyphenol facilitated by the matrix. This was also discussed in several studies 
[309,316,341,345]. In the study of Egert and co-workers [309] the bioavailability of quercetin 
in quercetin-enriched cereal bars and quercetin powder-filled hard capsules was 
investigated. The ingestion of quercetin-enriched cereal bars yielded higher area under the 
curve compared to the ingestion of quercetin powder-filled hard capsules and a higher 
solubility of quercetin in the cereal bars was discussed. An increase in the solubility is one of 
the main factors for an increase of the bioavailability. There are a variety of methods that are 
used to increase the solubility of lipophilic compounds such as complexetion, micellization, 
coselvency [324], adjustment of the pH [325] and BSA optimization [326]. The increase of the 
solubility of XN by cyclodextrines is described in the patent application of Yamaguchi et al. 
[346]. 
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In this thesis it was shown that XN is taken up by liver cell lines (in vitro) and is highly 
metabolized (in vivo). As the pharmacological data of XN metabolites and related 
compounds are scarce, the effect of a series of chalcones on the viability, proliferation and 
cytotoxicity was investigated in three hepatic and one colorectal cancer cell line using MTT 
and CV assay. Compounds 13 and 14 were found to be less toxic compounds. Compound 2 
was the compound with the lowest IC50 value. A different effect of the compounds was 
observed in the study of Vogel et al. using HeLa cells [150–152]. Compound 13 showed the 
strongest viability inhibition (IC50 value 5.2 ± 0.8 µM) followed by 2 > XN > 6 > 14 > 7 = 4 > 3 
> 5 and 17 [152,151,150]. The differences in the effectiveness are probably explainable 
because of the different cell lines and method handling. 
In this thesis a correlation between the lipophilicity of the tested substances and their 
cytotoxicity could be partially observed. The lipophilicity was compared by HPTLC. E. g. 15 
was one of the more lipophilic compounds and showed the lowest IC50 value in RAW 264.7. 
A correlation between the cytotoxicity and lipophilicity was also observed in a variety of other 
studies. For example 15 showed the weakest viability inhibitory activity in RAW 264.7 cells 
followed by 16 and 17 [271]. The latter flavokawains are more lipohilic than 15. These results 
for the flavokawains were also confirmed in this study. The studies of local anesthetics [287] 
and heat shock proteins [288] revealed a similar correlation between the cytotoxicity and 
lipophilicity. The studies showed that lipophilic chemicals exhibit higher cytotoxicity in human 
T-lymphoma cells [287] or induce heat shock proteins [288]. An explanation might be the 
ability of lipophilic substances to approximate to and interact with lipophilic centers of 
enzymes [288,289]. XN can interact with mitochondrial proteins, induce the release of ROS 
and lead to apoptosis [157]. In addition XN (1) can change the membrane fluidity [290]. This 
process might lead to a faster infiltration and a higher cytotoxicity, but the exact mechanism 
is not investigated yet. Nevertheless, the lipophilicity might not to be the only explanation. 
Compound 2 is less lipophilic and showed comparatively high reduction of the cell viability. It 
carries a prenyl chain with a hydroxyl group which might be responsible for the observed 
effects. The presence of a prenyl chain was also correlated with the effect to inhibit the 
growth of microorganism [19,291], phase II enzymes [135], BACE1 [292], the invasion of 
cancer cells [187] as well as their proliferation and 5-LOX activity [289]. In addition the 
adherence of prenyl groups to apigenin and liquiritigenin was shown to increase the 
cytotoxicity in different cell lines [293]. 
The molecular mechanism of the effects of XN (1), XN metabolites and related compounds 
was not investigated in this study. Each assay investigates different aspects of cellular 
behavior. The MTT assay describes an increase or decrease in the viability which can be 
caused by a drop of the cell count and a decrease in mitochondrial activity. The CV assay is 
only based on the cell count. With increasing concentrations 2 first inhibited the viability and 
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then the cell count in the MTT and CV assay. This might point to an inhibition of the 
mitochondria function by 2 without a decrease of the cell count. The compounds 6 and 7 
showed the opposite behavior. First a decrease in the cell count was observed followed by a 
decrease in the viability. Thus, the mechanism of 6 and 7 might be another as by 2. The 
behavior of 1, 3 and 13 concerning cell viability and cell count depends on the cell line. It is 
known that XN induces cell death in different cancer cell lines and through different 
mechanisms (see 1.1.7 Pro-apoptotic mechanism). The behavior of 2, 6 and 7 differed from 
XN in most cell lines and thus might be investigated in further detail in following studies. 
 
In addition the NO production and the iNOS expression were investigated for XN, XN 
metabolites and related compounds (see Chapter 3). The compounds were tested on their 
activity to inhibit the NO production which was induced with 10 ng/ml LPS in the first assay. 
In order to compare the influence on the NO production with the iNOS expression the second 
Griess assay was performed with 10 ng/ml LPS and 200 ng/ml IFN-γ 
All compounds except of the used hydrogenated derivatives showed a significant inhibition of 
the NO production in the performed Griess assay (10 ng/ml LPS). In the literature it is 
discussed that the α,β-unsaturated carbonyl moiety is responsible for the inhibition [181,295]. 
Compounds without this moiety led to no or only little decreases in the NO production [181]. 
Therefore the hydrogenated compounds in comparison to the other XN metabolites and 
related compounds were tested. In the second Griess assay (10 ng/ml LPS and 
200 ng/ml IFN-γ) compound 10 a hydrogenated chalcone showed a significant inhibitory 
effect on the NO production at 8 µM. This is in agreement with the study of Peluso et al. 
[178]. Peluso et al. studied the influence of flavonoids and dihydro flavonoids on the 
expression of MCP-1 and IL-6 in LPS stimulated monocytic THP-1 cells. As aforementioned 
the activity to inhibit the NO production were not observed in solely LPS (10 ng/ml LPS) 
stimulated cells in the Griess assay by the hydrogenated compounds. LPS stimulates the NO 
production via the NF-κB pathway. IFN-γ activates the NO production via the JAK/STAT 
pathway. Compound 10 may inhibit the NO production more effective through the JAK/STAT 
pathway with its tetrahydropyran structure characteristics. 
Compound 6 significantly inhibited the NO production and carry a closed prenyl chain at the 
A ring. The correlation between the higher NO inhibition activity and the open prenyl chain at 
the A ring of the chalcone were investigated with compound 9 and the closed prenyl chain in 
the Acetylchroman 8. Compound 8 led to higher inhibitory effects compared to 9. As 
aforementioned 10 spread effective inhibitory activity on the NO production compared to the 
other hydrogenated chalcones (10 ng/ml LPS and 200 ng/ml IFN-γ). Thus the A ring with the 
closed prenyl chain at the A ring might be beneficial for the inhibition of the NO production 
and the iNOS expression independent of the used stimuli. 
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Further comparison of the structure of the investigated compounds revealed that the prenyl 
chain did not enhance the inhibition of the NO production. The same was observed by Zhao 
et al. [181]. However 2 was an outlier of this conclusion and the most active compound of the 
prenylated chalcones. Compound 5 showed the weakest activity. A similar correlation was 
also observed in the study of Peluso et al. [178]. Compound 5 was found to be less active 
than XN and 17 [178]. There is no explanation for this behavior up to now 
Furthermore, 13 which is a non-prenylated chalcone showed the highest inhibitory activity on 
the NO production and iNOS expression. Compound 18 spread higher activity as 13 but was 
less active in the second NO assay (10 ng/ml LPS and 200 ng/ml IFN-γ). Compound 18 
might inhibit the NO production predominantly through the NF-κB pathway. No correlation 
between the lipophilicity and the inhibitory effects on the NO production and the iNOS 
expression could be observed. 
 
7 Summary 
XN is an abundant chalcone in hops and spread a wide range of pharmacological effects. 
The lipophilicity of XN is a challenge for water based in vitro studies. For this reason suitable 
experimental set-ups for in vitro experiments were established. A content of 10% FCS in the 
cell culture medium was found to efficiently increase the solubility of XN. However the 
application of 10% FCS did not fully prevent the adsorption of XN to several cell culture 
materials. In Greiner culture flasks, TPP culture flasks and Petri dishes but not in centrifuge 
tubes and 96 well plates a solubility concentration of 10 µM XN could be reached. 
XN is mainly found in beer in the human diet and is ingested with other minor hop 
compounds. After ingestion XN is highly metabolized (see Chapter 5). For this reason it is 
necessary to determine the effects of minor hop chalcones, XN metabolites and related 
compounds in order to investigate if the compounds are more or less active compared to XN. 
XN is a potent anti-inflammatory compound that leads to the inhibition of inflammatory and 
angiogenetic factors and exhibits anti-cancer effects. The compounds were investigated 
concerning their ability to influence the viability, proliferation and cytotoxicity in MTT and CV 
assays. 
Compound 2 had the lowest IC50 values in the MTT assay. In the CV assay 6 and 7 showed 
the lowest IC50 values in most of the investigated cell lines. Thus these XN metabolites and 
related compounds might be candidates for advanced studies. 
The ability to influence inflammatory factors such as the NO production and iNOS expression 
was determined in a Griess assay and an iNOS expression assay. Compound 10 effectively 
inhibited the NO production in RAW 264.7 cells stimulated with 10 ng/ml LPS. The iNOS 
expression was significantly inhibited by the tested hydrogenated chalcones. In the group of 
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the chalcones the tetrahydropyran-chalcone 6 had a remarkable potential to inhibit the NO 
production and iNOS expression. The non-prenylated chalcones 13 and 14 showed a higher 
activity to inhibit the NO production with both stimuli compared to the prenylated chalcones. 
In the group of the non-prenylated chalcones the chalcones with one hydroxyl group led to 
more effective inhibition of the NO production and iNOS expression compared to those with 
two or no hydroxyl groups. In the group of the prenylated chalcones 2 showed the highest 
and 5 the lowest activity in inhibiting the NO production (stimulus 10 ng/ml LPS) and iNOS 
expression. Prenylated chalcones with free hydroxyl groups inhibited the NO production 
more efficient than the O-methoxylated and O-acetylated derivatives. 
Compounds 2, 4, 6 and 7 differ in their activity in the performed assays and might be 
candidates for the study of molecular mechanism in more detail. 
XN exhibits a low bioavailability. The exact uptake mechanism of XN is not fully understood 
yet. In this thesis the XN uptake was studied in hepatic and colorectal cancer cell lines and 
primary hepatocytes. HSC, Caco-2 and PH cells exhibited a 52, 63 and 47 fold higher XN 
concentration compared to the medium which was initially supplemented with 10 µM XN. In 
HuH-7 cells the measured XN concentration was only 3 fold higher. This might be explained 
by differences in the ABC-transporters, metabolism and amount of proteins per cell. But the 
reason is not known yet and needs to be further investigated. The results showed that XN is 
accumulated in hepatic cancer cell lines and primary hepatocytes and might thus exhibit a 
low bioavailability. This prompted us to investigate the bioavailability as well as the 
distribution and metabolism of XN in the liver, serum, bile, feces and urine of BALB/c mice. 
The BALB/c mice were fed with 100 mg XN/kg, 500 mg XN/kg and 1000 mg XN/kg body 
weight (73% XN) for 3 and 7 days respectively. There was no linear correlation between the 
fed amount of XN and the XN concentration in serum. Thus it seems advisable to determine 
suitable concentration ranges for every compound prior to in vivo experiments. The 
distribution measurements revealed that the highest XN concentrations were detected in the 
bile followed by the feces, urine, liver and serum. This pointed to an entero-hepatic 
circulation of XN. The serum XN (unmetabolized) concentration was between 0.01 and 
0.12 µM. XN was highly metabolized. The ratio between conjugated and unconjugated XN 
was between 21 and 163. 
In order to investigate the influence of the matrix on the XN absorption, BALB/c mice were 
fed with 73% XN (27% matrix) and 98% XN. The BALB/c mice received a diet with 
1000 mg XN/kg body weight for 3 and 7 days respectively. The absorption of XN was 
significantly higher in the group that was fed with 73% XN. In addition the studies showed 
that XN is highly metabolized. The highest XN concentrations were detected in the bile 
followed by the serum, liver, urine and feces. 
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9 Appendix 
9.1 Abbreviation 
XN  
(1, is used  
additionally in chapter 3) 
Xanthohumol 
2 Xanthohumol H 
3 4-Acetoxyxanthohumol 
4 4-Methoxyxanthohumol 
5 Desmethylxanthohumol 
6 Xanthohumol C 
7 Dihydroxanthohumol C 
8 Acetylchroman 
9 Prenylacetophenon 
10 Tetrahydroxanthohumol 
11 Dihydro-Helichrysetin 
12 Dihydro-Flavokawain C 
13 Helichrysetin 
14 3-OHHelichrysetin 
15 Flavokawain A 
16 Flavokawain B 
17 Flavokawain C 
18 Alpinetin chalcone 
8-PN 8-prenylnaringenine 
AAPH 2,2′-azobis(2-methylpropionamide) dihydrochloride 
Ah receptor Aryl hydrocarbon receptor 
AIF Apoptosis-inducing factors 
ALT Alanine aminotransferase 
AP Apical 
aP2 Adipocyte lipid binding protein 
AR Androgen receptor 
ARE Antioxidant response element 
Asm Acid sphingomyelinase 
AST Aspartate aminotransferase 
ATCC American type culture collection 
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ATF6 Activating transcription factor 6 
BaP Benzo(a)pyrene 
BL Basolateral 
BSA Bovine serum albumine 
BSEP Bile salt export pump 
BVDV Bovine viral diarrhea virus  
C/EBP CCAAT/enhancer-binding protein 
C/EBPα CCAAT/enhancer binding protein α 
Caco-2 Human colorectal cell line 
CD Concentration to double inducation 
CHOP Homologous protein 
CHS Chalcone synthase 
COX Cyclooxygenase 
CR Chloroquine-resistant 
CS Chloroquine-sensitive 
CV Crystal violet 
DHE 2-Hydroxyethidium 
DMEM Dulbecco’s modified Eagle medium 
DPPH 1,1-diphenyl-2-picrylhydrazyl radical 
EC50 Effective concentration 
EGF Epidermal growth factor 
ER Endoplasmatic reticulum 
ER Estrogen receptor 
FACS Fluorescence activated cell sorter 
FCS Fetal calf serum 
FRAP Fluorescence recovery after photobleaching 
FXP Farneosid X receptor 
GPR Glucose-regulated proteins 
GS Glutathione synthetase 
GSH Glutathion 
GST Glutathione S-transferase 
HAA heterocyclic aromatic amine 
HASMC Human aortic smooth muscle cells 
HCV Hepatits C virus 
HepG2 Human hepatoma cell line 
HIPT-1 Humulus lupulus prenyltransferase-1 
HO 1 Heme-oxygenase 1 
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HPTLC High performance thin layer chromatography 
HSC Human hepatic stellate cell line 
HuH-7 Human hepatoma cell line 
HUVEC Human umbilical vein endothelial cells 
Hydro XAN C Hydroxanthohumol C 
HYSA Hydroxysafflor yellow A 
IC50 Inhibition concentration  
ICAM-1 Intracellular adhesion molecule-1 
IKK IκB kinase 
IL-6 Interleukin-6 
iNOS Inducible NO synthase 
IQ 2-Amino-3-methylimidazol[4,5-f]quinoline 
IRE1 Inositol-requiring enzyme 1 
IXN Isoxanthohumol 
JAK Januskinase 
JNK C-Jun N-terminal kinase 
Keap 1 Kelch-like ECH-associated protein 1 
LDH Lactate dehydrogenase 
LOD Limit of detection 
LOQ Limit of quantification 
LOX Lipoxygenase 
LPS Lipopolysaccharides 
MAPK Mitogen activated protein kinase 
MCP-1 Monocyte chemo-attractant protein-1 
MDCKII-MDR Madin-Darby canine kidney-MDR 
MDR Multidrug resistant 
MelQx 2-Amino-3,8-dimethylimidazol[4,5-f]quinoxaline 
MIC Minimum inhibitory concentration 
MRP5 ATP-binding cassette transporter multi-drug resistance 
associated protein 5 
MTP Microsomal triglyceride transfer protein 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbro
mide 
NAC N-Acetylcystein 
NBT Nitro blue tetrazolium chloride 
NEAA Non essential amino acids 
NED Naphtyletyhlene diamine dihydrochloride 
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NF-κB Nuclear factor kappa light chain enhancer of activated 
B-cells 
NMR Nuclear magnetic resonance spectroscopy 
Nrf 2 Nuclear factor-erythroid 2 (NF-E2)-related factor 2 
OMT O-Methyltransferase 
ORAC Oxygen radical absorbance capacity assay 
PARP Poly (ADP-ribose) polymerase 
PBS Phosphate buffered saline 
PERK RNA-activated protein kinase –like ER kinase 
PfCRT P. falciparum chloroquine resistant transporter 
PH Primary hepatocytes 
PhIP 2-amino-1-methyl-6-phenylimidazol[4,5-b]pyridine 
PPARγ Peroxisome proliferator-activated receptor γ 
QR NAD(P)H:quinone reductase 
RANKL Receptor activator of NF-κB ligand 
RAW 264.7 Mouse macrophage 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
RPMI Roswell Park Memorial Insitute 
RUNX2 Runt-related transcription factor 2 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SE Standard error 
SHP Small heterodimer partner 
SOD Superoxid dismutase 
SP Sodium pyruvate 
SREBP Sterol regulatory element binding protein 
STAT Signal transducers and activators of transcription 
TBH tert-Butylhydroperoxide 
TCID50 Tissue culture infection dose 
TI Therapeutic index 
TLR4 Toll-like receptor 4 
TNF Tumor necrosis factor 
TPA 12-O-Tetradecanoylphorbol-13-acetate (TPA) 
UDP Unfolded protein response 
UGT UDP-glucuronosyltransferase 
VEGF Vascular endothelial growth factor 
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XE Extract with 73% Xanthohumol and 23% Matrix 
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9.2 NMR spectra of hydrogenated chalcones 
The 1H NMR spectra of the hydrogenated chalcones are depicted in Figure 9-1. 
 
A Compound 10 
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B Compound 12 
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C Compound 11 
 
  
Figure 9-1: The 1H NMR spectra of 10 (A), 12 (B) and 11 (C). The molecular structures were 
confirmed by NMR using a Bruker Avance spectrometer (400 MHz). 1H NMR spectra were 
recorded at ambient temperature. For this purpose, 10 and 12 were dissolved in CDCl3 
Compound 11 was dissolved in deuterated acetone. 
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